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Alkaptonuria (AKU) is an ultra-rare autosomal recessive disorder resulting from a deficiency 
of the homogentisate 1,2-dioxygenase (Hgd) enzyme and is characterized by accumulation 
of homogentisic acid (HGA) in plasma. The disorder has three distinct stages of disease 
beginning with the excretion of large quantities of HGA in the urine, followed by deposition 
of HGA as a polymerized pigment in collagenous tissues principally in the cartilages of 
loaded joints (termed ochronosis), and finally the early onset of severe and devastating 
osteoarthropathy. There is currently no effective treatment available to AKU patients. 
Studying the extreme osteoarthritis (OA) phenotype seen in AKU is helping to increase 
understanding of more common OA, and may help elucidate the mechanisms behind the 
initiation and progression of OA. Although a murine model of AKU has previously been 
reported, published studies reported that Hgd-/- mice did not develop ochronosis. The aim 
of this thesis was to make a comprehensive survey of Hgd-/- mice to identify if ochronosis 
was present, determine the pathogenesis of the disorder, and to establish whether a 
potential treatment could prevent pigment deposition in tissues. 
Through studying a large number of Hgd-/- mice, of a wide variety of ages, this thesis has 
provided novel findings in relation to the presence of ochronosis in these mice. Using a 
modified version of Schmorl’s stain, which can specifically identify ochronotic pigment, 
ochronosis was observed in Hgd-/- mice for the first time. The identification of the earliest 
stages of ochronosis in Hgd-/- mice provided an opportunity to follow the pathogenesis of 
the disease throughout their lifespan. Pigmentation was initially identified in the pericellular 
matrix (PCM) of chondrons in the articular calcified cartilage (ACC), before progressing 
intracellularly. Examination of aged mice revealed widespread pigmentation throughout all 
areas of the tibio-femoral joint. Quantification of the pigmented chondrons demonstrated a 
progressive, linear increase in pigmentation with increasing age. Similar to ochronosis 
observed in AKU patients, Hgd-/- mice exhibited signs of ochronotic osteoarthropathy which 
became progressively worse with age. The early identification of ochronosis and its 
associated osteoarthropathy in Hgd-/- mice is helping to investigate the biochemical and 
pathological changes associated with AKU in humans. 
Following the identification of ochronosis Hgd-/- mice were treated with nitisinone, which 
had been identified as a possible therapeutic for AKU. Administration of nitisinone 
throughout the lifespan completely prevented deposition of ochronotic pigment. When 
given mid-life, nitisinone stopped any further pigment deposition but was unable to reverse 
the effects of ochronosis which had already taken place. The results showed nitisinone to be 
an effective treatment against the initiation and progression of AKU. 
During the course of investigation to identify ochronotic pigment at the ultrastructural level, 
high resolution transmission electron microscopy revealed the presence of previously 
undescribed microanatomical concentric lamellae in the ACC of Hgd-/- and wild type mice. 
Although the pathogenesis of these structures is still undetermined they may play a role in 
OA development as they appear to be associated with tidemark advancement and increased 
cartilage mineralization. 
In summary the studies reported in this thesis present novel findings on the identification of 
pigmentation, and on the initiation, progression and mechanism of ochronosis which leads 
to ochronotic osteoarthropathy in Hgd-/- mice. The prevention of ochronotic pigmentation, 
using the drug nitisinone, was also reported for the first time. 
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ABBREVIATIONS 
ACC – Articular calcified cartilage 
ACL – Anterior cruciate ligament 
AKU – Alkaptonuria  
ADAMTS – A disintegrin and metalloproteinase with thrombospondin motifs 
BCP – Basic calcium phosphate 
BMP – Bone morphogenetic protein  
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BSU – Biological services unit 
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ERT – Enzyme replacement therapy 
FGF – Fibroblast growth factor 
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HAC – Hyaline articular cartilage  
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HPLC – High performance liquid chromatography 
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HPPD – 4-hydroxyphenylpyruvate dioxygenase 
HT-1 – Hereditary tyrosinemia type 1 
IL – Interleukin 
ITM – Interterritorial matrix 
LFC – Lateral femoral condyle 
LM – Lateral meniscus 
LTP – Lateral tibial plateau 
MAA – Maleylacetoacetic acid 
MFC – Medial femoral condyle 
MM – Medial meniscus 
MMP – Matrix metalloproteinase 
MMTL – Medial meniscotibial ligament  
MTP – Medial tibial plateau 
NFR – Nuclear fast red 
OA – Osteoarthritis 
OARSI – Osteoarthritis research society international 
PBFS – Phosphate buffered formalin solution 
PBS – Phosphate buffered saline 
PCL – Posterior cruciate ligament 
PCM – Pericellular matrix 
PCR – Polymerase chain reaction 
rER – Rough endoplasmic reticulum 
ROS – Reactive oxygen species 
SCB – Subchondral bone 
SEM – Scanning electron microscopy 
TEM – Transmission electron microscopy 
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TGF – Transforming growth factor 
TIMP – Tissue inhibitors of metalloproteinases 
TM – Territorial matrix 
TNF – Tumour necrosis factor  
TP – Tibial plateau 
WT – Wild type 
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1.1 ALKAPTONURIA 
1.1.1 History 
Alkaptonuria (AKU) is an ultra-rare autosomal recessive disorder characterised by 
the deposition of homogentisic acid (HGA) as a polymerized pigment in collagenous 
tissues (ochronosis). A deficiency in the homogentisate 1,2-dioxygenase (Hgd) 
enzyme results in an inability to completely metabolise the amino acids tyrosine 
and phenylalanine, leading to the deposition of HGA as a black pigment, primarily in 
the cartilages of load-bearing joints (Fig. 1.1). This results in an early onset, 
devastating osteoarthropathy for which there is currently no effective treatment. 
AKU is renowned for being the first disease to be described as an ‘inborn error of 
metabolism’ by the distinguished English physician, Sir Archibald Garrod [1, 2]. It 
was also one of the first disorders to conform to the laws of Mendelian inheritance. 
Although Garrod was the first to describe the features of AKU as one single 
disorder, several previously published articles documented symptoms consistent 
with a diagnosis of AKU. 
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The earliest documented case of ochronosis dates back to 1500 B.C. and the 
Egyptian mummy, Harwa. Radiological and biochemical analysis of the 
intervertebral discs, and the hip and knee joints from the mummy confirmed the 
diagnosis [3, 4]. Scribonius, writing in 1584, reported that the urine of a school boy 
was as ‘dark as ink’ [5]. This was the first time a clinical symptom of AKU had been 
described in man. In 1859, Boedeker described the reducing abilities of a compound 
found in the urine of a man presenting with lumbar spine pain and severely reduced 
mobility. Boedeker observed that the compound was able to reduce alkaline copper 
solutions, whilst also noting that it absorbed large volumes of atmospheric oxygen 
in the presence of alkali solutions leading to the compound darkening rapidly. This 
led Boedeker to name the compound ‘alkapton’ which was derived from alkali and 
the Greek word meaning “to absorb greedily”. The term ochronosis was first 
described in 1866 by Virchow [6] following the discovery of black pigmentation in 
the articular cartilage, intervertebral discs, menisci, and both laryngeal and tracheal 
cartilage of a 67 year old man who died from congestive heart failure. Although 
Figure 1.1 – Diagram highlighting the enzyme defect which results in AKU.  
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macroscopically the pigmentation was black, microscopic analysis revealed the 
colour to be yellowish-brown or ‘ochre’ leading Virchow to describe the findings as 
ochronosis. Research by Wolkow and Baumann, published in 1891, detailed the 
structure and formula of the compound previously termed alkapton. They noted its 
involvement in AKU and proceeded to name it HGA. Albrecht, writing in 1902, 
recognized the link between AKU and ochronosis and concluded that long term 
suffering from AKU resulted in ochronosis. The discovery of ochronotic arthritis was 
made by Allard and Gross, in 1907, who noted that patients with AKU had very 
advanced arthritis of both upper and lower limbs. Garrod arguably made the most 
important contributions to AKU research including identifying the disorder as an 
‘inborn error of metabolism’, and showing there was an association between the 
amount of tyrosine and phenylalanine consumed and the amount of HGA excreted 
in individuals with AKU [1, 7]. Garrod presented his work at the Croonian lectures in 
1908 were he discussed his work on AKU and demonstrated that AKU, along with 
several other disorders, followed the laws of Mendelian inheritance [8]. 
 
1.1.2 Epidemiology 
The incidence of AKU worldwide is estimated to be between 1:250,000 and 
1:1,000,000 [9], highlighting its ultra-rare nature. There are however certain 
countries which are ‘hotspots’ for AKU and have a much higher prevalence. Slovakia 
and the Dominican Republic are thought to have an incidence of around 1:19,000 
[10, 11]. Recent research carried out in Jordan showed there to be a large number 
of individuals from the same family, and village suffering from AKU [12, 13]. 
Although the exact numbers are not known it is thought that Jordan may have the 
highest frequency of AKU patients in the developed world due to the high number 
of consanguineous marriages that occur there. A large number of novel mutations 
of the Hgd gene have been identified in both Slovakia and Jordan [14-16] 
demonstrating the high prevalence of the disorder in both countries. 
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1.1.3 Clinical presentations 
AKU has several distinct clinical features which are present at different stages 
throughout life. The earliest and most obvious clinical symptom of AKU is the 
excretion of HGA in the urine of affected individuals. Upon standing the urine 
darkens, though this can be quickened by addition of an alkaline solution. The 
appearance of dark staining of nappies in infants, following the excretion of HGA is 
the only clinical sign of the disorder in very young patients [17]. Although darkening 
of the urine can be used as a diagnostic tool for AKU, further analysis of the urine 
using high performance liquid chromatography (HPLC) [18, 19], or 
spectrophotometric analysis [9] is usually undertaken to ensure the diagnosis is 
accurate. 
 
Over a period of time, due to continually high levels of HGA in the body, there is 
deposition of a dark pigment - resulting from polymerization of HGA - in tissues 
throughout the body [20]. This process, known as ochronosis, is a hallmark sign of 
AKU and can help with diagnosis of the disorder. Darkening of the sclera and pinna 
can be seen from the third decade of life and is the most obvious sign of ochronosis 
in AKU patients [9]. Ochronosis of the skin is also common in AKU patients [21] 
however it is also common in people using hydroquinone cream, for conditions 
such as melasma [22] therefore it is not used on its own as a diagnostic tool for 
AKU. The tissues most severely affected by pigment deposition, including load-
bearing joints such as the knees and hips, are only observed during post-mortem 
studies or joint replacement surgery. There has been many cases reporting severe 
pigmentation of the knee and hip joints, along with other joints in AKU patients [23-
26]. These tissues show both macroscopic pigmentation which can be easily 
identified, and microscopic pigmentation which has shown different degrees of 
ochronosis in the affected tissues. Pigmentation of tendons has also been reported, 
with both the patellar and Achilles tendons showing discolouration [27]. Recent 
work by Taylor et al [28] has shown there to be an association between collagen 
fibres and ochronotic pigment in the ligamentous capsule, indicating how these 
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tissues may become pigmented. Other cartilaginous tissues that have shown signs 
of ochronosis include the trachea and bronchi [29]. Aside from cartilaginous tissues, 
post-mortem studies have revealed the involvement of the heart in AKU patients. 
There have been a number of cases reporting calcification and pigment deposition 
in the aorta [30-32]. Although AKU is not a fatal condition, the involvement of the 
cardiac system in the disorder highlights the susceptibility of different tissues with 
regards to becoming ochronotic. Recently ochronosis has been identified in a 
mediastinal cyst which was surgically removed from a patient previously diagnosed 
with AKU [33].  
 
Although darkening of urine and visible signs of ochronosis sometimes present as 
the initial symptom of AKU, the most common symptom leading to diagnosis is the 
development of osteoarthritis (OA)-like pain in the joints. Usually detected either 
clinically or radiographically, the diagnosis of AKU is confirmed by measuring the 
plasma levels of HGA. Ochronosis in the joints occurs over a sustained period of 
time leading to destruction of the joint. This is commonly known as ochronotic 
osteoarthropathy and is the most severe symptom of AKU. The hips and knees 
often present as the most severely affected joints, however the earliest and most 
common presentation of the osteoarthropathy is often related to the spine. In a 
study of 163 cases of AKU involvement of the spine was observed in 159 patients 
with a significantly lower number presenting with knee and hip pain [34, 35]. In a 
separate, more recent study of 45 AKU patients a third showed a loss in height 
highlighting the severity of spinal involvement in the disorder [9]. Ochronotic 
osteoarthropathy in the knees and hips presents radiographically as severe OA with 
joint space narrowing, subchondral sclerosis, and joint surface irregularities often 
observed [26]. With no current therapeutics widely available for AKU patients the 
use of surgical intervention to remove the affected joint is the primary form of 
treatment. Although this form of treatment is far from ideal it has provided a library 
of samples which are helping researchers understand the pathogenesis of the 
disorder. Association of the cartilaginous matrix and ochronotic pigment has been 
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consistently observed in surgical samples [36-38] indicating a possible mechanistic 
pathway for the initiation of pigmentation. 
 
1.1.4 Pathogenesis 
The pathogenesis of AKU is still yet to be fully understood. It has only been in 
recent years that possible mechanisms relating to the deposition of ochronotic 
pigment have been suggested. Taylor and colleagues first identified the association 
of pigment with the periodicity of fibrillar collagen, suggesting a possible 
preferential binding site for ochronotic pigment on collagen fibres [28]. Further 
work by Taylor showed that pigmentation appeared to initiate in the pericellular 
matrix (PCM) of chondrons deep in the articular calcified cartilage (ACC) [36]. The 
authors suggest that this may have resulted from alteration of the composition and 
organisation of the collagen fibres in the PCM, thus leading to pigment deposition. 
Chow showed that ochronotic cartilage is more disordered than normal cartilage at 
the atomic level [39] which appears to support the mechanism proposed by Taylor 
[36]. Once pigmentation is initiated deep in the ACC it appears then to progress up 
through the hyaline articular cartilage (HAC) leaving the cartilage in a state of 
‘blanket’ pigmentation. These findings suggest that areas of focal damage initially 
precede pigment deposition, and then progressively become worse resulting in 
widespread pigmentation of the tissue. Although significant progress has been 
made to determine the pathogenesis of AKU further work is needed to determine if 
other mechanisms result in pigment deposition. The pathogenesis of AKU in Hgd-/- 
mice is reported in Chapters 3 and 4 of this thesis. 
 
1.1.5 Therapeutic options    
The current lack of effective therapeutics for the treatment of AKU is a major 
problem. Due to the ultra-rare nature of the disorder there has been limited 
research, particularly from pharmacological companies, with regards to identifying 
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possible new and effective treatments. Several possible therapies have been 
identified however they have shown mixed results in man. 
 
1.1.5.1 Ascorbic acid (Vitamin C) 
Ascorbic acid was the first compound to be identified as a possible treatment for 
AKU [40]. Studies incorporating ascorbic acid in the treatment of AKU patients have 
shown it to inhibit HGA polyphenol oxidase resulting in a reduction in the amount 
of benzoquinone acetic acid (BQA) synthesized [41], which itself is an intermediary 
in the formation of ochronotic pigment. However in this study a concentration of 
10mM ascorbic acid was used to inhibit the enzyme, something which would be 
almost impossible to achieve in vivo. Forslind, writing in 1988, noted that “ascorbic 
acid is not effective in the treatment of symptomatic ochronosis” [42]. It has also 
been suggested that due to ascorbic acid being a co-factor for 4-
hydroxyphenylpyruvate dioxygenase (HPPD), treatment with the compound may 
actually increase the amount of HGA produced. Treatment with ascorbic acid may 
also contribute to the formation of renal oxalate stones in AKU patients [9]. The 
overwhelming evidence appeared to show that ascorbic acid was not beneficial in 
the treatment of AKU. 
 
1.1.5.2 Low protein diet 
There has been some research on the incorporation of a low protein diet as a way 
of reducing the levels of HGA in AKU patients. Similar to the use of ascorbic acid in 
AKU there is not much evidence suggesting a low protein diet has any future as a 
treatment option for AKU patients. A study from Mayatepek showed that a low 
protein diet may actually increase the amount of BQA produced [43], which would 
lead to an increase in the amount of ochronotic pigment formed. A separate study 
conducted by Haas and colleagues showed that HGA levels were reduced by a low 
protein diet, however this only occurred in patients under 12 years of age after 
which the effect was lost [44]. The authors also noted that compliance with dietary 
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restriction decreased progressively with age, and that behavioural problems 
emerged during diet restriction [44]. Similar to ascorbic acid use in AKU patients, 
the incorporation of a low protein diet did not appear to have a beneficial effect. 
 
1.1.5.3 Enzyme replacement therapy 
As AKU results from a single enzyme deficiency the ideal treatment, at least in 
principle, would be the replacement of the Hgd enzyme thereby ensuring effective 
metabolism of HGA. In theory this technique should be possible, as long as the 
recombinant enzyme can be delivered to the liver without issue. Recent studies of 
enzyme replacement therapy (ERT) in Pompe disease, which itself is an autosomal 
recessive disorder causing damage to muscle and nerve cells, has shown beneficial 
effects in both infantile and adult patients [45-47]. This is positive news for AKU 
patients as it highlights the potential of ERT as a practical treatment for the 
disorder. 
 
1.1.5.4 Nitisinone 
Nitisinone is currently the most effective treatment option for AKU patients. 
Originally developed as a herbicide [48], it is routinely used for the treatment of 
hereditary tyrosinemia type 1 (HT-1) [49, 50]. Nitisinone reversibly inhibits 4-HPPD 
which is responsible for the conversion of hydroxyphenylpyruvate into HGA (Fig. 
1.1). Following its effectiveness in treating HT-1 it was proposed as a potential 
treatment for AKU. Using a murine model of AKU, Suzuki and colleagues 
demonstrated that nitisinone could effectively reduce plasma HGA levels in a dose-
dependent manner [51]. Initials trials of nitisinone in AKU patients demonstrated a 
significant reduction in plasma HGA levels, falling below the level of detectability in 
a number of patients in the trial. Patients who received nitisinone for more than 
one week also reported decreased pain in their affected joints [52]. Although the 
initial data appeared positive, there were several adverse effects including the 
passing of kidney stones and the elevation of tyrosine plasma levels. Elevated 
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tyrosine poses significant risks as it can cause corneal crystal formation and corneal 
epithelial damage. A larger scale study of nitisinone use in AKU patients provided 
mixed results due largely in part to the end point chosen [53]. Hip rotation was 
defined as the parameter to determine the efficacy of nitisinone however the 
results showed considerable variability in hip rotation in the same patients from 
visit to visit [53]. It is clear that nitisinone has potential as a possible treatment for 
AKU as it significantly reduces plasma HGA however whether it can prevent 
pigmentation in affected individuals is still unclear. The use of nitisinone in Hgd-/- 
mice is reported in Chapter 5 of this thesis, along with its efficacy on preventing 
pigment deposition throughout the mouse lifespan. 
 
1.2 HOMOGENTISATE 1,2-DIOXYGENASE – STRUCTURE, FUNCTION, MUTATIONS 
AKU results from a deficiency in the Hgd enzyme, specifically a mutation in the gene 
coding for the enzyme. The normal human Hgd gene is 54,363bp in length and 
codes for a 1715 nucleotide sequence. This is split into 14 exons which vary in 
length from 35 to 360bp [54]. The gene encodes a 445-amino acid protein that 
forms a dimer of two trimers, producing a functional hexamer which can effectively 
metabolise HGA [55]. Fernandez-Canon and colleagues mapped the Hgd gene to 
chromosome 3 (3q21-q23), and showed that expression of the gene was restricted 
to the liver, kidneys, small intestine, colon, and prostate [56]. The crystalline 
structure of the enzyme was detailed by Titus and colleagues who described the 
structure as intimately associated 280-residue N-terminal and 140-residue C-
terminal domains, surrounding a central β-sandwich structure [57]. The Hgd 
enzyme is essential in tyrosine catabolism as it converts HGA to maleylacetoacetic 
acid (MAA), which is then further metabolised and excreted from the body (Fig. 
1.1). Loss of function of the enzyme, as seen in AKU, leads to a build-up of HGA as it 
can no longer be metabolised. To date there are currently 115 known Hgd 
mutations [58]. Two-thirds of these mutations are missense, with splicing, 
frameshift, deletion, expansion and stop mutations comprising the rest. The 
mutations are distributed throughout the entire Hgd gene however there is a 
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higher prevalence in exons 6, 8, 10, and 13 [58]. There is no correlation with the 
type of Hgd mutation, the level of HGA in the plasma and urine, and the severity of 
the disorder. 
 
1.3 HOMOGENTISIC ACID 
HGA is a small highly water soluble molecule which upon oxidation, either with the 
addition of NaOH or in the presence of molecular O2, forms a highly reactive 
quinone intermediate known as BQA. This molecule subsequently undergoes 
polymerization to produce the pigmented polymer deposited in the tissues of AKU 
patients. During autoxidation HGA produces oxygen radicals, O2
-, OH., and H2O2, 
which are thought to play a role in the development of ochronotic 
osteoarthropathy [59]. HGA is also found in species of marine bacterium where it 
has been identified as the primary precursor of melanin synthesis [60]. These 
bacteria produce a compound known as pyomelanin, through metabolism of HGA, 
which is also known as alkapton [61, 62]. 
 
1.4 CARTILAGE 
Cartilage is a flexible connective tissue found throughout the human body. There 
are three types which are distinguished by their unique composition which relates 
to their specific function in the body. The three types of cartilage are known as 
hyaline, elastic, and fibrocartilage. Although compositionally different there are 
similarities between each type of cartilage. The most distinct properties of cartilage 
are that it is both avascular and aneural. Cartilage contains only one cell type which 
is responsible for the production and maintenance of the collagen rich matrix; these 
cells are known as chondrocytes. Hyaline cartilage is the most predominant 
cartilage in the body and is found in several tissues of the body including the 
trachea and on the end of long bones, where it is known as articular cartilage. The 
matrix of hyaline cartilage consists primarily of type II collagen and chondroitin 
sulphate. Elastic cartilage is found in the pinna, Eustachian tube, and epiglottis. 
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Histologically it is similar in appearance to hyaline cartilage containing both type II 
collagen and chondroitin sulphate however it also contains a significant amount of 
elastic fibres throughout its matrix. Fibrocartilage is found in several tissues of the 
body including the intervertebral discs, the pubic symphysis, and the menisci of the 
knees. Unlike hyaline and elastic cartilage, fibrocartilage contains type I collagen 
which provides strength and durability, hence it is located in tissues requiring these 
traits. 
 
1.4.1 Composition of the peri- and extracellular matrix in articular cartilage 
The PCM directly surrounds chondrocytes in articular cartilage and is thought to 
play a role in the biomechanics of joints [63]. The PCM is rich in hyaluronan (HA), a 
non-sulphated glycosaminoglycan (GAG), fibronectin, and proteoglycans including 
perlecan, biglycan, and decorin. Type VI collagen is the primary collagen type 
present in the PCM, however types II and IX are also present but in much smaller 
amounts. Type X collagen is also found in the PCM of chondrocytes, primarily in 
hypertrophic cells located in the ACC. The composition of the extracellular matrix 
(ECM), which compromises the territorial and interterritorial matrices (TM/ITM), in 
articular cartilage relates directly to its function. Biomechanical loads are constantly 
applied to joints therefore the tissue must be able to withstand these pressures to 
function normally, and to prevent any mechanical damage. The main constituent of 
ECM is water which accounts for between 65-80% of the wet weight of the tissue. 
The presence of water helps with distribution of load and ensures the cartilage does 
not become deformed when put under enormous stress. Water helps with the 
transport and distribution of nutrients in articular cartilage which is an essential 
process due to the avascular nature of cartilage, whilst also providing a source of 
lubrication for articulation of the joints. Collagen is the most abundant 
macromolecule in cartilage, constituting between 10-20% of the wet weight of the 
tissue. Collagen fibres provide tensile strength to cartilage whilst also providing a 
binding site for proteoglycans (Fig. 1.2). Type II collagen is the principal fibre type in 
cartilage, however other collagens including types I, IV, VI, IX, X, and XI are present 
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but in significantly lower amounts. Proteoglycans, which comprise around 10-15% 
of the wet weight of the ECM, are heavily glycosylated proteins usually consisting of 
a central protein unit with one or more covalently attached GAG chain. There are a 
variety of proteoglycans in the cartilaginous matrix which are essential for normal 
function. The largest and most abundant proteoglycan is aggrecan which contains 
more than 100 chondroitin sulphate and keratan sulphate chains (Fig. 1.2). 
Aggrecan provides cartilage with its osmotic properties, which are critical to resist 
compressive loads. The smaller proteoglycans include decorin and bigylcan, which 
interact with collagens type II and IV respectively and help with many processes in 
cartilage. HA, a nonsulphated GAG, is another key component of the ECM and 
contributes significantly to cell proliferation and migration. Chondrocytes are the 
only cell type in cartilage and are responsible for the synthesis of all matrix 
components as well as regulating matrix turnover [64]. Chondrocytes are not 
present in large numbers in the ECM, in fact they account for around just 5% of the 
total volume of the cartilage. They receive nutrients through osmotic diffusion as 
cartilage is avascular. The concentration of oxygen is remarkably low in cartilage so 
it is quite surprising that chondrocytes survive in such a harsh environment. 
Mechanical loading affects the functions of chondrocytes, and can lead to the 
production of matrix degradation enzymes. 
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1.4.2 Structure of articular cartilage 
The structure of articular cartilage, much like the composition of the tissue, is 
critical to its function in protecting joints from excessive loading. Morphologically 
there are four zones; the superficial zone is the uppermost layer which is followed 
by the middle, deep and calcified zones. The superficial, middle, and deep zones 
form the unmineralized portion of articular cartilage and are collectively known as 
HAC. The mineralized area is commonly referred to as ACC (Fig. 1.3). 
Figure 1.2 – Diagram highlighting the interactions of collagen, chondrocytes, and 
proteoglycans in the extracellular matrix of articular cartilage. Type II collagen 
fibres, which provide cartilage with tensile strength, interact with proteoglycan 
aggregates trapping them within the collagen network. Aggrecan is the largest 
proteoglycan and is critical to cartilage structure. It interacts with HA to form 
stable tertiary complexes in the matrix. Non-aggregating proteoglycans including 
decorin and fibromodulin also interact with collagen fibrils, and play a role in 
fibrillogenesis. Chondrocytes are the only cell type in cartilage and are responsible 
for production and maintenance of the matrix, including synthesizing proteoglycan 
subunits. 
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1.4.2.1 Superficial zone 
The superficial zone is the thinnest of the four layers of articular cartilage. The 
chondrocytes located in this zone are flattened and are aligned parallel to the joint 
surface. They synthesize a protein called lubricin which plays an important role in 
the articulation of the joints [65]. The chondrocytes also synthesize large amounts 
of fibrillar collagen which is aligned parallel to the joint surface, and provides the 
superficial zone with the greatest tensile strength in articular cartilage [66]. Any 
damage to this zone can lead to alterations of the mechanical properties and be a 
causative effect in the development of OA.  
 
1.4.2.2 Middle zone 
Chondrocytes located in the middle zone are more spherical than chondrocytes in 
the superficial zone. They are embedded in an extensive ECM which is rich in 
aggrecan. The collagen fibrils in this zone are much larger in diameter than the 
superficial zone and are more randomly orientated. The middle zone is effective in 
transferring the sheer forces from the superficial zone throughout the rest of the 
zones of cartilage. 
 
1.4.2.3 Deep zone 
The chondrocytes in the deep zone are spherical in shape and are aligned 
perpendicular to the joint surface. Collagen fibrils in the deep zone also lie 
perpendicular to the joint surface. Cell density is at its lowest in the deep zone yet 
aggrecan is found at its highest concentration. Similar to the middle zone, the deep 
zone distributes load and resists compression. 
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1.4.2.4 Calcified zone 
As stated previously, the calcified zone is commonly known as ACC. It is separated 
from the unmineralized zones by the tidemark which is highly basophilic, and may 
play a role in the biomechanics of joints [67]. The chondrocytes in ACC express a 
hypertrophic phenotype and are unique in that they synthesize type X collagen 
which upon release from the cell calcifies the surrounding matrix [68]. As the 
chondrocytes in ACC are surrounded by a calcified matrix they show very low 
metabolic activity. Calcification of the matrix provides important structural integrity 
which along with the subchondral bone (SCB) is important for the shock absorbance 
properties of the tissue. 
 
 
 
 
 
 
 
 
Figure 1.3 – Zones of articular cartilage. Chondrocytes located in the superficial 
zone are flat, lie parallel to the articular surface, and occupy around 10-20% of the 
cartilage volume. Chondrocytes located in the middle zone are spherical in shape 
and occupy around 40-60% of the cartilage volume. Chondrocytes in the deep zone 
appear spherical in shape, lie perpendicular to the articular surface, and account 
for around 30-40% of the cartilage volume. Chondrocytes in the calcified zone 
express a hypertrophic phenotype and help to calcify their surrounding matrix. The 
tidemark, indicated by the black line, separates HAC and ACC. The red line 
indicates the SCB plate which separates the ACC from the underlying SCB. 
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1.4.3 Chondrocytes 
Chondrocytes are the only cell type in cartilage and are responsible for maintaining 
the ECM. Under normal physiological conditions chondrocytes maintain a stable 
equilibrium between the synthesis and degradation of matrix components. 
Chondrocytes survive in a low oxygen environment, and rely on osmotic diffusion to 
receive nutrients as cartilage is avascular. They express different phenotypes 
depending on what zone they are located in, this allows them to carry out functions 
specific to that area of cartilage. Chondrocytes are surrounded by the PCM which is 
rich in type VI collagen and proteoglycans [69] (Fig. 1.4). Type XI collagen, and 
chondroitin and keratan sulphates, both of which are components of aggrecan, 
have also been identified in the PCM [70-72]. The chondrocyte and its surrounding 
PCM form a functional and metabolic unit which is termed the ‘chondron’ [73]. 
When cartilage becomes damaged and its matrices disrupted, chondrocytes 
respond by increasing synthesis of inflammatory cytokines including interleukin-1 
(IL-1) and tumour necrosis factor-α (TNF-α). These cytokines increase synthesis of 
matrix metalloproteinases (MMPs) which breakdown the ECM, this is thought to be 
a factor in the onset of OA [74, 75](Fig. 1.4). 
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1.4.4 Collagen 
Collagen is the most abundant protein present in the ECM. Collagens consist of 
three polypeptide chains arranged in a triple helical formation. The domains in the 
structure form as a result of glycine being used as the third amino acid in a 
repeating peptide triplet to give Gly-X-Y, where X and Y are often proline and 
hydroxyproline respectively [76]. Individual collagen fibrils have a distinct 
periodicity at 67nm which give it an unmistakeable banding pattern. Type II 
collagen is the primary fibre type in ECM however there are others present 
throughout each different zone of the matrix. The PCM is rich in type VI collagen, 
the TM and ITM although both rich in type II collagen also contain types IX and XI, 
Figure 1.4 – Diagram of chondrocyte structure and function. . Chondrocytes are 
contained in lacuna which are filled with extracellular fluid, and are surrounded by 
the PCM which is rich in type VI collagen and aggrecan. The TM and ITM constitute 
the majority of the cartilage in which the chondrocytes lie. The function of 
chondrocytes can become altered when they are placed under mechanical stress 
leading to an increase in synthesis of matrix degradation enzymes. MMPs, 
amongst others, degrade collagen fibres resulting in severely damaged cartilage 
and the development of OA.  
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whilst type X collagen is present extensively throughout ACC. Collagen fibres are 
fundamental in providing the tensile strength of cartilage and as a result any 
degradation of collagen can cause significant problems, particularly in weight 
bearing joints. 
 
1.4.5 Collagen biosynthesis, assembly and supramolecular organisation 
The biosynthesis of collagen is a complex multistep process, involving both 
intracellular and extracellular processes. The first stage involves transcription of the 
collagen genes producing mRNA. The ribosome-bound mRNA is then translated in 
the rER into procollagen α chains. Following the formation of procollagen a series of 
post-translational modifications take place, including hydroxylation of proline and 
lysine residues. 4-hydroxyproline is essential for intramolecular hydrogen bonds 
which are critical to ensuring the stability of the triple helices, whilst hydroxylysine 
residues are involved in the cross-linking of collagen molecules during fibril 
formation [77]. Other post-translational modifications include trimerization, 
disulphide bonding, and folding of the procollagen chains into procollagen trimers; 
the latter requiring enzymes including peptidyl-prolyl cis-trans-isomerase for 
effective formation and folding. Once procollagen molecules have been assembled 
they are transported to the Golgi complex where they are released into the 
extracellular space, via secretory vesicles. Following secretion the procollagen 
trimers are processed, which involves cleavage of the C- and N-propeptides by 
specific proteases belonging to the ADAMTS and BMP1/Tolloid-like families [78, 
79]. The final stage of collagen biosynthesis is the formation of covalent cross-links 
which help stabilize fibril formation. This process is regulated by a number of 
different enzymes, including members of the lyase oxidase family which are vital to 
the cross-linking of the fibrillar collagens, including types I, II and III. Lyase oxidase 
converts lysine or hydroxylysine residues in the C- and N-telopeptide regions to 
peptidyl aldehydes which then spontaneously react with several other molecules to 
form covalent cross-links [80]. One characteristic trait shared by all members of the 
collagen family is the formation of the triple helix structure. Prior to the assembly of 
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the triple helix, a glycine residue must be present in every third position of the α-
procollagen chains leading to the assembly of a triple helix. For instance, type II 
collagen is composed of three α1(II)-chains forming a homotrimeric molecule, 
whilst type VI collagen forms a heterotrimer composed of three different α-chains. 
Following the synthesis and assembly of collagen fibrils they form supramolecular 
structures which provide the tensile strength and stability for a range of tissues. 
There are a number of different collagen families based on their supramolecular 
organisation, these include fibril-forming collagens, fibril-associated collagens with 
interrupted triple helices (FACIT), network forming collagens, microfibrillar 
collagens, transmembrane collagens and basement membrane collagens. Fibril-
forming collagens include types I and II, which are the major constituents of bone 
and articular cartilage respectively. These collagens assemble into supramolecular 
aggregates with the fibrils defined by their characteristic 67nm banding pattern. 
  
1.5 BONE 
1.5.1 Formation, structure, and function 
Bone is a highly specialized tissue which has many important functions in the body. 
Bone is formed by two processes during fetal development; intramembranous, and 
endochondral ossification. Intramembranous ossification occurs primarily during 
formation of the flat bones of the skull, and relates to the formation of bone from 
connective tissue. Endochondral ossification occurs extensively throughout the 
body, including the long bones of joints, and relates to the formation of bone 
initially from hyaline cartilage which becomes ossified in two separate areas leading 
to development of the epiphyseal plate (EP) and articular cartilage. There are two 
types of bone in the body, cortical and trabecular. Cortical bone is a rigid structure 
forming the outer layer of bones, whilst trabecular bone which has a much larger 
surface area than cortical bone is located internally. Bone marrow is located within 
the trabecular bone and is primarily involved in the formation of the cellular 
components of blood (haematopoiesis). Bone is almost completely composed of 
bone matrix which can be split into both organic and inorganic components. Type I 
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collagen forms the majority of the organic matrix in bone and is initially laid down 
as osteoid before becoming mineralized. The inorganic matrix is predominantly 
composed of hydroxyapatite which is also laid down as osteoid before becoming 
mineralized. The primary function of bone is to provide structural support to the 
body particularly during movement, including distribution of mechanical loads 
across joints. Bone also acts as a storage area for minerals including calcium and 
phosphorus which are vitally important for homeostasis. 
 
1.5.2 Cells 
There are three main cell types in bone, each with their own specific and important 
function. Osteoblasts are crucial to bone formation and mineralization. They also 
synthesize hormones and produce alkaline phosphatase which itself plays a role in 
the mineralization of bone. Osteoclasts are large multinucleated cells responsible 
for the resorption of bone. They are derived from hematopoietic lineage and 
migrate to the bone surface to begin the process of resorption which they do with a 
phagocytic-like mechanism, similar to macrophages. Osteocytes are derived from 
osteoblasts which have become entombed in the matrix they themselves produced. 
Similar to chondrocytes the space they occupy in the matrix is known as a lacuna. 
Osteocytes are thought to play a role in regulating bone’s response to mechanical 
loading [81]. 
 
1.5.3 Remodelling 
Bone is continually altered in response to biomechanical and biochemical stimuli. 
Constant mechanical loading can cause micro-damage which ultimately needs to be 
repaired in order for the bone to sustain its function of providing structural support 
to the body. Remodelling of bone is a critical process which helps maintain bone 
structure and function. It occurs only if there is a balance between resorption and 
formation of bone. The process of bone remodelling is mediated by osteoclasts, 
osteoblasts, and osteocytes which were only recently implicated in the process 
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[82]. Osteoclastic resorption of bone releases stored calcium into the systemic 
circulation which then ceases allowing osteoblasts to mineralize the calcium at the 
site of resorption. 
 
1.5.4 Subchondral bone 
Beneath the layer of ACC in long bones lies the SCB which is important to for the 
stability of joints. The two tissues, although structurally different, are vitally 
important in helping to distribute the mechanical load placed upon articulating 
joints. SCB undergoes constant remodelling which can alter the properties of joints 
and cause severe consequences. SCB is known to be extremely important in the 
pathogenesis of OA [83, 84], so much so that it has been suggested as a possible 
therapeutic target for the prevention of OA [85, 86]. It is thought that SCB also 
plays an important role in the initiation and progression of ochronotic arthropathy 
in AKU [36]. 
 
1.6 OSTEOARTHRITIS 
1.6.1 Epidemiology 
OA is a progressive joint disease characterized by articular cartilage degeneration, 
SCB remodelling, and osteophyte formation. OA is the most common form of joint 
pain in the developed world [87]. There is limited literature on the prevalence and 
incidence of OA due to the problems of accurately diagnosing the disorder 
radiographically and clinically. Symptomatic knee OA, which is one of the most 
common forms of OA, is thought to affect around 10-15% of patients aged 60 and 
over in the USA [88]. Other frequently affected sites include the spine, hands and 
hips.  
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1.6.2 Pathogenesis 
There are a variety of factors believed to be involved in the initiation and 
progression of OA however there is no definite agreement to what is the actual 
cause. One of the most cited reasons for development of OA is abnormal loading of 
joints resulting in microtrauma to the cartilage and underlying SCB [89-91]. 
Abnormal loading of cartilage is thought to alter the function and phenotype of 
chondrocytes leading to activation and/or upregulation of matrix degrading 
enzymes. The process of chondrocyte induced degradation of the matrix is known 
as chondrocytic chondrolysis [92]. Normal physiological loading of joints has been 
shown to be beneficial, particularly in mice, as it can accelerate bone healing, and 
reduce the levels of the cartilage degradation enzyme MMP-13 [93, 94]. Ageing has 
also been linked to OA progression due to the continuous loading of joints (wear 
and tear) throughout an individual’s lifetime. Similar to abnormal loading of joints, 
the continuous stress placed on joints in ageing individuals can lead to cartilage 
degradation due in part to accumulation of damaged matrix molecules which are 
not replaced during matrix turnover. Once the structure and integrity of the matrix 
becomes compromised it can lead to further degenerative changes. OA was 
originally thought to involve only cartilage however it is now accepted that the SCB 
has a role in OA pathogenesis [83, 84, 95]. Remodelling of the SCB has been linked 
with OA, Radin et al have speculated that it leads to altered joint biomechanics 
resulting in secondary changes in cartilage structure [96]. Severe subchondral 
sclerosis is observed in OA, whilst there is also evidence that vascularization of the 
ACC from the SCB is related to the development of OA [97]. Whether changes in the 
SCB precede cartilage damage, or they are as a result of changes in the cartilage is 
still up for discussion. Obesity has been linked with the development of OA due in 
part to the abnormal load placed on joints in obese individuals [98]. There also 
appears to be metabolic and systemic factors involved in obesity which act both 
directly and indirectly on chondrocytes leading to an increased risk of developing 
OA [99]. Adipokines are thought to be one of the major factors linking obesity to 
OA, in particular leptin which has been identified in OA cartilage. It appears to act 
as a catabolic factor in cartilage metabolism through induction of MMPs [99]. Other 
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proinflammatory cytokines including TNF-α and IL-1 are thought to act on 
chondrocytes and upregulate catabolic processes which are degenerative to the 
ECM. It is clear that the pathogenesis of OA is linked to a myriad of factors, and 
while this presents a significant number of targets for potential therapeutic 
intervention, without a clear understanding of which factors trigger OA initiation it 
may be a long time before an effective treatment is available. 
 
1.6.3 Relationship between OA and AKU 
The pathogenesis of both OA and AKU are still yet to be fully understood. Advances 
have been made in elucidating the mechanisms behind the initiation and 
progression of both disorders however more work is needed in this area. Although 
the exact mechanisms behind both disorders are still unknown, there is little doubt 
that OA and AKU are very closely linked to one another. Early onset of severe 
osteoarthropathy is the most devastating consequence that AKU patients suffer. 
Beginning in the third and fourth decade of life, AKU patients begin to suffer 
excruciating pain resulting from joint damage caused by deposition of ochronotic 
pigment. Studies have shown ochronotic joints, obtained at the time of joint 
replacement surgeries, to be severely osteoarthritic with cartilage erosion visible 
macroscopically. Microscopic examination of AKU joints has shown further signs of 
an extreme OA phenotype with complete resorption of the SCB seen in some 
samples [36]. Similar to OA initiation and progression, both the ACC and SCB appear 
to play a role in the initiation and progression of ochronotic osteoarthropathy [36, 
84, 100] highlighting the close association between the two disorders. Studying the 
extreme phenotypes of OA seen in AKU may help elucidate mechanisms behind 
joint destruction and help to identify potential therapeutic targets. 
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1.7 ANIMAL MODELS OF DISEASE 
1.7.1 Importance 
Animal experimentation has long been used by the scientific community. Although 
the use of animals remains controversial, particularly in predicting the effectiveness 
of treatments in clinical trials [101, 102], they are important research tools in aiding 
the understanding of disease pathology. Although not every treatment tested in 
animals is successful in clinical trials, there are examples of treatments which found 
success after being first trialled in animals. One of the most well-known cases was 
the development of penicillin as a treatment for bacterial infections. Although 
initially discovered by Alexander Fleming, it was Howard Florey and Ernst Chain 
who showed that mice which had been infected with a lethal amount of bacteria, 
survived when given penicillin [103, 104]. This demonstrated that penicillin was 
effective against serious bacterial infections and led to the mass production and use 
of the drug. Although other animals are used, rodents are the primary animal 
model used to study disease pathogenesis and potential therapeutics, particularly 
since the development of transgenic mice [105, 106]. Mice share more than 98% of 
their DNA with humans making them an excellent model to study disease in. 
Knockout mice, which are engineered to contain defective genes, are the most 
common type of animal used for research purposes. Disorders including heart 
disease, diabetes, obesity, Alzheimer’s, and arthritis have all been studied in 
transgenic mice. Without these models of disease it would be difficult to 
understand the basic mechanisms behind initiation and progression, and to identify 
potential targets for therapeutic intervention. 
 
1.7.2 AKU animal models 
There have been many reports of spontaneous AKU developing in animals including 
horses, dogs, macaques, chimpanzees, and orang-utans, however ochronosis was 
rarely documented in these animals [107, 108]. Early attempts to induce AKU in an 
animal model was undertaken by Moran and colleagues who injected HGA into 
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rabbits [109]. The animals receiving HGA through intra-articular injections exhibited 
darkening of the urine and developed joint damage while the animals receiving 
HGA through intraperitoneal or intravenous routes did not display signs of 
ochronosis. The first mouse model of AKU was developed in 1994 by Montagutelli 
and colleagues at the Pasteur Institute in Paris [110]. Although the mice had high 
circulating levels of HGA, and displayed darkening of their urine the authors did not 
observe any ochronotic lesions in the joints. They hypothesized this was a result of 
endogenous production of ascorbic acid by the mice which prevented 
polymerization of HGA [110]. Ochronosis has since been observed in a second 
murine model of AKU, originally used to study HT-1 [111]. These mice required 
nitisinone to survive however when it was removed a very small proportion 
underwent a spontaneous loss of heterozygosity of Hgd in their liver nodules to 
become Hgd-/-, effectively making them AKU mice. Severe renal pathology was also 
observed in the mice making them unsuitable for investigative study. Chapter 3 of 
this thesis details the use of a novel staining method to identify ochronotic 
pigmentation, and to document the natural history of the disorder in Hgd-/- mice. 
 
1.7.3 Mouse models of OA 
As previously discussed OA is a debilitating condition for which there is currently no 
effective therapy. The aetiology of the disease also remains unclear making it 
difficult to identify any possible targets for therapeutic intervention. The use of 
mouse models to study OA is becoming increasingly wide-spread as they allow for 
the investigation of pathological changes in OA joints in a relatively short period of 
time. The anatomy of the mouse knee in particular is ideal for identifying OA 
changes as the entire tibio-femoral joint can be analysed in a single histological 
section (Fig. 1.5). Cartilage degradation is localized to the lateral femoral condyle 
(LFC), medial femoral condyle (MFC), lateral tibial plateau (LTP), and the medial 
tibial plateau (MTP). Ossification of the lateral and medial menisci (LM & MM) can 
occur in osteoarthritic joints. Any damage caused to the anterior and/or posterior 
cruciate ligaments (ACL & PCL) almost inevitably leads to the onset of OA. 
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There are a range of mouse models used to study OA, including C57BL/6 and 
STR/ort strains [112, 113] which develop spontaneous OA throughout their lifetime. 
Genetic mouse models of OA are commonly used as they allow researchers to 
identify the roles of specific genes in the disorder. The production of MMPs, which 
lead to breakdown of the ECM, is regulated by their endogenous inhibitors, tissue 
inhibitors of metalloproteinases (TIMP). TIMP-3 null mice exhibit mild cartilage 
degradation, and show elevated levels of aggrecan and type II collagen cleavage 
products in the articular cartilage [114]. Mice overexpressing MMP-13 have been 
shown to have increased cartilage degradation at an early age [115]. The mice also 
Figure 1.5 – Anatomy of the mouse knee joint. H&E staining of a single coronal 
section encompassing the entire tibio-femoral joint. The four main areas of the 
tibio-femoral joint are the; LFC, MFC, LTP, and MTP. These areas are most affected 
by the onset of OA. The LM and MM provide protection during movement and 
help disperse weight throughout the joint. Stability in the joint is provided by the 
ACL and PCL. The EP forms during endochondral ossification.  
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show high levels of type X collagen expression in HAC suggesting that the 
chondrocytes in these areas are expressing a different, and abnormal phenotype. 
Mice deficient for fibroblast growth factor (FGF) receptor-3 have also been shown 
to develop early onset OA [116].  
 
Surgical induction of OA in mice is also routinely used as it allows for rapid 
development of moderate to severe OA. Kamekura et al described four surgical 
models of OA in mice including complete transection of the ACL and MM [117]. 
Different stages of OA were reported for all four models including cartilage 
degradation and SCB erosion. Glasson and colleagues introduced another surgical 
model of OA in mice known as destabilization of the medial meniscus (DMM) [118]. 
DMM is now the preferred method of inducing OA in mice as changes in the joint 
can be classified into mild, moderate, and severe depending on the time course of 
the experiment. The DMM model also showed more severe histological changes in 
the cartilage than the models developed by Kamekura [118]. 
 
Although treatment options for OA are currently limited, the availability of mouse 
models with different stages of OA is important for the testing of any potential 
treatments. Recently mice with surgically induced OA, resulting from ACL 
transection, showed no cartilage degradation due to inhibition of transforming 
growth factor (TGF) β1 by an anti-TGF-β1 antibody. Not only did this show that TGF-
β1 appeared to be involved in the pathological changes related to OA, but also that 
mouse models of OA are important and help develop understanding of the 
pathogenesis of the disorder, as well as providing a model on which to try new and 
potentially effective therapeutics. 
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1.8 AIMS OF THE STUDY 
Although progress has been made in understanding the mechanisms behind the 
initiation and progression of AKU, research is limited to samples obtained from joint 
replacement surgeries, which usually show advanced ochronosis. Without an 
established animal model of AKU there is little opportunity to study the progression 
of the disease, and therefore understand its pathogenesis. It also prevents the 
testing of any potential therapeutics of which there are currently none widely 
available to treat AKU. The main aims of this thesis were therefore to try and 
identify if Hgd-/- mice became pigmented and exhibited signs of ochronotic 
osteoarthropathy, and to test the efficacy of a potential therapy in preventing 
deposition of ochronotic pigment.  
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2. Materials and Methods 
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2.1 ETHICAL APPROVAL 
2.1.1 Mouse tissue 
All mouse tissue used in this project was obtained under ethical approval from the 
Home Office in accordance with their UK guidelines. Under the Animals (Scientific 
Procedures) Act 1986, a project license granted to Professor Jonathan Jarvis and a 
personal license (PIL. 40/9710) granted to Craig Keenan allowed for the completion 
of experiments, Schedule 1 humane killing of mice and use of their tissue for 
analysis.  
 
2.2 MOUSE HUSBANDRY 
All mice were housed and maintained within the University of Liverpool’s Biological 
Services Unit (BSU) in accordance with Home Office UK guidelines. They had full 
access to drinking water and food, and were kept in a hygienic environment. 
Cleaning of cages and changes of bedding was carried out on a daily basis. 
 
2.3 MOUSE BREEDING, GENOTYPING AND TREATMENTS 
2.3.1 Breeding 
2.3.1.1 BALB/c Hgd-/- 
Four Hgd-/- (AKU) mouse breeding pairs on a BALB/c background strain were 
obtained from Dr. X Montagutelli (Pasteur Institute, France) and a colony was 
established at the University of Liverpool, UK. Control wild type (WT) BALB/c J mice 
were purchased from Charles River Laboratories, UK.  
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2.3.1.2 BL/6 Hgd-/- 
HgdFah (Hgd+/-, Fah-/-) mice on a BL/6 background strain were crossed with WT 
BL/6 mice and their offspring genotyped. Any resulting Hgd+/-, Fah+/- were 
interbred to eventually yield Hgd-/-, Fah+/+ (AKU) mice on the BL/6 background. 
 
2.3.2 Genotyping 
2.3.2.1 Hgd  
Genomic DNA was extracted from tail tips using DNeasy Blood and Tissue kits 
(Qiagen, UK), and the Hgd gene typed as previously described [119] with slight 
modifications. Primer sequences were:  
 forward primer 5’-CATTTTCACCGTGCTGACTG-3’ 
 reverse primer 5’-TTTAGTCGCTGCATCACCTG-3’ 
 A 25µl PCR reaction mix contained 12.5µl of HotStarTaq Mastermix (Qiagen, UK), 
1µl of each 100mM primer stock, 2µl of DNA sample and 8.5μl of water. PCR 
conditions were: 15min at 95°C + 30 cycles (30s at 94°C, 30s at 52°C, 1min at 72°C) 
+ 7min at 72°C. A 1.5µl aliquot of product was digested at 37°C with 0.3µl of 
HpyCH4III, 1.5µl of New England BioLabs Buffer 4 and 11.7µl of water, for at least 
2hrs. Samples were electrophoresed for 30min at 200V on a 3% agarose gel 
containing SybrSafe (Invitrogen, UK). WT samples produced 170bp and 120bp 
digest bands, and mutant samples a nondigested 290bp band.  
 
2.3.2.2 Fah 
Genomic DNA was extracted from tail tips using DNeasy Blood and Tissue kits 
(Qiagen, UK), and the Fah gene typed as follows. Primer sequences were:  
 forward primer 5’- GGATTGGGAAGACAATAGCAGGC-3’  
 reverse primer 5’-TTGCCTCTGAACATAATGCCAAC-3’  
 WT primer 5’-TGAGAGGAGGGTACTGGCAGCTAC-3’  
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A 25µl PCR reaction mix contained 12.5µl of HotStarTaq Mastermix (Qiagen, UK), 
0.25µl of mutant primer, 0.5µl of reverse primer, 0.5µl of WT primer, 2µl of DNA 
sample and 9.25µl of water. PCR conditions were: 15min at 95°C + 30 cycles (30s at 
94°C, 30s at 52°C, 1min at 72°C) + 7min at 72°C. Samples were electrophoresed for 
30min at 200V on a 3% agarose gel containing SybrSafe (Invitrogen, UK). WT 
samples produced a 250bp band, and mutant samples a 145bp band. 
 
2.3.3 Treatments 
2.3.3.1 Nitisinone – whole life 
A cohort of 16 BALB/c Hgd-/- mice (eight male, eight female) were provided with an 
ad libitum supply of water containing 4mg/l of nitisinone (Shanghai Elittes Organics, 
China) from 8 to 67 weeks of age. The control group of 16 BALB/c Hgd-/- mice (nine 
male, seven female) had no drug in their drinking water from 11 to 70 weeks of age. 
Plasma was taken immediately prior to treatment, and then sampled regularly by 
tail bleed over the mouse lifetime. 
 
2.3.3.2 Nitisinone – mid-life 
A cohort of 8 BALB/c Hgd-/- mice (four male, four female) were provided with 
filtered water from 8 to 34 weeks of age. They were then provided with an ad 
libitum supply of water containing 4mg/l of nitisinone from 35 to 80 weeks of age. 
The control group of 8 BALB/c Hgd-/- mice (four male, four female) had no drug in 
their drinking water from 8 to 80 weeks of age. Plasma was taken immediately prior 
to treatment, and then sampled regularly by tail bleed over the mouse lifetime. 
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2.3.3.3 HGA supplementation 
A cohort of 10 BL/6 Hgd-/- mice (five male, five female) were provided with an ad 
libitum supply of water containing 5mM of HGA from 8 to 74 weeks of age. The 
control group of 10 BL/6 Hgd-/- mice (five male, five female) had no HGA in their 
drinking water from 8 to 72 weeks of age. Plasma was taken immediately prior to 
treatment, and then sampled regularly by tail bleed over the mouse lifetime. 
 
2.4 MURINE SURGERY 
2.4.1 Regulation of surgical procedure 
Before surgery was performed approval was required from the Home Office to 
allow the procedure to be carried out. Both the project license and personal license 
were amended to include the surgical procedure(s) once it had been approved by 
the Home Office under the Animals (Scientific Procedures) Act 1986. 
 
2.4.2 Surgical preparation 
2.4.2.1 Suiting up and scrubbing of surgeons 
All surgical procedures were carried in collaboration with Dr. Hazel Sutherland who 
has extensive experience of performing animal surgery. Upon entering the BSU 
surgical scrubs, gloves, a mop cap and a facemask were required to be put on 
before carrying out any preparation work. Scrubbing with a disinfectant and 
dressing in sterile gowns and gloves were required before surgery was performed. 
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2.4.2.2 Instrument preparation 
All instruments were washed, wrapped and sterilised in a large oven prior to being 
used in surgery. A range of different sizes of surgical scissors and fine forceps were 
sterilised to ensure enough instruments were available to complete the surgery. 
 
2.4.2.3 Anaesthesia 
Prior to surgery the mice were anaesthetised. Inhalation anaesthetics were used as 
it allowed for a constant plane of anaesthesia to be maintained during surgery 
compared with injectable anaesthetics. The mice were anaesthetised using a 
combination of Isoflurane, NO2, and O2. The level of anaesthesia required by the 
mice varied which was usually due to weight differences between them. Mice 
weighing more than 30g tended to take longer to become fully anaesthetised and 
typically required a higher amount of Isoflurane (1.5-2.0%). Levels of NO2 and O2 
were always maintained at 1.5% regardless of the weight of the mice. The amount 
of Isoflurane administered never went above 2.0% as this can cause terminal 
anaesthesia. During surgery, the mice were kept anaesthetised with the same level 
of Isoflurane required to initially anaesthetise them. The body temperature of the 
mice was also closely monitored; if a drop in temperature was recorded a heat mat 
was introduced to help maintain body temperature at 37oC. 
 
2.4.2.4 Site of surgery preparation 
Once anaesthetised, the mice were prepped for surgery. Baytril (Enrofloxacin), an 
antibiotic, was administered subcutaneously at a dose of 5mg/kg (diluted in 
distilled water). Temgesic (Buprenorphine), an analgesic, was administered 
intramuscularly into the rectus femoris muscle at a dose of 0.1mg/kg (diluted in 
distilled water). The area of interest was then shaved and sterilised with iodine. 
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2.4.3 Destabilization of the medial meniscus  
2.4.3.1 General information 
DMM is a procedure introduced by by Dr S Glasson et al [118] to induce a mild to 
moderate form of OA in mice. The procedure requires the transection of the medial 
meniscotibial ligament (MMTL) to free the MM from the tibial plateau (TP). This 
prevents the meniscus from distributing the body’s weight load causing increased 
mechanical stress and a higher risk of injury. The procedure was followed from the 
original publication and adapted where necessary. 
 
2.4.3.2 DMM procedure 
Using surgical scissors the skin of the left hind limb was incised over the patella and 
patella ligament to expose the knee joint. Micro surgical scissors were then used to 
make a small incision medial to the patella ligament, and small amounts of fat 
removed with blunt dissection. This was frequently followed by bleeding which was 
stemmed with a cotton bud, while saline was used to keep the joint moist. 
Identification of the MMTL proved to be difficult in BALB/c Hgd-/- mice as the 
ligament seemed to be almost translucent. As the MM was easier to identify it was 
used as a guide to determine where the MMTL attached on both the MM and the 
TP. Once definitively identified the MMTL was transected using micro surgical 
scissors. The ability to push the MM in and out of the joint cavity was used as 
confirmation the MMTL had been transected and the surgery had been successful. 
The incision in the patella ligament was sutured with a running stitch using 7.0 
proline and the skin sutured with a subcutaneous stitch using 6.0 proline. The mice 
were then immediately transferred to the post-operative recovery room. 
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2.4.4 Post-operative recovery 
Immediately following surgery the mice were placed in a heated room where a 
temperature of 25oC was maintained to aid their recovery. A second dose of 
temgesic was administered to help with pain relief. Once the mice had been 
returned to the BSU they were examined on a daily basis to ensure the surgical 
wound was healing properly. The general health of the mice was also checked as 
surgery can often cause a delayed adverse reaction. Restricted movement, weight 
loss and lack of grooming are known signs of abnormality and were therefore 
checked. If none of these were apparent upon examination of the mice they were 
classed as healthy. 
 
2.4.5 Humane killing of animals using schedule 1 procedures 
2.4.5.1 General information 
All mice were humanely killed using Schedule 1 procedures in accordance with 
Home Office UK guidelines under the Animals (Scientific Procedures) Act 1986. 
 
2.4.5.2 Overdose of an anaesthetic 
Mice were euthanized by a lethal dose of pentoject (sodium pentobarbitone 20% 
w/v) prompting a rapid loss of consciousness. Pentoject was administered 
intraperitoneally to minimise any distress. 
 
2.4.5.3 Concussion of the brain and dislocation of the neck 
Concussion was caused by striking the cranium of the mice against the edge of the 
worktop with sufficient force to cause immediate loss of consciousness and/or 
death. After loss of consciousness was induced, death was confirmed by neck 
dislocation. 
38 
 
2.4.6 Dissection and harvesting of tissue 
2.4.6.1 General information 
Once death had been confirmed the mice were dissected either immediately in the 
BSU or later in the same day in the histology laboratory. It was imperative to collect 
the tissue on the day of death to prevent autolysis and necrosis. Tissues collected 
were fixed in either 10% phosphate buffered formalin solution (PBFS) for 
histological analysis, or 2.5% glutaraldehyde for ultrastructural analysis. 
 
2.4.6.2 Harvesting of tissue 
2.4.6.2.1 Hind limb 
The skin was removed from the hind limbs exposing the full anatomy of the joint. 
The majority of the muscle was dissected away and the joint was dissected out by 
severing close to the femoral head which allowed for removal of the whole hind 
limb. The tibia was then severed just above the ankle to leave an intact knee joint. 
After washing in phosphate buffered saline (PBS) the limbs were fixed for analysis. 
 
2.4.6.2.2 Heart 
An incision was made into the skin of the mice to allow visualisation of the thoracic 
cavity which was subsequently opened by cutting through the sternum with surgical 
scissors. The heart was pried away from its surrounding connective tissue and was 
removed with its major vessels intact. The heart was washed with PBS to remove 
excess blood before fixation. 
 
2.4.6.2.3 Liver and Kidneys 
The liver was dissected out of the abdominal cavity ensuring none of the lobes were 
damaged. Once removed, the liver was washed in PBS and small sections of each 
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lobe were taken to allow for easy fixation and analysis. The kidneys were exposed 
after removal of the liver. They were dissected out of the abdominal cavity, washed 
in PBS and sectioned in half to allow for easy fixation and analysis. 
  
2.4.7 Fixation of carcass 
After the tissue(s) had been harvested the viscera (guts) were removed and 
discarded. The carcass was fixed in 150ml of PBFS to ensure adequate fixation. The 
fixing solution was changed after 24hrs and again if it altered colour as this 
indicated the solution had become acidic. 
 
2.5 HISTOLOGY 
2.5.1 Reagents 
Haematoxylin, eosin, potassium ferricyanide, ferric chloride, and nuclear fast red 
(NFR) were purchased from VWR, UK. Ethylenediaminetetraacetic acid (EDTA), 
chromic potassium sulphate, bovine gelatine and DPX microscopy mountant were 
purchased from Sigma, UK. Premium frosted glass slides and 50mm cover slips were 
purchased from VWR, UK. 
 
2.5.2 Fixation of tissues 
2.5.2.1 General information 
Fixation is a chemical process which prevents biological tissue from undergoing 
autolysis and necrosis. Fixation stops any ongoing biochemical reactions leaving the 
tissue in a life-like state. Tissues harvested were fixed in 10% PBFS solution. 
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2.5.2.2 Preparation of fixative 
PBFS (2.5L) was made up as follows: - 
 250ml of Formaldehyde (37% w/v) 
 250ml of PBS (10x) 
 2000ml distilled water 
 Mixed well  
 pH adjusted to 7.2–7.4, if required a small amount of HCl (1M) was added 
 
2.5.2.3 Fixation procedure 
Once harvested the tissues were immediately placed in PBFS to prevent autolysis. 
The amount of fixative used was generally 15-20 times greater than the tissue 
volume. Fixation was carried out at room temperature for 24hrs. 
  
2.5.3 Decalcification of mineralized tissue 
2.5.3.1 General information 
Decalcification is the process of removing calcium from mineralized tissue. 
Decalcification was performed using 12% EDTA, a chelating agent that binds 
calcium thus allowing the tissue to decalcify. 
 
2.5.3.2 Preparation of decalcifying solution 
Mineralised tissues were decalcified using 12% EDTA. EDTA (2.5L) was made up as 
follows: - 
 300g of EDTA 
 2000ml distilled water 
 A few drops of phenol red indicator were added and solution mixed 
 pH needed to be maintained at 8 to dissolve EDTA (NaOH pellets)  
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 Once dissolved pH was adjusted to 7.2–7.4 using concentrated HCl 
 Solution was made up to a final volume of 2500ml 
 
2.5.3.3 Decalcification procedure 
Following fixation, mineralized tissues were placed into EDTA for an initial period of 
24hrs. The EDTA solution was then changed and tissues were left to decalcify for a 
further 6 days (7 days total). Decalcification was complete when tissues were 
flexible and soft enough to bend. 
 
2.5.4 Processing of tissue 
Following decalcification tissues were removed from EDTA and washed several 
times with PBS. Tissues were processed first through increasing grades of ethanol 
(70% (15mins), 90% (30mins), and 100% (x4) (1hr)) to dehydrate the tissue. Once 
dehydrated, tissues were cleared using two changes of xylene (45 minutes in each) 
before being passed through two changes of paraffin wax (1hr in each) to complete 
the processing. Processing was performed using a Leica TP1020 tissue processor 
(Leica, Germany). 
 
2.5.5 Embedding of tissue 
Following processing, tissues were placed into heated metallic moulds, submerged 
in molten paraffin wax and embedded in an orientation which allowed for 
sectioning of the area of interest. Knee joints from all mice were embedded in the 
coronal plane to enable simultaneous evaluation of the medial and lateral tibio-
femoral joint as recommended by the Osteoarthritis Research Society International 
(OARSI) histopathology initiative [120]. A plastic chuck was placed on top of the 
mould to allow sectioning of the block. Tissue blocks were cooled to solidify and 
then removed from their metallic mould. 
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2.5.6 Sectioning of tissue 
Tissue blocks were cut to remove excess wax, and shaped to have a trapezoid 
cutting surface. Blocks were initially trimmed at 10µm until the tissue could be seen 
coming through the block. Sections were then taken every 5µm before being 
mounted on subbed slides and placed in an incubator at 50oC overnight. Sections 
from the knee joints of all mice were taken every 5µm from posterior to anterior 
until the whole joint had been sectioned. Blocks were sectioned using a Leica 
RM2245 semi-automated microtome (Leica, Germany). 
 
2.5.7 Subbing of slides 
2.5.7.1 General information 
Microscope slides were subbed with a gelatine solution to help sections adhere to 
the slide. 
 
2.5.7.2 Subbing solution 
 400ml distilled water 
 0.8g type B bovine gelatine  
 Gelatine dissolved in distilled water with heat – NOT EXCEEDING 50oC 
 0.08g chromic potassium sulphate added when gelatine dissolved  
 
2.5.7.3 Subbing procedure 
 Slides rinsed in 100% ethanol for 30 seconds 
 Left to dry for 5 minutes 
 Slides then immersed in subbing solution for 30 seconds 
 Dried overnight at room temperature – cover slides to prevent dust building up 
 
 
43 
 
2.5.8 Staining of tissue 
2.5.8.1 Haematoxylin and eosin 
Haematoxylin and eosin (H&E) is the standard dye used in histology to show the 
gross anatomy of tissues. Haematoxylin stains cell nuclei dark blue whereas eosin 
stains proteins pink, therefore muscle fibres and connective tissue stain varying 
shades of pink. There are a number of different haematoxylins which can be used in 
combination with eosin for staining, each having their own advantages and 
disadvantages. For the purposes of this research Ehrlich’s haematoxylin was used as 
it has the ability to show the cartilaginous elements of tissue as blue/purple, due to 
the staining of GAGs, in contrast to the pink of collagenous tissue [121]. 
 
2.5.8.1.1 Stock solutions 
 Ehrlich’s haematoxylin (ripened) 
 Eosin (1%) 
 Concentrated HCl 
 
2.5.8.1.2 Staining procedure 
 Slides were deparaffinised in two changes of xylene - 5 minutes in each 
 Hydrated through ethanol (100%, 100%, 70%, 70% - 2 minutes in each) to water 
 Stained in haematoxylin for 2-3 minutes 
 Washed in running warm water for 3 minutes 
 Dipped in 1% HCl for 10-15 seconds to remove residual haematoxylin 
 Washed vigorously in running cold water for 5 minutes 
 Counterstained in eosin for 1-2 minutes 
 Dipped in running cold tap water for 10 seconds to remove residual eosin 
 Dehydrated through ethanol (70%, 70%, 100%, 100% - 2 minutes in each) 
 Cleared in two changes of xylene - 3 minutes in each 
 Mounted with DPX and left to dry 
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2.5.8.2 Schmorl’s stain 
Schmorl’s stain is generally used to test for the presence of late lipofuscins and 
melanin in cells. These compounds reduce ferricyanide to ferrocyanide, producing 
varying shades of blue with a positive result. As Schmorl’s stain is used to stain 
melanin it was theorised it could, in principal, be used to stain for ochronotic 
pigment as both compounds are thought to have similar structures and are derived 
from the tyrosine catabolic pathway. By modifying the procedure to include a 
longer incubation time, Schmorl’s stain has been shown to identify the presence of 
ochronotic pigmentation in murine and human tissues [122].  
 
2.5.8.2.1 Incubating solution 
 1% Ferric chloride – 37.5ml 
 1% Potassium ferricyanide – 5ml 
 Distilled water – 7.5ml 
 
2.5.8.2.2 Staining procedure 
 Slides were deparaffinised in two changes of xylene - 5 minutes in each 
 Hydrated through ethanol (100%, 100%, 70%, 70% - 2 minutes in each) to water 
 Immersed in Schmorl’s stain for  up to 15 minutes 
 Washed well in running cold water to remove any residual ferricyanide 
 Treated with 1% acetic acid for 5 minutes to prevent over-staining 
 Counterstained in NFR for 3-5 minutes 
 Washed in running cold water to remove any residual NFR 
 Dehydrated through ethanol (70%, 70%, 100%, 100% - 2 minutes in each) 
 Cleared in two changes of xylene - 3 minutes in each 
 Mounted with DPX and left to dry 
  
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2.5.9 Quantification of pigmented chondrons in the tibio-femoral joint 
The first whole section that encompassed the entire tibio-femoral joint (MTP, MFC, 
LTP, & LFC) was selected as representative of each mouse for quantification 
analysis. From these sections, pigmented chondrons present in the articular 
cartilage and entheses of the femoral condyles and articular cartilage of the TP 
were quantified (Fig. 2.1). 
 
 
 
 
 
 
Figure 2.1 – Areas of quantification in the tibio-femoral joint of Hgd-/- mice. The 
red lines on the image highlight the areas where pigmented chondrons were 
quantified in the tibio-femoral joint (* = entheses). Bar = 50µm. 
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2.5.10 Light microscopy analysis 
Analysis of all tissues used for histology was performed using light microscopy. Two 
different microscopes were used in this thesis, one being a Nikon Eclipse Ci 
microscope fitted with a Ds-Fi2 camera and the other a Zeiss Axio Imager 2 
microscope. The Zeiss Axio Imager 2 was used strictly for acquiring panoramic 
images. NIS Br elements was used for image analysis with the Nikon Eclipse 
microscope. 
 
2.6 STATISTICAL ANALYSIS 
An independent samples t-test was used to identify any significant differences 
between the number of pigmented chondrons in both the control and treated 
groups in the mid-life nitisinone study. A two-tailed, two-sample, unequal variance 
t-test was used to determine any significant differences in plasma HGA 
concentrations of nitisinone-treated mice. A Wilcoxon signed-rank test was used to 
identify any significant differences between the severity of OA in experimental and 
control limbs in the DMM study. A retrospective power calculation was performed 
on both the 8 weeks and 12 weeks post-op groups in the DMM study. This was used 
to determine the required sample size in any future studies. All statistical analysis 
was performed using Stata 13 (StataCorp. 2013. Stata Statistical Software: Release 
13. College Station, TX: StataCorp LP.) and JMP9 (JMP®, Version 9. SAS Institute Inc., 
Cary, NC, 1989-2007). 
  
2.7 TRANSMISSION ELECTRON MICRSCOPY 
2.7.1 Reagents 
Glutaraldehyde, chloroform and acetone were purchased from Sigma, UK. Osmium 
tetroxide, uranyl acetate, and Agar 100 resin were purchased from Agar Scientific, 
UK. Superfrosted microscope slides were purchased from Thermo-Scientific, UK. 
Paraformaldehyde, propylene oxide and 100 mesh hexagonal copper grids were 
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purchased from TAAB, UK. Lead citrate was made from a solution of lead nitrate 
and sodium citrate. Pioloform was purchased from SCI-CHEM, USA. 
 
2.7.2 Preparation of tissue  
Tissues selected for transmission electron microscopy (TEM) analysis were micro-
dissected to give pieces less than 1mm3. Once dissected into manageable sizes the 
samples underwent fixation and decalcification. 
 
2.7.3 Fixation of tissue 
Tissues were fixed in 4% paraformaldehyde with 2.5% glutaraldehyde in 0.1M 
sodium cacodylate (pH 7.4) or 10% PBFS for 24hrs at room temperature. 
 
2.7.4 Decalcification of tissue 
Following fixation, mineralised tissues were placed into EDTA for an initial period of 
24hrs. The EDTA solution was then changed and tissues were left to decalcify for a 
further 6 days (7 days total). Decalcification was complete when tissues were 
flexible and soft enough to bend. 
 
2.7.5 Processing of tissue 
Following decalcification tissues were washed several times with distilled water 
then post-fixed in freshly made 1% osmium tetroxide for 3hrs at room temperature. 
Samples were then washed several times with distilled water before being bloc 
stained in 1% aqueous uranyl acetate for 24hrs at room temperature. Following 
treatment with uranyl acetate samples were dehydrated through ethanol (30%, 
50%, 70%, 90% and 100% (x 4) – each for 10 minutes) on ice, and cleared with 
propylene oxide for 10 minutes. Samples were then infiltrated with Agar 100 resin. 
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2.7.6 Resin infiltration 
Dilutions of resin were made up in propylene oxide. The infiltration of samples with 
resin was as follows: - 
 30% resin for 24hrs at room temperature 
 50% resin for 2hrs at room temperature 
 75% resin for 1hr at room temperature 
 100% resin for 24hrs at room temperature 
 100% resin for 1hr at room temperature 
Samples were then embedded in a resin mould using fresh 100% resin and placed in 
an oven at 60oC for 3 days to polymerize. 
  
2.7.7 Sectioning of tissue 
Blocks were initially trimmed using a glass knife until the section was at the surface. 
A small square (300nm x 300nm x 150nm) was then trimmed to isolate the region 
of interest on the tissue. 70nm sections were cut using a Diatome diamond knife. 
Blocks were sectioned using a Leica EM UC6 ultramicrotome (Leica, Germany). 
 
2.7.8 Preparation of grids 
Plastic coated copper grids were used for the mounting of sections. Large quantities 
of 100 mesh hexagonal copper grids were cleaned with 100% ethanol and acetone 
then left to dry. A 0.3% solution of Pioloform diluted in chloroform was prepared 
fresh to coat the grids. Superfrosted microscope slides were polished with chamois 
leather and wiped clean with lint free tissue before being dipped into the pioloform 
solution for 3-4 seconds. The slides were removed with care to ensure the 
pioloform film had no horizontal lines present and were air dried for 20-30 seconds. 
Once dry a razor blade was used to cut around the edges of the film which was then 
separated free by breathing on both sides of the slide. The slide was slowly lowered 
vertically into a container filled with distilled water to remove the film from either 
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side of the slide. The grids were then placed shiny side up on the film and collected 
on a clean slide by placing the slide at a 90o angle and dropping it straight down 
completely submerging the film. Slides were dried for 24hrs in a condenser. 
 
2.7.9 Post staining of sections 
Post staining of sections was performed using lead citrate and uranyl acetate (5% 
by weight in 50% ethanol and 50% distilled water). Both reagents were spun down 
to reduce precipitation before use. Grids were placed section side down into uranyl 
acetate for 5 minutes then washed in three changes of distilled water for 20 
seconds in each. Grids were then placed section side down in lead citrate for 5 
minutes and again washed with three changes of distilled water for 20 seconds in 
each. Grids were left to dry on filter paper for 24hrs. 
 
2.7.10 TEM analysis 
TEM was performed using an FEI 1210kV Tecnai G2 Spirit BioTWIN electron 
microscope, and all images were captured using an SIS Megaview III camera. 
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3. Natural history of ochronosis in murine models of alkaptonuria 
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3.1 INTRODUCTION 
The first objective of this thesis was to document the natural history of ochronosis 
in Hgd-/- mice. The murine model of AKU was created by Montagutelli and 
colleagues at the Pasteur Institute, Paris [110]. Eight week old mice, from an inbred 
stock carrying seven recessive mutations (agouti (a), brown (tyrosinase related 
protein or Tyrp1), albino (tyrosinase or Tyr), dilute (myosinVa or Myo5a), short ear 
(bone morphogenetic protein 5 or Bmp5), pink-eyed dilution (p), and piebald 
(endothelin receptor type B or Ednrb)) [123, 124], were given a single injection of 
ethylnitrosourea (250mg/kg) intraperitoneally to induce mutagenesis. These mice 
were subsequently mated with 129/Sv-T/+ mice and independent micro-pedigrees 
were achieved by systematic sibling mating for more than 10 generations. The AKU 
mutation (Hgd-/-) was then backcrossed onto BALB/cByj (albino) and C57/BL/6J 
(pigmented) backgrounds. Diagnosis of AKU in the mice was confirmed by 
darkening of the urine when pipetted onto filter paper infused with 0.5M sodium 
hydroxide. Although these mice excreted high levels of HGA in their urine, 
histological studies showed no signs of ochronosis in any of the tissues examined 
(knee, hip, ankle, spine, liver, kidneys and tail) [110].  
 
A second murine model of AKU was discovered by Manning and colleagues in mice 
originally containing the tyrosinemia type 1 mutation (FAH-/-) [125]. These mice 
were used to study HT1 but became ochronotic when crossed with AKU 
heterozygote’s (FAH-/-, Hgd+/-). Nitisinone was administered to the mice to 
prevent HT1, however when removed a very small proportion underwent a 
spontaneous loss of heterozygosity of Hgd in their liver nodules to become Hgd-/-, 
effectively making them AKU mice. Although ochronosis was observed in the knees 
and kidneys of these mice [111], it is not considered a suitable model of AKU as 
ochronosis is caused by a spontaneous mutation and is also associated with severe 
renal pathology, therefore these mice were not used in this study. 
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Montagutelli hypothesised that ochronosis was not observed in his histological 
studies of the Hgd-/- mice due to endogenous production of ascorbic acid which is a 
known antioxidant [110]. It has also been suggested that superior renal function in 
mice prevents the build-up of HGA in plasma, due to high levels of urinary excretion 
[110]. Recent research by Tinti et al [122] has shown that the use of Schmorl’s stain 
can identify the presence of ochronotic pigmentation in tissues at very low levels. 
Schmorl’s stain is routinely used to identify melanins. Ochronotic pigment and 
melanin are believed to be similar structures (cross-linked polymers) and both are 
products of the tyrosine catabolic pathway, which is why it can be used for the 
staining of ochronotic pigment. Using a modified Schmorl’s stain, as a novel method 
to detect ochronosis, the aim of this work was to identify the presence of 
ochronotic pigmentation in Hgd-/- mice and to document its natural history. The 
following Chapter shows the results from these studies in BALB/c and BL/6 mice. 
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3.2 DESIGN OF STUDY 
Twenty nine BALB/c Hgd-/- mice and twenty five BL/6 Hgd-/- mice, covering a wide 
range of ages from 6.5 – 71.7 weeks, were culled and their left knee analysed 
histologically. Once sections had been prepared, they were stained with Schmorl’s 
stain to identify if ochronotic pigmentation was present, and H&E to identify any 
histological changes including signs of osteoarthropathy. 
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3.3 RESULTS 
3.3.1 Histological detection of ochronotic pigment in BALB/c Hgd-/- mice 
BALB/c mice were obtained from Dr X. Montagutelli and a colony set up at the 
University of Liverpool as described in Chapter two. Once weaned, the mice were 
culled at different time points ranging from 6.5 to 65.7 weeks and their knee joints 
analysed histologically. The left knee was used for the experimental studies and was 
sectioned posterior to anterior in each animal.  
 
3.3.1.1 BALB/c Hgd-/- 132.1 (♀), 132.2 (♀), 132.3 (♀) – 6.5 weeks 
The earliest time point looked at for this study was 6.5 weeks. It was central to the 
study to look at a wide range of ages to help identify if pigmentation was present, 
when it initiated and how it progressed. Initial observations from staining of the 
knee joints from all three mice at 6.5 weeks of age showed a complete absence of 
pigmented chondrocytes through the whole joint. This was consistent throughout 
the HAC and ACC of the femur and tibia (Fig. 3.1). 
 
 
 
 
Figure 3.1 - Ochronotic pigmentation was not detectable in a 6.5 week old 
BALB/c Hgd-/- mouse. Schmorl’s staining of BALB/c Hgd-/- 132.2 (♀) showed no 
signs of pigmentation in the HAC or ACC of the (A) LFC and (B) MFC. Bar = 20µm. 
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Three BALB/c Hgd-/- mice (129.2 (♂), 131.1 (♂), 131.2 (♂)) aged 7.8 weeks showed 
no pigmented chondrons with Schmorl’s staining. No images are shown as they are 
identical to the mice aged 6.5 weeks above. 
 
3.3.1.2 BALB/c Hgd-/- 93.2 (♂), 94.1 (♀) – 15.7 weeks 
The third time point analysed was 15.7 weeks with two mice, one male and one 
female, being culled at this age. Schmorl’s staining identified ochronotic pigment 
deposited in the PCM of a small number of chondrocytes in both the femur and 
tibia of both mice. This was the first time pigmentation of chondrocytes or their 
matrices had been seen in Hgd-/- mice. The pigmented chondrons were localized to 
the ACC (Fig. 3.2). 
 
 
 
 
Figure 3.2 – Initial appearance of pigmentation in a 15.7 week old BALB/c Hgd-
/- mouse. Schmorl’s staining of BALB/c Hgd-/- 94.1 (♀) showed the appearance 
of a ‘halo’ around a small number of chondrocytes in the ACC of the MFC. Bar = 
10µm. 
 
56 
 
The identification of PCM pigmentation around individual chondrocytes in the ACC 
was significant as it showed that Hgd-/- mice do become pigmented and display 
symptoms of ochronosis, contrary to early published data [110]. Identification of 
the pigment also showed that Schmorl’s stain was an effective method of 
identifying ochronosis in mice as it is in humans.  
 
There did appear to be an increase in the number of hypertrophic chondrocytes 
(Fig. 3.2), from around eight to twenty, when compared to the mice of 6.5 (Fig. 3.1) 
and 7.8 weeks of age. Chondrocyte hypertrophy occurs naturally during 
endochondral ossification allowing for calcification of the matrix, leading to the 
formation of bone in developing mouse embryos. Increased calcification is 
characteristic of joints which are developing OA. It is possible that the increased 
chondrocyte hypertrophy seen in BALB/c Hgd-/- 94.1 (15.7 weeks) is related to the 
early initiation of OA, a known side effect from ochronosis, however it is likely to be 
due to chondroptosis and active turnover of the cartilage and its matrix by the 
chondrocytes. Two males aged 19.6 weeks (data not shown) displayed an increase 
in the number of pigmented chondrocytes compared to those from mice aged 15.7 
weeks (Fig. 3.18). 
  
3.3.1.3 BALB/c Hgd-/- 106.1 (♀), 106.2 (♀), 106.3 (♀) – 23.5 weeks 
Having identified pigmentation of the PCM in mice at 15.7 weeks of age, the next 
objective was to see how pigmentation of chondrocytes progressed throughout the 
tibio-femoral joint. Ochronosis is thought to become progressively more severe 
with age in humans, ultimately leading to the destruction of load bearing joints.  
 
It was apparent straightaway that all of the mice had a significant increase in the 
number of pigmented chondrocytes in comparison to younger mice which had been 
examined (Fig. 3.18). All three mice showed pericellular pigmentation but also, and 
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more importantly, cellular pigmentation (Fig. 3.3). The progression of pigmentation 
to the cell itself is characteristic of ochronotic chondrons in humans. 
  
 
 
 
 
 
 
Analysis of two females aged 25.2 weeks (data not shown), showed slightly lower 
numbers of pigmented chondrons, 37 and 32 respectively, to those seen in BALB/c 
Hgd-/- 106.1, 106.2 and 106.3 who were 23.5 weeks (76, 53 and 33 respectively) 
(Fig. 3.18). 
 
Figure 3.3 – Advancement of pigmentation to cellular compartment of 
chondrons in a 23.5 week old BALB/c Hgd-/- mouse. Schmorl’s staining of 
BALB/c Hgd-/- 106.1 (♀) showed the spread of pigmentation from the PCM to 
the cell itself (arrows). This observation was consistent with the progression of 
ochronosis in human tissue samples. Bar = 20µm. 
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3.3.1.4 BALB/c Hgd-/- 99.1 (♂), 99.2 (♂) – 27.4 weeks 
BALB/c Hgd-/- 99.1 (♂) and 99.2 (♂) (27.4 weeks) both showed pigmented 
chondrons in the ACC as expected, with some accompanying signs of 
osteoarthropathy (Fig. 3.4). 
 
 
 
 
 
 
 
The numbers of pigmented chondrons present in BALB/c Hgd-/- 99.1 (♂) and 99.2 
(♂) was consistent with the numbers seen in BALB/c 106.1 (♀), 106.2 (♀), 106.3 (♀) 
(23.5 weeks) and BALB/c Hgd-/- 86.1 (♀) and 86.2 (♀) (25.2 weeks) (Fig. 3.18). With 
Figure 3.4 – Ochronotic pigmentation in a 27.4 week old BALB/c Hgd-/- mouse 
with accompanying early signs of osteoarthropathy. H&E staining revealed 
duplicate tidemarks located in the LFC (A) and the LTP (B, red arrows) of BALB/c 
Hgd-/- 99.1 (♂). Schmorl’s staining showed pigmented chondrons in the LFC (C) 
showed varying degrees of staining. Pigmentation was present in clusters of 
chondrons in the LFC (C) and in individual chondrons in the MFC (D). Bar = 20µm. 
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only a four week age difference between the three sets of mice and with them all 
being still relatively young, it is not surprising that the amount of pigmented 
chondrons are fairly similar and quite low. This most likely indicates that although 
the mice have AKU, it is still at an early stage and has not yet manifested into the 
severe ochronotic osteoarthropathy which is seen in the third and fourth decades 
of life in humans. Certain chondrons appeared to be more ochronotic than 
surrounding cells (Fig. 3.4 (C & D)). This is an interesting observation as these 
chondrons clearly appear to be significantly more damaged than some of their 
neighbours, but with no obvious reason as to why this is the case. The presence of 
duplicate tidemarks in the LFC (Fig. 3.4 (A)) and LTP (Fig. 3.4 (B)) along with an 
increasing number of hypertrophic chondrocytes in the ACC are signs of 
osteoarthritic changes. Tidemark duplication is an recognised sign of OA [126] and 
is associated with increased mineralization of the cartilage. The identification of 
tidemark duplication in BALB/c Hgd-/- mice is significant as the early onset of OA is 
a well-known side effect resulting from AKU.  
 
3.3.1.5 BALB/c Hgd-/- 92.1 (♂), 92.2 (♂) – 30.9 weeks  
BALB/c Hgd-/- 92.1 (♂) and 92.2 (♂) displayed similar traits to the previous mice. 
Both showed chondron pigmentation in the ACC and duplication of the tidemark in 
the femoral and tibial condyles. BALB/c Hgd-/- 92.2 (♂) also showed signs of SCB 
remodelling and projection of the SCB into the articular cartilage (Fig. 3.5). 
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The number of pigmented chondrons present in BALB/c Hgd-/- 92.1 (♂) and 92.2 
(♂) (30.9 weeks) was slightly increased compared to the younger mice examined 
(Fig. 3.18). Both mice showed different stages of chondron pigmentation within the 
same region, with some cells showing only peri-cellular pigmentation while other 
cells were fully pyknotic. BALB/c Hgd-/- 92.2 displayed signs of SCB remodelling in 
the MFC. Projection of SCB into the ACC and its subsequent vascularisation was also 
observed in the same condyle. Both remodelling of the SCB and vascularisation of 
Figure 3.5 – Ochronotic pigmentation in 30.9 week old BALB/c Hgd-/- mice 
with signs of subchondral bone remodelling and projection of the subchondral 
bone into the articular calcified cartilage. Schmorl’s staining of BALB/c Hgd-/- 
92.1 (♂) showed pigmented chondrons in the LFC (A & B). Some chondrons 
appeared to be fully pigmented while others (arrowed) showed only pericellular 
pigmentation. H&E staining revealed SCB remodelling in the MFC of BALB/c 
Hgd-/- 92.2 (♂) (C, right arrow). Vascularisation of the ACC in the MFC was also 
observed (C, left arrow & D). Bar = 20µm. 
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the ACC are indications of OA, as is the presence of duplicate tidemarks which were 
also observed in both mice.  
 
Two males, BALB/c Hgd-/- 91.1 (♂) and BALB/c Hgd-/- 91.2 (♂), aged 34.4 weeks 
(data not shown) displayed similar results to BALB/c Hgd-/- 92.1 (♂) and 92.2(♂) 
(30.9 weeks). The number of pigmented chondrons throughout the tibio-femoral 
joint was comparable with that seen in BALB/c Hgd-/- 92.1 and 92.2 (Fig. 3.18), as 
was the progression of chondron pigmentation in the ACC. While no damage or 
degradation to the surface of the articular cartilage was seen, there was tidemark 
duplication and some SCB remodelling present in both mice. The amount of 
pigmentation and the osteoarthritic changes in the cartilage were consistent with 
what had previously been seen in Hgd-/- mice of similar ages. 
 
3.3.1.6 BALB/c Hgd-/- 86.3 (♀) – 40.4 weeks 
BALB/c Hgd-/- 86.3 (♀) was the first mouse to show large scale pigmentation across 
the whole tibio-femoral joint. There was a significant increase in the total amount 
of pigmented chondrons in the femur and tibia (Fig. 3.18), many of which were 
severely ochronotic (Fig. 3.6). 
 
62 
 
 
 
 
 
 
 
 
 
Figure 3.6 – Extensive ochronotic pigmentation in a 40.4 week old BALB/c 
Hgd-/- mouse. Schmorl’s staining of BALB/c Hgd-/- 86.3 (♀) highlighted large 
numbers of pigmented chondrons in the MTP (A & B), the MFC (C & D) and the 
intercondylar area of the tibia (E & F). Hypertrophic pyknotic chondrons were 
distributed throughout the MTP (A & B, arrowed). A binucleated pyknotic 
chondron (C, right arrow) was present in the MFC as were peri-pigmented and 
fully pyknotic chondrons (D, arrowed). Significant amounts of pigmented 
chondrons were also present (E & F, arrowed), for the first time, in the 
intercondylar area of the tibia. All sections stained with Schmorl’s. Bar = 20µm. 
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BALB/c Hgd-/- 86.3 (♀) (40.4 weeks) represented a significant milestone in the 
natural history study of the Hgd-/- mice as it was the first mouse to show large scale 
pigmentation across the whole tibio-femoral joint, as well as a new site of 
pigmentation; the insertion of the ACL and PCL into the MTP (intercondylar area). 
Some hypertrophic chondrons showed only pericellular pigmentation (Fig. 3.6 (D), 
left arrow), in areas which were occupied largely with heavily pigmented 
chondrons. A single binucleated cell was situated in the MFC (Fig. 3.6 (C), right 
arrow), a feature previously unseen until now. Pigmentation was observed for the 
first time at the intercondylar area of the MTP. There were large numbers of 
pigmented chondrons located at this site, which is an area of considerable stress in 
the tibio-femoral joint.  
 
3.3.1.7 BALB/c Hgd-/- 55.1 (♂) – 47.4 weeks 
BALB/c Hgd-/- 55.1 (♂) showed widespread pigmentation throughout the tibio-
femoral joint. Pigmentation was also located, for the first time, in the 
fibrocartilaginous entheses of the femoral condyles. Again, like previous mice, there 
was a mix of unpigmented, peri-pigmented and fully pigmented chondrons in close 
proximity to one another. There was also pigmentation in the intercondylar area of 
the tibia (Fig. 3.7). 
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3.3.1.8 BALB/c Hgd-/- 54.3 (♀) – 49.6 weeks 
BALB/c Hgd-/- 54.3 (♀) (49.6 weeks) was heavily pigmented throughout the tibio-
femoral joint. Ochronotic chondrons were located in all areas of the joint with areas 
of high stress particularly pigmented. Severe degradation and damage to the 
cartilage was observed, for the first time in the Hgd-/- mice. The MTP showed 
complete loss of the articular surface while there was erosion of the HAC and the 
Figure 3.7 – Extensive ochronotic pigmentation in a 47.4 week old BALB/c Hgd-
/- mouse. Peri-pigmented chondrons (A & C, left arrow) were present in areas 
heavily populated by pyknotic chondrons. Slight fibrillations on the articular 
surface of the MFC could be seen (A, right arrow). Large numbers of pigmented 
pyknotic chondrons were present in the fibrocartilaginous entheses of both 
femoral condyles (MFC shown) (B, arrowed). The intercondylar area contained 
pigmented chondrons in small numbers (D, right arrow). All sections stained with 
Schmorl’s. Bar = 20µm. 
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presence of vertical clefts extending from the HAC to ACC. Near complete loss of 
the articular surface on the MFC was also observed. Chondrons in differing stages 
of pigmentation were visible in close proximity to one another throughout ACC (Fig. 
3.8). Large numbers of pigmented chondrons were located at the intercondylar 
area of the TP (Fig 3.9). 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 – Hyaline articular cartilage damage and degradation in a 49.6 week 
old BALB/c Hgd-/- mouse. A peri-pigmented and a heavily pigmented chondron 
were located only microns apart from each other in the MFC (A, arrowed). 
Complete loss of the articular surface (B, left arrow), and the presence of a 
vertical cleft running through the MTP (B, right arrow) illustrated the severity of 
OA in the mouse. All sections stained with Schmorl’s. Bar = 20µm. 
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3.3.1.9 BALB/c Hgd-/- 61.3 (♀), 61.4 (♀) – 60 weeks 
BALB/c Hgd-/- 61.3 (♀), and 61.4 (♀) (60 weeks) were both heavily pigmented (Figs. 
3.18 & 3.19). The number of pigmented chondrons was significantly higher than 
that seen in BALB/c 54.3 Hgd-/- (♀, 49.6 weeks) (Fig. 3.18). Ochronotic 
pigmentation was widespread in all areas of the tibio-femoral joint including the 
fibrocartilaginous entheses of the femoral condyles and the intercondylar area of 
the femur and tibia. 
 
Figure 3.9 – Large numbers of pigmented chondrons located at the insertion of 
ligaments into the tibial plateau of a 49.6 week old BALB/c Hgd-/- mouse. An 
overview of the TP (A) showed a significant amount of pigmentation running 
across the area of ACL and PCL insertion into the TP. Bar = 100µm. Inset: (B) 
Large numbers of pigmented chondrons were located at the insertion site of the 
ligament(s). Section stained with Schmorl’s. Bar = 20µm. 
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Both mice had osteophytes present on the medial side of the femur and tibia which 
were heavily pigmented. A single heavily pigmented chondron was observed in the 
tibial growth plate of both BALB/c Hgd-/- 61.3 (♀) and BALB/c 61.4 (♀), this was 
something which had not been previously seen in any of the Hgd-/- mice (Figs. 3.10 
& 3.11). 
 
 
  
 
 
 
 
 
 
Figure 3.10 – Osteophyte formation and growth plate pigmentation in a 60 
week old BALB/c Hgd-/- mouse. A heavily pigmented osteophyte was located 
on the MFC (A, right arrow). Heavily pigmented isogenous groups of chondrons 
were present close to the formation of the osteophyte (O) (A, left arrow). A 
single pigmented pyknotic chondron was present in the tibial growth plate (B, 
arrowed). A heavily pigmented osteophyte was also located on the MTP (C, right 
arrow), surrounded by empty marrow space (C, left arrow). An unstained serial 
section of the MTP shows ochre coloured chondrons (D, arrowed). All images 
taken from BALB/c Hgd-/- 61.3 (♀). A, B & C stained with Schmorl’s, D 
unstained. Bar = 20µm. 
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Both mice exhibited extensive pigmentation throughout the tibio-femoral joint and 
showed significant signs of OA including osteophyte formation, tidemark 
duplication, fibrillations of the articular surface and large amounts of hypertrophic 
chondrons in the ACC. The pathology identified in both mice was consistent with 
the progression of ochronosis in humans. 
 
 
Figure 3.11 – Joint pathology in a 60 week old BALB/c Hgd-/- mouse. Staining 
with H&E showed the presence of an ochre coloured chondron close to the SCB 
interface in the LFC (A, arrowed). Bar = 10µm. A single pigmented chondron was 
present in the growth plate of the tibia (B, arrowed). Large numbers of 
pigmented chondrons were present in (C) the intercondylar area of the TP and 
(D) the fibrocartilaginous enthesis of the MFC. All images taken from BALB/c 
Hgd-/- 61.4 (♀). B, C & D stained with Schmorl’s. Bar = 20 µm. 
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3.3.1.10 BALB/c Hgd-/- 59.2 (♀), 59.3 (♀) – 61.3 weeks 
BALB/c Hgd-/- 59.2 (♀) and BALB/c 59.3 (♀) (61.3 weeks) both contained large 
amounts of pigmentation with the former containing the highest amount of 
pigmented chondrons observed in the study (Fig. 3.18). Osteophyte formation, 
degradation of cartilage and tidemark duplication was observed in both mice (Fig. 
3.12) which was consistent with previous data. Large numbers of pigmented 
chondrons were located in the intercondylar area of both the femur and tibia (Fig. 
3.13). 
 
 
 
 
 
 
Figure 3.12 – Osteophyte formation and pigmentation in a 61.3 week old 
BALB/c Hgd-/- mouse. Staining with H&E displayed ochre coloured peri-cellular 
pigmentation in chondrons in the ACC, and in an osteophyte on the MTP (A, 
arrowed). A near serial section stained with Schmorl’s showed isogenous groups 
of hypertrophic chondrons in the ACC (B, left arrow). Large groups of 
hypertrophic pyknotic chondrons (C & D, left arrow) and a heavily pigmented 
osteophyte (C & D, right arrow) were present on the MFC. All images taken from 
BALB/c Hgd-/- 59.2 (♀). B, C & D stained with Schmorl’s. Bar = 20 µm. 
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3.3.1.11 BALB/c Hgd-/- 50.3 (♀) – 65.7 weeks 
The final mouse analysed as part of the BALB/c Hgd-/- natural history study was 
BALB/c Hgd-/- 50.3 (♀). At 65.7 weeks of age, BALB/c 50.3 was over four weeks 
older than the previous set of mice examined. Large numbers of pigmented 
chondrons were observed throughout the joint (Figs. 3.14 & 3.15). However, small 
numbers of unpigmented and peri-pigmented chondrons were still present in close 
proximity to the pyknotic chondrons. Again, identical to that seen in younger mice, 
there were substantial numbers of pigmented chondrons in the intercondylar area 
Figure 3.13 – Cartilage damage and areas of substantial pigmentation in a 61.3 
week old BALB/c Hgd-/- mouse. Staining with H&E showed the presence of a 
cleft in HAC (A, right arrow) and duplicate tidemarks (A, red arrow) in the MTP. 
Areas of extensive pigmentation were seen in the intercondylar area of the MTP 
(B) and the fibrocartilaginous entheses of the femoral condyles (MFC shown) (C 
& D). All images taken from BALB/c Hgd-/- 59.2 (♀). B, C & D stained with 
Schmorl’s. Bar = 20 µm. 
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of the femur and tibia and in the fibrocartilaginous entheses of the femur. Three 
heavily pigmented pyknotic chondrons were located in the growth plate of the 
tibia, an occurrence which had only previous seen in BALB/c Hgd-/- 61.3 (♀) and 
61.4 (♀), where they were also located in the tibial growth plate. Tidemark 
duplication could be seen in the femur and tibia while minor fibrillations of the 
articular surface were present on the lateral aspects of the joints (Fig. 3.16).  
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Figure 3.14 – Extensive ochronotic pigmentation in a 65.7 week old BALB/c Hgd-/- mouse. A panoramic image of BALB/c Hgd-/- 50.3 (♀) 
tibio-femoral joint showing the extent of pigmentation. The number of heavily pigmented pyknotic (blue) chondrons in contrast to normal 
unstained chondrons was substantial. Section stained with Schmorl’s. Bar = 50 µm. 
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Figure 3.15 – Pathology of ochronosis in a 65.7 week old BALB/c Hgd-/- mouse. 
Different stages of chondron pigmentation, pericellular (A, left arrow) and 
pyknotic (A, right arrow), was seen in close proximity to each other in the LTP. 
Large numbers of hypertrophic chondrons (B) were located in the MFC. Three 
pyknotic chondrons were present in the tibial growth plate (C, arrowed), a rare 
event in AKU mice. Substantial numbers of pigmented chondrons were present 
at the intercondylar area of the tibia (ligamentous fibres arrowed) (E) and the 
fibrocartilaginous enthesis of the LFC (F). All sections stained with Schmorl’s. Bar 
= 20 µm. 
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Figure 3.16 – Cartilage degradation in a 65.7 week old BALB/c Hgd-/- mouse. 
Minor fibrillations to the articular surface of the LTP were observed (A, 
arrowed). The articular surface had been lost in some places along the LTP, but 
was intact in other areas. A small osteophyte (O) appeared to be located on the 
MTP, as did small amounts of SCB remodelling (B, arrowed). Numerous duplicate 
tidemarks were seen throughout the joint; here three tidemarks can be seen in 
the LTP (C, arrowed, (red arrows indicate duplicate tidemarks)). An unstained 
section of the MFC highlighted the actual colour of ochronotic chondrons (D). A 
binucleated (D, left arrow) and a pyknotic (D, right arrow) chondron have been 
highlighted in the image. A, B & C stained with H&E, D unstained. Bar = 20 µm. 
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3.3.1.12 BALB/c WT (♂) – 21.7, 43.5 and 69.1 weeks 
BALB/c WT mice were culled at three different time points and stained with 
Schmorl’s stain to provide a control in the natural history study. All WT mice 
analysed showed no pigmentation of chondrons and no osteoarthritic changes as 
expected (Fig. 3.17).  
 
 
 
 
Figure 3.17 – Absence of ochronotic pigmentation in BALB/c wild type mice. 
Images of 21.7 week old (A & B), 43.5 week old (C & D) and 69.1 week old (E & F) 
BALB/c WT, all showed no ochronotic chondrons throughout the tibio-femoral 
joint.  All sections stained with Schmorl’s. Bar = 20 µm. 
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3.3.2 Quantification of pigmented chondrons in BALB/c Hgd-/- mice 
The number of pigmented chondrons in each mouse involved in the natural history 
study was quantified. When the data was collated a clear pattern showing a 
progressive, linear increase in the amount of pigmentation with increasing age was 
observed (Fig. 3.18). 
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Figure 3.18 – The effect of age on the number of pigmented chondrons observed 
in BALB/c Hgd-/- mice. Scatter chart demonstrating the linear increase seen in the 
total number of pigmented chondrons with increasing age in BALB/c Hgd-/- mice. 
Quantification of pigmented chondrons was performed on a single section from 
each mouse; this does not represent the total cell number in each mouse. 
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3.3.2.1 Inter-observer variability in BALB/c Hgd-/- mice 
Quantification of pigmented chondrons in BALB/c Hgd-/- mice was performed by a 
second individual to assess the reliability of the method for scoring pigmented 
chondrons. 
 
 
 
 
 
 
To determine whether or not there was a significant difference between the two 
counts the intra-class correlation coefficient (ICC) was calculated to quantify the 
agreement between measurements. The ICC was 0.86 and was significantly 
different from 0 (p<0.001). The closer the ICC is to 1 signifies that the difference 
between paired measurements is small in comparison to the difference between 
subjects. 
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Figure 3.19 – Inter-observer variability in the number of pigmented chondrons in 
BALB/c Hgd-/- mice. Scatter chart demonstrating the variability in the number of 
pigmented chondrons in BALB/c Hgd-/- mice when counted by two different 
individuals. 
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The pigmented chondron counts from the two individuals show that while inter-
observer variability was seen the difference between the counts was not significant, 
indicating the method for scoring pigmented chondrons was reliable. 
 
The data obtained from the natural history study showed BALB/c Hgd-/- mice 
developed ochronosis in their knee joints, which is one of the primary sites of 
ochronosis in AKU patients. The pathology seen in AKU mice was analogous with 
ochronosis in humans, starting with the initial pericellular pigmentation of 
chondrons. The observation of early ochronosis in BALB/c Hgd-/- mice was an 
important finding as it showed that AKU, though presenting in humans as a painful 
syndrome in mid-life, is the result of a lifelong pathological process. Furthermore, 
as AKU is associated with the onset of early OA, we can use the model to identify 
the initiating events in OA by studying the role of SCB and ACC as both play an 
important role in the pathology of AKU and OA. 
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3.3.3 Histological detection of ochronotic pigment in BL/6 Hgd-/- mice 
HgdFah (Hgd+/-, Fah-/-) mice on a BL/6 background strain were crossed with WT 
BL/6 mice to yield Hgd-/-, Fah+/+ (AKU) mice on the BL/6 background. Once 
weaned, the mice were culled at different time points ranging from 6.1 to 46.5 
weeks and their knee joints analysed histologically. The left knee was used for the 
experimental studies and was sectioned posterior to anterior in each animal. 
 
3.3.3.1 BL/6 Hgd-/- 166.2 (♂), 166.3 (♂), 167.3 (♀), 167.4 (♀) – 6.1 weeks   
The earliest time point analysed in BL/6 Hgd-/- mice was 6.1 weeks, which was 
slightly earlier than the first time point examined in BALB/c Hgd-/- mice. Schmorl’s 
staining of the mice showed no pigmented chondrons throughout the tibio-femoral 
joints of all four mice. H&E staining showed no cartilage degradation or other signs 
of osteoarthritic nature (Fig. 3.20). 
 
 
 
 
 
 
 
Figure 3.20 – Ochronotic pigment is not detectable in a 6.1 week old BL/6 Hgd-
/- mouse. Schmorl’s staining of the LTP showed no pigmentation of the cells or 
their surrounding matrices (A). H&E staining of the MTP indicated the cartilage 
was in excellent condition as no fibrillations or clefts in the articular surface were 
observed (B). Images taken from BL/6 Hgd-/- 167.4 (♀). Bar = 20 µm. 
 
 
 
 
 
80 
 
3.3.3.2 BL/6 Hgd-/- 161.1 (♂), 161.2 (♂), 162.1 (♀), 162.2 (♀) – 10.4 weeks 
Of the four BL/6 mice analysed at 10.4 weeks of age, BL/6 Hgd-/- 162.2 (♀) 
displayed early signs of ochronosis. A very small number of pigmented chondrons 
were observed in the ACC of the LFC and in the intercondylar area of the TP (Fig. 
3.21). A number of chondrons appeared heavily pigmented and pyknotic which is 
somewhat surprising as these chondrons are typically associated with late or end-
stage ochronosis. The cartilage of all the mice looked healthy with no obvious 
damage to the articular surface.  
 
 
 
 
 
 
 
The appearance of heavily pigmented chondrons in BL/6 Hgd-/- 162.2 (♀) marked 
the earliest identification of ochronotic chondrons in both BL/6 and BALB/c Hgd-/- 
strains of Hgd-/- mice. BL/6 Hgd-/- 98.4 (♂), 99.3 (♀) (16.1 weeks), which were the 
next mice in the study, showed comparable numbers of pigmented chondrons to 
the mice at 10.4 weeks (Fig. 3.40) therefore no images from them are shown. 
 
Figure 3.21 – Earliest identification of ochronotic chondrons in a 10.4 week old 
BL/6 Hgd-/- mice. Schmorl’s staining of the LFC of BL/6 Hgd-/- 162.2 (♀) 
revealed two heavily pigmented pyknotic chondrons (A, arrowed). The 
chondrons were slightly hypertrophic as opposed to most chondrons 
surrounding them. A single pigmented chondron was located in the 
intercondylar area of the TP (B, arrowed). Bar = 20 µm. 
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3.3.3.3 BL/6 Hgd-/- 71.2 (♂), 72.1 (♀) – 27.8 weeks 
The next two mice analysed, BL/6 Hgd-/- 71.2 (♂) and 72.1 (♀) (27.8 weeks), were 
11 to 12 weeks older than the previous mice examined. As expected, from all the 
BALB/c and BL/6 Hgd-/- data seen so far, there was an increase in the number of 
pigmented chondrons located throughout the tibio-femoral joint (Fig. 3.40). The 
majority of pigmented chondrons, in both mice, were localised to the medial aspect 
of the joint and were heavily pigmented. All of the pigmented chondrons were 
hypertrophic, particularly the ones which were severely ochronotic. There was no 
obvious damage or degradation to the articular surface of the cartilage, however 
there was some duplication of the tidemarks in both the MFC and MTP (Fig. 3.22).  
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3.3.3.4 BL/6 Hgd-/- 101.3 (♂), 102.3 (♀) – 29.1 weeks 
BL/6 Hgd-/- 101.3 (♂) and 102.3 (♀) (29.1 weeks) both showed a large increase in 
the number of pigmented chondrons present in the tibio-femoral joint, compared 
to all previous BL/6 Hgd-/- mice (Fig. 3.40). Pigmented chondrons were localised to 
the ACC and intercondylar areas of the femur and tibia with the medial aspect of 
the joint containing the most, this was consistent with previous data. Again the 
Figure 3.22 – Ochronosis and tidemark duplication in a 27.8 week old BL/6 
Hgd-/- mouse. H&E staining of the MFC showed tidemark duplication at the 
mineralisation front (A, red arrows). An isogenous group of heavily pigmented 
chondrons (B, right arrow) was located in the MFC adjacent to a single 
pigmented, pyknotic chondron (B, left arrow). A peri-pigmented chondron (C, 
left arrow) neighbouring a heavily pigmented chondron (C, right arrow) was 
seen in the MTP. Small numbers of pigmented chondrons were located in the 
intercondylar area of the tibia (D, arrowed). All images are taken from the right 
knee of BL/6 Hgd-/- 72.1 (♀). B, C & D stained with Schmorl’s. Bar = 20 µm. 
 
 
 
 
 
83 
 
majority of the chondrons were heavily pigmented but there was a noticeable 
increase in the amount of peri-pigmented chondrons throughout the joint. There 
was one particular chondron present in BL/6 Hgd-/- 101.3 (♂) which showed 
intense peri-pigmentation and cellular pigmentation (Fig. 3.23 (D)). Staining such as 
this had not been observed in any of the BL/6 mice examined so far, and was rarely 
seen in the BALB/c natural history study. Tidemark duplication was observed 
throughout the joint, the most prominent example being present in the MFC of 
BL/6 Hgd-/- 101.3 (♂) (Fig. 3.23 (A)). The replication of the mineralisation front has 
been seen in the majority of mice in both strains, and always appears before any 
cartilage damage. There did appear to be some possible cartilage damage on the 
LTP of BL/6 Hgd-/- 101.3 (♂), identified by the large clustering of chondrons near 
the articular surface (Fig. 3.23 (B)). The quality of the articular surface appears to 
have been degraded with small lesions visible. The clustering of the chondrons may 
be a response to increased mechanical stimuli in the damaged area as an attempt 
to prevent further degradation of the cartilage. 
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It was interesting to note that the number of pigmented chondrons in the tibio-
femoral joint of both BL/6 Hgd-/- 101.3 (♂) and 102.3 (♀) (29.1 weeks) was around 
three times as much as BL/6 Hgd-/- 71.2 (♂) and 72.1 (♀) (27.8 weeks) which were 
only 1.5 weeks younger (Fig. 3.40). This was a substantial increase for such a short 
space of time, and is close to 12 weeks earlier than similar numbers were observed 
Figure 3.23 – Ochronosis and tidemark duplication in a 29.1 week old BL/6 Hgd-
/- mouse. H&E staining of the MFC showed tidemark duplication at the 
mineralisation front (A, red arrows). Clusters of chondrons were present at the 
articular surface of the LTP (B, left arrow). There appeared to be some minor 
lesions in the cartilage where the clustering was located (B, right arrow). A range 
of chondrons in different stages of pigmentation were present in the LTP. Two 
chondrons showing end stage pigmentation have been highlighted (C, arrowed). 
A heavily pigmented chondron residing in the deep layer of the MFC, surrounded 
by unpigmented and peri-pigmented chondrons is highlighted (D, arrowed). A & 
B stained with H&E, C & D stained with Schmorl’s. Bar = 20 µm. 
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in the BALB/c Hgd-/- mice. These are interesting results as they suggest BL/6 Hgd-/- 
mice have an earlier onset of severe ochronosis in the tibio-femoral joint, while also 
suggesting there is a rapid change in the composition or organisation of the 
cartilage matrix allowing for increased deposition of ochronotic pigment in a short 
space of time. 
 
3.3.3.5 BL/6 98.3 (♂), 99.4 (♀) – 31.7 weeks 
BL/6 Hgd-/- 98.3 (♂) and 99.4 (♀) (31.7 weeks) contained high numbers of 
ochronotic chondrons, similar to those seen previously in BL/6 Hgd-/- mice aged 
29.1 weeks. The pigmented chondrons were fairly evenly distributed throughout 
the femur and tibia, but like all mice examined the majority of pigmented 
chondrons were localised to the ACC. There was an increasing number of 
ochronotic chondrons situated at the intercondylar area of the tibia, an area of high 
stress where the ACL and PCL attach, but this was only a small proportion compared 
to the amount present in the ACC. Chondrons in all different stages of pigmentation 
were scattered throughout the joint. Non-pigmented chondrons were primarily 
located in the HAC, although small numbers were also present in the ACC. Peri-
pigmented and fully pyknotic chondrons were distributed throughout the ACC; 
pyknotic chondrons were present in higher numbers than peri-pigmented 
chondrons. Staining of the PCM was visible in an H&E section of the MFC in BL/6 
Hgd-/- 99.4 (♀) (Fig. 3.24 (C)), suggesting there were large deposits of ochronotic 
pigment in the matrix of this particular chondron as Schmorl’s stain was not 
required to identify it. There also appeared to be subchondral sclerosis in the LFC of 
BL/6 Hgd-/- 99.4 (♀) and vascularisation of the ACC (Fig 3.24 (A)). This is strikingly 
similar to BALB/c Hgd-/- 92.2 (♂) which showed subchondral sclerosis and 
projection of the bone into ACC at 30.9 weeks of age. There is evidence that 
advancement of the tidemark and the resultant vascularisation of the ACC are 
associated with OA in humans [97].  
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Figure 3.24 – Vascularisation of the articular calcified cartilage in a 31.7 week 
old BL/6 Hgd-/- mouse. H&E staining of the LFC of BL/6 Hgd-/- 99.4 (♀) 
highlighted vascularisation of the ACC (A, arrowed). A near serial section of the 
LFC stained with Schmorl’s shows the vascularised area surrounded by 
pigmented chondrons (B, arrowed). An area of the MFC which appeared to show 
resorption of the SCB (C, right arrow) and the presence of ochronotic pigment in 
the PCM of a pyknotic chondron (C, left arrow). Schmorl’s staining of the 
intercondylar area of the tibia showed pigmented chondrons present (D). All 
images taken from BL/6 Hgd-/- 99.4 (♀). A & C stained with H&E, B & D stained 
with Schmorl’s. Bar = 20 µm. 
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3.3.3.6 BL/6 Hgd-/- 94.1 (♂), 95.1 (♀) – 37.8 weeks 
Pigmentation in both BL/6 Hgd-/- 94.1 (♂) and 95.1 (♀) (37.8 weeks) was at a level 
relatively comparable to the previous two ages examined in the BL/6 study (Fig. 
3.40). BL/6 Hgd-/- 95.1 showed a slight increase in the total amount of pigmented 
chondrons throughout the tibio-femoral joint while BL/6 Hgd-/- 94.1 showed a very 
small decrease. Most of the pigmented chondrons in the mice were heavily 
ochronotic and hypertrophic (Fig. 3.25 (C & D)). A single pigmented chondron in the 
deep zone of the ACC displayed interesting properties as it appeared some of the 
cellular components were pigmented while the nucleus remained unpigmented 
(Fig. 3.25 (B)). This is interesting as it appears to shows the nucleus of the cell is the 
last region to pigment. Several signs of OA were evident in the mice in the form of 
ACC vascularisation (Fig 3.25 (A)), tidemark duplication (Fig 3.25 (B)), SCB 
remodelling and resorption (Fig. 3.25 (C)) as well as initial osteophyte formation 
(not shown). No damage to the surface of the cartilage was apparent suggesting 
that the initiation of OA may begin at the SCB/ACC interface and progress up 
through the cartilage just as ochronosis does in both mice and humans. 
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Figure 3.25 – Vascularisation of the articular calcified cartilage and subchondral 
bone remodelling and resorption in a 37.8 week old BL/6 Hgd-/- mouse. H&E 
staining of the MFC of BL/6 Hgd-/- 95.1 (♀) showed vascularisation of the ACC 
(A, arrowed). A single pyknotic chondron, in the deep zone of ACC in the MTP, 
displayed pigmentation of some cellular compartments but not the nucleus (B, 
left arrow). Tidemark duplication was also present in the MTP (B, red arrow) (Bar 
= 10 µm). Schmorl’s staining showed pigmented chondrons located at areas of 
subchondral remodelling and resorption in the MTP (C, arrowed). Numerous 
pigmented chondrons were located at the intercondylar area of the TP (D), 
which is consistent with both BL/6 and BALB/c Hgd-/- mice of increasing age. A & 
B stained with H&E, C & D stained with Schmorl’s. Bar = 20 µm. 
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3.3.3.7 BL/6 Hgd-/- 82.1 (♂), 83.1 (♀) – 41.3 weeks 
The number of pigmented chondrons in BL/6 Hgd-/- 82.1 (♂) and 83.1 (♀) (41.3 
weeks) was similar to the previous four to six BL/6 mice examined (Fig. 3.40). There 
was an increased number of pigmented chondrons located at the intercondylar 
area of the femur and tibia (Fig. 3.26 (D)). Non-pigmented chondrons were 
distributed sparsely throughout the joint signifying how advanced and severe 
ochronosis in the mice had become. There was some interesting osteoarthritic 
pathology observed in BL/6 Hgd-/- 82.1 (♂), most noticeably the formation of a 
meniscal ossicle in the LM (Fig. 3.26 (A)). Meniscal ossification is common in mice 
but very rare in humans [127, 128]. Although it is seen in mice that develop OA, the 
formation of meniscal ossicle’s is a normal phenomenon associated with ageing. 
Subchondral remodelling was observed across the tibio-femoral joint of both mice. 
The MTP was the most extensively remodelled area (Fig. 3.26 (B)) which may relate 
to it having the greatest mechanical stresses in the knee joint. Tidemark duplication 
was located in the articular cartilages of both mice but was most prominent in the 
MTP. 
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Figure 3.26 – Meniscal ossification, subchondral bone remodelling and 
ochronosis in a 41.3 week old BL/6 Hgd-/- mouse. H&E staining of the LM of 
BL/6 Hgd-/- 82.1 (♂) showed formation of cortical bone in the centre of the 
meniscus surrounded by cartilage (A, arrowed). This feature is known as 
meniscal ossification. Subchondral remodelling and the subsequent deposition 
of new bone were present in the MTP of BL/6 Hgd-/- 82.1 (B, arrowed). Minor 
fibrillations on the articular surface of the MFC were observed (C, arrowed). An 
increase in the number of pigmented chondrons at the intercondylar area of the 
tibia was also identified (D). All images taken from BL/6 82.1 (♂). A & B stained 
with H&E, C & D stained with Schmorl’s. Bar = 20 µm. 
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3.3.3.8 BL/6 Hgd-/- 66.3 (♀), 67.1 (♂) – 46.5 weeks 
BL/6 Hgd-/- 66.3 (♀) displayed a particularly large increase in the number of 
pigmented chondrons present throughout its tibio-femoral joint compared previous 
BL/6 mice (Fig. 3.40). BL/6 Hgd-/- 67.1 (♂) showed numbers of pigmented 
chondrons comparable with the previous four to six BL/6 Hgd-/- mice analysed. The 
detection of pigmented chondrons in the entheses of the femur (Fig. 3.27 (D)), 
while being the first time seen in BL/6 Hgd-/- mice, was routinely seen in BALB/c 
Hgd-/- mice of similar ages. BL/6 Hgd-/- 66.3 (♀) showed significant amounts of 
bone remodelling in the MTP, an area which had dense amounts of pigmentation 
present (Fig 3.27 (B)). Remodelling of SCB appeared in both the femur and tibia of 
both mice suggesting an osteoarthritic phenotype in the joints of the mice, 
although there was no obvious damage or degradation to the articular cartilage. 
H&E staining of the MFC of BL/6 Hgd-/- 66.3 (♀) showed a peri-pigmented 
chondron located at the boundary of the ACC and SCB (Fig. 3.27 (A), left arrow). 
Pigmentation in humans is believed to start at this boundary and progress up 
throughout the cartilage; the identification of peri-pigmented chondrons at the 
SCB/ACC interface in Hgd-/- mice indicates the process of pigmentation initiation 
and progression is very similar between the two species. 
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Figure 3.27 – Ochronosis and osteoarthritic pathology in a 46.5 week old BL/6 
Hgd-/- mouse. H&E staining of the MFC of BL/6 Hgd-/- 66.3 (♀) depicted a 
pigmented chondron adjacent to the SCB (A, left arrow); the zone where it is 
thought pigmentation initiates. Two chondrons appeared to be separated by an 
area of pigmented PCM (A, right arrow). Ochronotic chondrons located in the 
MTP were heavily pigmented (B, right arrow). Large areas of SCB remodelling 
were also present in the MTP (B, left arrow). Significant numbers of pigmented 
chondrons were located at (C) the intercondylar area of the tibia and (D) the 
fibrocartilaginous entheses of the femur. All images taken from BL/6 82.1 (♀). B, 
C & D stained with Schmorl’s. Bar = 20 µm. 
 
 
 
 
93 
 
3.3.3.9 BL/6 Hgd-/- 62.3 (♀) – 62.6 weeks 
BL/6 Hgd-/- 62.3 (♀) was heavily pigmented throughout the tibio-femoral joint (Fig 
3.28). Large numbers of pigmented chondrons were located in the entheses of the 
femur (Fig. 3.28 (C)) and the intercondylar area of the tibia (Fig. 3.28 (D)); both are 
areas which are known to be associated with high mechanical stress. Clusters of 
non-pigmented chondrons were located in the ACC (Fig. 3.28 (A)). The fact that 
these clusters were surrounded by groups of severely ochronotic chondrons is 
interesting and shows that although most of the cartilage has become ochronotic 
there are still some small areas which are unaffected. Angiogenesis and 
vascularisation of the ACC (Fig. 3.28 (B)) were observed in the MFC. Although fewer 
pigmented chondrons were present in the area of angiogenesis, that it did occur in 
the ACC, indicated the cartilage was osteoarthritic. 
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Along with angiogenesis (Fig. 3.29 (A)), signs of SCB remodelling were present 
extensively throughout the tibio-femoral joint. In the MFC there were clear signs of 
bone formation and resorption in the SCB plate (Fig. 3.29 (B)), again indicating the 
joint was osteoarthritic.  
 
 
Figure 3.28 – Severe ochronosis and angiogenesis in a 62.6 week old BL/6 Hgd-
/- mouse. A cluster of non-pigmented chondrons in the LFC surrounded by 
severely ochronotic chondrons (A, arrowed). Vascularisation of the MFC 
highlighted the OA changes in the joint of BL/6 Hgd-/- 62.3 (B, arrowed). Large 
numbers of heavily pigmented chondrons were located in (C) the 
fibrocartilaginous entheses of the femur (LFC shown) and (D) the intercondylar 
area of the tibia. All sections stained with Schmorl’s. Bar = 20 µm. 
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Cartilage damage was located on the LTP of BL/6 Hgd-/- 62.3. Large numbers of 
chondrocytes in the HAC appeared to be undergoing cellular division (Fig. 3.30, left 
arrows) in response to what looked like damage to the articular surface and the 
HAC. The articular surface was no longer attached to the LTP as evident by the lack 
of chondroblasts in the cartilage; only fully matured chondrons which were situated 
in the transitional and deep zones of the cartilage could be identified. Fibrocartilage 
was also located on the LTP (Fig. 3.30, right arrow) which suggested the HAC had 
been severely damaged, leading to scarring and attempted repair of the injured 
area. Fibrocartilage has completely different properties and structure to the HAC 
and its formation in the joint will have only exacerbated the osteoarthritic 
symptoms seen in the mouse. Meniscal ossification was observed in the LM of BL/6 
Hgd-/- 62.3. Staining with Schmorl’s stain showed the cartilage of the meniscus was 
heavily pigmented (Fig. 3.31). 
 
 
Figure 3.29 – Angiogenesis and subchondral bone remodelling in a 62.6 week 
old BL/6 Hgd-/- mouse. Angiogenesis in ACC of the MFC (A, arrowed); adjacent 
new areas of bone formation are present. SCB remodelling, shown in the MFC (B, 
arrowed), was present extensively throughout the knee joint. All sections taken 
from BL/6 Hgd-/- 62.3 and stained with H&E. Bar = 20 µm. 
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Figure 3.30 – Chondrocyte proliferation and articular cartilage damage in a 62.6 
week old BL/6 Hgd-/- mouse. H&E staining of the LTP of BL/6 Hgd-/- 62.3 (♀) 
showed large amounts of cell division (left arrows) in the HAC. Some of the HAC 
appeared to have been damage and replaced by fibrocartilaginous tissue (right 
arrow). Bar = 20 µm. 
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3.3.3.10 BL/6 Hgd-/- 49.2 (♀) – 68.3 weeks 
BL/6 Hgd-/- 49.2 (♀) (68.3 weeks) displayed a reduction in the amount of 
pigmented chondrons located throughout the tibio-femoral joint in comparison 
with BL/6 Hgd-/- mice of similar ages (Fig. 3.40). Although it was quite a significant 
reduction it was noted as an anomaly as no other mouse showed such a large 
reduction in the numbers of pigmented chondrons. The most densely populated 
area of pigmentation was the intercondylar area of the tibia (Fig. 3.32 (B)). Two 
chondrons in the ACC (Fig. 3.32 (A)) demonstrated the differences that can occur in 
chondrons in close proximity to one another. One chondron (left) was only lightly 
pigmented while the chondron adjacent to it was heavily pigmented and pyknotic.  
 
Figure 3.31 – Meniscal ossification in a 62.6 week old BL/6 Hgd-/- mouse. 
Schmorl’s staining of the LM of BL/6 Hgd-/- 62.3 showed the presence of 
pigmented chondrons in the cartilage of the meniscus. Bar = 100 µm. 
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Fibrillations were observed on the articular surface of the MFC (Fig. 3.33) of BL/6 
Hgd-/- 49.2. Parts of the HAC had also been eroded to the point where the ACC was 
nearly exposed. Heavily pigmented chondrons were situated close to the damaged 
surface (Fig. 3.34) but it did not appear the damage had caused a proliferation in 
the number of pigmented chondrons.  
Figure 3.32 – Ochronotic pigmentation in a 68.3 week old BL/6 Hgd-/- mouse. 
Two chondrons in close proximity in the MTP; one was lightly pigmented (left) 
yet the other was heavily pigmented and pyknotic (right) (A, arrowed). Large 
numbers of pigmented chondrons were located in the intercondylar area of the 
tibia (B). All sections taken from BL/6 Hgd-/- 49.2 and stained with Schmorl’s. Bar 
= 20 µm. 
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Figure 3.33 – Fibrillations and erosion of the articular surface in a 68.3 week old 
BL/6 Hgd-/- mouse. H&E staining of the MFC from BL/6 Hgd-/- 49.2 displayed 
fibrillations and erosion of the articular surface (arrowed). Bar = 20 µm. 
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3.3.3.11 BL/6 Hgd-/- 35.1 (♂) – 71.7 weeks 
BL/6 Hgd-/- 35.1 (♂) displayed levels of pigmentation consistent with that of mice 
of similar ages (Fig. 3.40). There were very few peri-pigmented or non-pigmented 
chondrons in the joint, showing the severity of ochronosis in the mouse. Dense 
areas of pigmentation were located throughout the tibio-femoral joint (Fig. 3.35). 
 
Figure 3.34 – Fibrillations and erosion of the articular surface in a 68.3 week old 
BL/6 Hgd-/- mouse (II). Schmorl’s staining of a near serial section of Fig. 3.33 
showed pigmented chondrons (arrowed) located near the damaged surface of 
the cartilage. Bar = 20 µm. 
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A small area of HAC had eroded exposing the underlying ACC in the joint (Fig. 3.36). 
Minor fibrillations were also present on the articular cartilage near the damaged 
area, resulting in the loss of the articular surface and the associated chondroblasts. 
Although no pigmented chondrons were located directly at the damaged HAC-ACC 
boundary, they were located in the ACC underneath the injured area (Fig. 3.37). 
Angiogenesis was also present in the MFC, leading to the vascularisation of the ACC 
(Fig. 3.38). 
Figure 3.35 – Extensive ochronotic pigmentation in a 71.7 week old BL/6 Hgd-
/- mouse. Schmorl’s staining revealed large amounts of pigmented chondrons 
present in the MFC (A), MTP (B), intercondylar area of the TP (C), and 
fibrocartilaginous enthesis of the LFC (D). All sections taken from BL/6 Hgd-/- 
35.1 and stained with Schmorl’s. Bar = 20 µm. 
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Figure 3.36 – Articular cartilage erosion and signs of pigment initiation in a 71.7 
week old BL/6 Hgd-/- mouse. H&E staining of the MFC from BL/6 Hgd-/- 35.1 
showed erosion of the HAC to the underlying ACC (right arrow). A fully 
pigmented chondron located at the boundary of the ACC and SCB (left arrow) - 
the site where pigmentation is hypothesised to initiate. Bar = 20 µm. 
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Figure 3.37 – Articular cartilage loss and pigmentation in a 71.7 week old BL/6 
Hgd-/- mouse. Schmorl’s staining of a near serial section of Fig. 3.36 (BL/6 Hgd-/- 
35.1) showed the location of pigmented chondrons in relation to the injured 
area. Bar = 20 µm. 
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Figure 3.38 – Vascularisation of the articular calcified cartilage in a 71.7 week 
old BL/6 Hgd-/- mouse. H&E staining of the MFC from BL/6 Hgd-/- 35.1 showed 
vascularisation of the ACC. Bar = 20 µm. 
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3.3.3.12 BL/6 WT (♂) – 69.1 weeks 
A BL/6 WT was culled at 69.1 weeks and stained with Schmorl’s to provide a control 
in the natural history study. The WT analysed showed no pigmentation or 
osteoarthritic changes as expected (Fig. 3.39). 
 
 
 
 
 
Figure 3.39 – Absence of ochronotic pigmentation in a BL/6 wild type mouse. 
Images of the MFC (A & B), the LTP (C), and the MTP (D, E & F) from a BL/6 WT 
showed no pigmented chondrons throughout the tibio-femoral joint. All sections 
stained with Schmorl’s. Bar = 20 µm. 
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3.3.4 Quantification of pigmented chondrons in BL/6 Hgd-/- mice 
The number of pigmented chondrons in each mouse involved in the natural history 
study was quantified. When the data was collated there was a clear pattern 
showing a progressive, linear increase in the amount of pigmentation with 
increasing age (Fig. 3.40). 
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Figure 3.40 – The effect of age on the number of pigmented chondrons in BL/6 
Hgd-/- mice. Scatter chart showing the effects of increasing age on pigmentation 
levels in BL/6 Hgd-/- mice. Quantification of pigmented chondrons was performed 
on a single section from each mouse; this does not represent the total cell number 
in each mouse. 
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3.3.5 Difference between BALB/c and BL/6 pigmented chondron levels 
A comparison of pigmented chondron counts between BALB/c Hgd-/- and BL/6 Hgd-
/- mice show small areas of intra- and inter- strain variability but the overall pattern 
is one of a linear increase in pigmentation with increasing age in Hgd-/- mice (Fig. 
3.41). 
 
 
 
 
 
 
Although not easily visible on the above chart (Fig. 3.41) BL/6 Hgd-/- mice did 
develop ochronosis at an earlier time point than the BALB/c Hgd-/- mice. This is 
shown in Figs. 3.2 and 3.20, both of which correspond to the earliest observation of 
pigmented chondrons in BALB/c and BL/6 Hgd-/- mice. Pigmentation was first 
observed in BALB/c Hgd-/- mice at 15.7 weeks (Fig. 3.2), while BL/6 Hgd-/- mice first 
became pigmented at 10.4 weeks (Fig. 3.21). The pathology seen in the BL/6 Hgd-/- 
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Figure 3.41 – A comparison of the number of pigmented chondrons between 
BALB/c and BL/6 Hgd-/- mice. Quantification of pigmented chondrons was 
performed on a single section from each mouse; this does not represent the total 
cell number in each section. 
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mice was very similar with ochronosis in humans, starting with the initial peri-
cellular pigmentation of chondrons. The very early ochronosis and subsequent 
progression observed in the BL/6 Hgd-/- mice was an important finding as it was 
consistent with the findings in the BALB/c Hgd-/- and also with what is thought to 
occur in ochronosis in humans. 
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3.4 DISCUSSION 
This Chapter presents the first original data on the natural history of ochronosis in 
murine models of AKU. Montagutelli et al [110] first described the Hgd-/- mouse 
model but failed to find any ochronotic lesions or signs of phenotypic AKU which is 
consistently seen in humans. Although the mice showed elevated levels of urinary 
HGA excretion [51, 110], which was synonymous with human ochronosis, it was 
suggested that endogenous production of ascorbic acid protected tissues from 
becoming pigmented [110]. A second murine model of ochronosis was developed 
inadvertently by Manning et al [125] who was using FAH-/- mice to study HT-1. 
After being crossed with Hgd heterozygote’s, a small number of these mice 
contained a double knockout, FAH-/-, Hgd-/-, which in effect made then AKU mice. 
Even though the mice displayed ochronosis in their tissues [111] the model was not 
considered suitable as it was produced by a spontaneous mutation occurring in a 
small minority of the mice. 
 
In this Chapter it has been shown that mice with the Hgd-/- mutation become 
ochronotic. This is the first study which has detailed the natural history of 
ochronosis in Hgd-/- mice throughout their entire lifespan. Data collected in this 
chapter revealed that ochronosis began at a very early age and increased with age, 
becoming more and more severe with time. Hgd-/- mice also developed OA 
alongside ochronosis, which is similar to the AKU phenotype in humans. The 
identification of ochronosis in the tibio-femoral joint also dispels the notion that 
endogenous production of ascorbic acid acts as a protective agent to prevent 
pigmentation. The discovery of ochronosis in the Hgd-/- mice is significant as it 
provides a robust model to evaluate new novel therapies for the treatment of AKU 
while also providing a new model of experimental OA. 
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3.4.1 BALB/c Hgd-/- mice 
Using Schmorl’s stain pigmentation was first identified in BALB/c Hgd-/- mice at 
15.7 weeks. Both mice examined at this age, BALB/c Hgd-/- 93.2 (♂) and 94.1 (♀), 
displayed pericellular pigmentation of chondrons located in the ACC, which is 
consistent with the initiation of pigmentation in humans [36]. It has been 
hypothesised that the PCM undergoes a change in its composition and organisation, 
resulting in the disordering of collagen in the matrix thus allowing for deposition of 
ochronotic pigment [36, 39]. Ultrastructural studies by Taylor et al [28] have shown 
that collagen fibres in areas of pigmentation are structurally abnormal compared to 
regular fibres yet show periodic binding of ochronotic shards along the fibres 
themselves. One of the main aims of the study was to discover when pigmentation 
initiated, so therapeutic intervention could be administered at the correct time 
point. The finding of peri-pigmented chondrons at such an early age was vitally 
important as it showed pigment deposition began very early on in life and not after 
years of exposure to high HGA, when clinical symptoms become observable.  
 
By 23.5 weeks pigmentation was located intracellularly as well as extracellularly in 
the chondrons. The number of pigmented chondrons in the ACC of the tibio-
femoral joint had also increased linearly with age. The progression of pigmentation 
to the intracellular compartment of the chondron was probably due to the initial 
transformation of its pericellular environment. Changes in the composition of the 
PCM are known to alter the biomechanical and micro environmental properties of 
the chondron [63, 129]. These changes are significant in terms of cell regulation and 
most likely allow for intracellular HGA deposition when altered.  
 
Pigmentation continued to increase linearly with age throughout the study but 
never reached a stage of blanket coverage like that seen in end stage ochronosis in 
humans [36]. Pigmentation in the mice was localised to chondrons in the ACC. 
Territorial and interterritorial matrices did not become pigmented. Macroscopic 
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observation of the tibio-femoral joints did not show any darkening of the cartilage, 
again a feature associated with ochronosis in humans. The absence of these 
features in Hgd-/- mice may be associated with a number of factors, one being the 
short murine lifespan. There is no rational data available on comparable ages 
between mice and humans but it is reasonable to suggest that a mouse living to a 
maximum of 70 weeks would not have the same gross accumulation of pigment 
characteristically seen in humans with AKU. Mice also experience reduced joint 
loading as they are quadrupedal by nature. Mechanical loading of the tibio-femoral 
joint can lead to micro trauma in humans [130] and it has been hypothesised that 
the ECM, while normally resistant to the deposition of pigment, undergoes 
biomechanical and biochemical changes following mechanically induced damage 
leading to the accumulation of pigment [36]. It is likely mice experience reduced 
joint loading due to them being quadrupedal, therefore they are unlikely to suffer a 
similar magnitude of loading, and micro trauma which may explain the absence of 
blanket pigmentation in the articular cartilage. The process of articular cartilage 
matrix remodelling is controlled by a number of molecules including bone 
morphogenetic proteins (BMPs), fibroblast growth factors (FGFs), TGF-β, and Wnts. 
These regulate the expression of proteases, most notably MMP-13 [131, 132] and 
ADAMTS-5 [133, 134], which are responsible for the degradation of the cartilage 
matrix. Cleavage of aggrecan, collagens, GAGs, and cartilage oligomeric matrix 
protein (COMP) among others, by MMP-13 and ADAMTS-5, causes changes in the 
composition of matrix which is a major factor in OA pathogenesis, therefore 
regulation of these proteases is significant to prevent matrix degradation [135-139]. 
Increased mechanical stresses applied to joints are thought to upregulate the 
expression of certain proteases causing degradation of the matrix. As previously 
stated it is thought the ECM undergoes changes resulting in the accumulation of 
pigment, highlighting the apparent link between mechanical loading and 
pigmentation. If mice do experience reduced mechanical loading it is possible the 
expression of key proteases, involved in cartilage degradation, is not as high as in 
humans reducing the amount of matrix degradation. This may have prevented the 
accumulation of pigment throughout the entire articular cartilage preventing 
blanket pigmentation.   
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Large numbers of pigmented chondrons were located in the fibrocartilaginous 
entheses of the femur and the intercondylar area of the femur and tibia, more so in 
the tibia, in Hgd-/- mice from around 40 weeks of age. Deposition of ochronotic 
pigment in these areas was probably as a result of the high stress placed upon the 
region where it attaches to the bone. The function of both ligaments is to distribute 
stress forced upon the joint by mechanical loading, yet these compressive forces 
can cause damage to the ligaments when they become excessive [140]. This stress 
is known to cause compositional changes of the ligamentous ECM, leading to 
cartilage-related molecules including chondroitin 6 sulphate, aggrecan and type II 
collagen becoming prominent in the ECM of the entheses, similar to the ECM of the 
articular cartilage [140, 141]. With the composition of both these matrices being 
similar it is likely that the entheses responds in a similar way to abnormal loading 
conditions resulting in deposition of ochronotic pigment. The entheses at both 
areas are heavily loaded, especially the tibial attachments, which may explain why 
significant amounts of pigmented chondrons are present at these sites. 
 
Interestingly, pigmented chondrons were also located in the EP in two aged mice. 
BALB/c Hgd-/- 61.3 (♀) and 61.4 (♀), who were both 60 weeks of age, each 
contained a single pigmented chondron located in the EP of the tibia (Figs. 3.10 & 
3.11). Chondrons located in the EP are involved in endochondral ossification 
therefore they express a number of different phenotypes and synthesize a number 
of different collagens and proteoglycans. There is scarce literature regarding the EP 
in aged mice, nearly all papers focus on its involvement in endochondral 
ossification, however Chambers et al reported that the EP remains open in aged 
mice and the embedded chondrocytes remain viable and actively synthesize type II 
collagen and aggrecan [142]. It is possible that pigment deposition in these two 
chondrocytes is related to the presence of collagen, as collagen fibres are thought 
to be a primary binding site for ochronotic pigment [28]. However if collagen is a 
binding site, it is still unclear why only one cell, in each of the mice, became 
pigmented as all cells in the EP actively synthesize collagen. This may be evidence 
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that other factors which alter cellular activity are required for the initiation and 
progression of pigmentation. 
 
Pigmentation in the mice was consistently associated with hypertrophic chondrons. 
From initial identification of pigmentation, in the PCM of hypertrophic chondrons at 
15.9 weeks of age (Fig. 3.2) to the heavily pyknotic chondrons consistent with 
severe ochronosis, pigmented chondrons were always in some state of 
hypertrophy. As the number of pigmented chondrons increased so did the number 
of hypertrophic chondrons, highlighting their association. Chondrocyte hypertrophy 
is an essential process in endochondral ossification, whereby cartilage is replaced 
by bone in the development of the skeletal system. Hypertrophic chondrons in the 
growth plate of developing bone secrete alkaline phosphatase in order to calcify 
the surrounding matrix leading to bone formation. Although chondron hypertrophy 
is crucial in endochondral ossification, its role in mature cartilage is unclear [143]. It 
has been suggested that the initiation of OA is linked with chondron hypertrophy 
and the resulting increased calcification of the matrix [144] but it has yet to be 
proved conclusively. Markers of hypertrophy, including type X collagen and MMP-
13, are known to be induced in human and murine OA cartilage [117, 145] 
suggesting increased hypertrophy does play a role in the degradation of the 
cartilage. The secretion of alkaline phosphatase from large numbers of 
hypertrophic chondrons in the ACC may be involved in the pathogenesis of OA 
[146]. As alkaline phosphatase release is involved in calcification, it is possible its 
secretion led to thinning of the HAC and thickening of the ACC and SCB by increased 
calcification of the matrix. Indeed, subchondral remodelling and sclerosis was seen 
in many of the mice from 30 weeks onwards along with other signs of OA, including 
tidemark duplication, osteophyte formation and thinning of the HAC and ACC. 
These findings are similar to what is seen in human ochronosis. The identification of 
large numbers of hypertrophic chondrons in the Hgd-/- mice suggests that 
calcification and ossification in the ACC may be an important step in the initiation of 
OA.  
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Along with the identification of hypertrophic chondrons, other signs of OA including 
tidemark duplication, osteophyte formation, HAC damage, subchondral remodelling 
and sclerosis and vascularisation of the ACC were observed in all of the BALB/c Hgd-
/- mice from 30 weeks onwards. The tidemark, first described by Fawns and 
Landells in 1953 [147], denotes the mineralization front separating the HAC and 
ACC. Tidemark duplication has long been thought to be involved in the initiation 
and progression of OA [148, 149] as it suggests increased mineralisation of the 
cartilage in the joint. The identification of duplicate tidemarks in the large majority 
of Hgd-/- mice in this study suggested early changes consistent with the initiation of 
OA were present in the tibio-femoral joint. The fact the changes were present in 
relatively young mice seemed to imply that ochronosis is linked with the initiation 
of early OA. Cartilage damage and degradation was also associated with tidemark 
duplication in a number of the mice. Most of the damage was limited to minor 
fibrillations along the articular surface, however some of the mice showed 
significant loss of articular cartilage along with the presence of deep vertical clefts 
running through HAC (Figs. 3.8 & 3.13). Lesions were most severe in the MTP which 
is consistent with previous observations in mice [150]. Cartilage erosion is a 
hallmark of human ochronotic and OA tissue [37, 151] so it was not surprising to 
see it in the murine model of AKU. Although it was not as severe in the animal 
model, the identification of cartilage degradation highlighted the correlation 
between ochronosis and OA in the tibio-femoral joint of the Hgd-/- mice. 
Osteophytes, which are another characteristic sign of OA [152], were identified in a 
number of aged mice. All of the osteophytes were heavily pigmented which again 
highlighted the relationship between ochronosis and OA. Interestingly, osteophytes 
are noticeably absent from human ochronotic tissue [153, 154]. This is surprising as 
osteophytes are a common feature of OA and most features of OA have been 
observed in AKU tissue, usually in a far more advanced state than in non-AKU OA 
samples. It is likely that the osteophytes in the mice were induced by TGF-β as they 
originated from the periosteum, not the growth plate [152]. Osteophytes are 
known to limit the movement of OA knees [155], which may have contributed to 
the absence of blanket pigmentation in the Hgd-/- mice. Increased mechanical 
stress from loading of the joint is thought to be one of the mechanisms responsible 
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for pigment deposition [36]. Therefore if the joint is unable to move freely when 
osteophytes are present it may limit the amount of pigment deposited in the 
cartilage due to the reduced amount of load placed on the joint. SCB remodelling 
and vascularisation of ACC was observed in a number of the mice from 30 weeks of 
age, most noticeably in BALB/c Hgd-/- 92.1 (♂) (Fig. 3.6). A significant amount of 
SCB remodelling was located in the MFC of BALB/c Hgd-/- 92.1 (♂) along with 
vascular invasion of ACC. The involvement of SCB in the initiation and progression 
of OA was first suggested by Radin and colleagues some 30 years ago [96], however 
it is still unclear what it’s true role is in the pathogenesis of OA. Remodelling of the 
SCB is initiated at areas of focal damage due to excessive loading [95], while 
vascular invasion of cartilage is known to be related to OA [156]. With pigment 
deposition thought to be related to changes in matrix composition, it may be the 
case that increased stiffness of the cartilage resulting from pigmentation leads to 
SCB changes due to the abnormal distribution of stress across the joint. As 
vascularisation of the ACC is associated with OA it is reasonable to assume that 
abnormal and excessive loading can induce vascular invasion of the cartilage which 
further damages the SCB and ACC and may factor in the deposition of pigment. 
 
3.4.2 BL/6 Hgd-/- mice 
BL/6 Hgd-/- 162.2 (♀) was the first mouse of this strain to show signs of 
pigmentation (Fig. 3.21). At 10.4 weeks of age it was considerably younger than 
BALB/c Hgd-/- 93.2 (♂) and 94.1 (♀) who were aged 15.7 weeks when the first signs 
of pigmentation were spotted in the BALB/c strain. Although BL/6 Hgd-/- 162.2 (♀) 
was the only one of a group of four mice at 10.4 weeks of age to display any 
pigmentation it was significant as it showed BL/6 Hgd-/- mice pigment earlier than 
BALB/c Hgd-/- mice. What was also interesting was that the chondrons that were 
pigmented appeared heavily pigmented and pyknotic which is symptomatic of 
chondrons in the final stages of pigmentation, so to see these types of chondrons in 
the initialization of pigmentation was somewhat surprising. The appearance of 
pigmented chondrons at an earlier age in BL/6 Hgd-/- mice than BALB/c Hgd-/- mice 
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may be due to the presence of melanin in the BL/6 Hgd-/- strain. Both ochronotic 
pigment and melanin are products of tyrosine catabolism, in fact pyomelanin, a 
type of melanin produced by microbes, is exactly the same pigment that is found in 
AKU [157, 158]. As melanin and ochronotic pigment are thought to be structurally 
related it is possible that higher natural levels of melanin in the BL/6 Hgd-/- strain 
lead to an increase in the amount of ochronotic pigment produced which accounts 
for the earlier deposition of pigment in the chondrons of the BL/6 Hgd-/- mice.  
 
Similar to BALB/c Hgd-/- mice, pigmentation in BL/6 Hgd-/- mice continued to 
increase with age and was always localized to the ACC, intercondylar areas of the 
femur and tibia and the entheses of the femur. A stage of blanket pigmentation was 
never observed in the BL/6 Hgd-/- mice, which was identical to BALB/c Hgd-/- mice. 
This differed greatly from ochronosis in humans where blanket pigmentation of the 
tissues is routinely seen. The increase in the number of pigmented chondrons with 
age correlates with what is seen in the BALB/c Hgd-/- strain and probably results 
from the same mechanism; compositional changes in the PCM of the chondrons 
and its surrounding matrices which allow for pigment deposition. The fact that 
heavily pigmented chondrons were present in the early stages of pigmentation in 
the BL/6 Hgd-/- mice is peculiar as they are usually associated with the later stages 
of ochronosis. It may be that the BL/6 Hgd-/- mice have larger scale disruption of 
their matrices and the collagens that reside in them, predominantly collagen types 
II, VI, and X, which allows for increased levels of the pigment to become deposited 
in these areas in a shorter time span. However, other unknown factors may also 
play a part in this process.  
 
Pigmentation in BL/6 Hgd-/- mice was always associated with hypertrophic 
chondrons; again this was analogous with what was seen in BALB/c Hgd-/- mice. 
Although there were large numbers of pigmented chondrons in BL/6 Hgd-/- mice 
there appeared to be less very hypertrophic chondrons than in BALB/c Hgd-/- mice. 
Stoop and colleagues observed something similar when comparing the OA changes 
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in both strains [159] and concluded it was no more than strain to strain differences 
between the mice. 
  
Osteoarthritic changes were observed in a large number of the BL/6 Hgd-/- mice 
throughout their whole life span. BL/6 Hgd-/- 35.1 (♂) showed significant signs of 
OA including erosion of the HAC on the MFC (Figs. 3.36 & 3.37), and vascularisation 
of the ACC (Fig. 3.38). The loss of HAC in Hgd-/- mice is likely to be due to 
degradation of type II collagen fibres, most prominently by MMP-13, as these fibres 
make up a large proportion of the HAC matrix. This is known to occur in OA and is 
also associated with calcification of the matrix [160]. Tidemark duplication was also 
present in the majority of the mice from 27 weeks onwards. As previously 
discussed, tidemark duplication is thought to be a marker of OA initiation as it 
suggests increased mineralisation occurring in the joint. Large numbers of 
hypertrophic chondrons were located in the ACC when multiple tidemarks were 
identified, suggesting that calcification is increased in OA. Clustering of 
chondrocytes towards the articular surface was observed in a number of mice (Figs. 
3.25 & 3.31), all of which had signs of OA present. Chondrocyte clustering is a 
known feature of OA pathogenesis [161], however its actual role in the disease is 
relatively unknown. At least in the results detailed in this chapter it seemed to 
occur in response to damage caused to the articular surface of the cartilage. The 
repopulation of these damaged areas with increased amounts of chondrocytes may 
have been an attempt to increase matrix synthesis in order to reduce the amount of 
cartilage degradation at that site. Vascularisation of the ACC was seen in a number 
of mice alongside remodelling of SCB. Significant osteoclastic resorption of the ACC 
had taken place in BL/6 Hgd-/- 62.3 (♀) (Fig. 3.28) which resulted in vascular 
invasion of the calcified cartilage protruding up close to the HAC. Vascularisation 
was present in mice of a wide age range, some of which had clear signs of OA while 
others didn’t. This shows that vascular invasion of the ACC and remodelling of SCB 
appear to both be initiating and late stage features of OA. Meniscal ossification was 
observed in two BL/6 Hgd-/- mice and was localised to the lateral menisci in both. 
Ossification of the meniscus is a common occurrence in mice and other rodents 
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[127], however it has been shown that overgrown calcified menisci can contribute 
to the formation of OA in mice [162]. The LM in BL/6 Hgd-/- 62.3 (♀) was extremely 
large and ossified whilst also containing a substantial number of pigmented 
chondrons. It has been suggested that meniscal calcification can alter the 
biomechanics of the tibio-femoral joint and contribute to OA lesions [163], and that 
SCB adapts and changes in response to the altered mechanical load placed upon the 
joint when calcification of the meniscus occurs [164]. Both BL/6 Hgd-/- mice which 
had ossification of the menisci showed phenotypic changes consistent with OA, 
therefore it is possible meniscal ossification contributed to the progression of OA in 
these animals. However as previously reported in this thesis, meniscal ossification is 
commonly seen with ageing so the formation of them in these two animals may be 
nothing more than a sign of ageing.  
 
Although signs of OA were present in both BALB/c and BL/6 strains of Hgd-/- mice it 
is not clear if these were as a result of the mice having ochronosis or whether they 
developed spontaneously. OA does develop spontaneously in both BALB/c and BL/6 
mice so it is possible the onset of OA in Hgd-/- mice was spontaneous and not 
related to the progression of ochronosis in the mice. Scoring of the OA changes in 
both Hgd-/- and WT mice throughout their lifetime, would provide a better 
understanding of whether the development of OA was spontaneous or directly 
resulted from the development of ochronosis in Hgd-/- mice.   
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3.4.3 Summary 
The identification of ochronotic osteoarthropathy in the Hgd-/- mice is a significant 
step forward in our understanding of the pathogenesis of AKU. From the results 
discussed it appears that initiation of pigmentation in the mice, which is associated 
with focal changes in chondrocytes and their surrounding matrices, is similar with 
the human disorder thus demonstrating the appeal of using the Hgd-/- mice to 
study the natural history of AKU. Both strains of mice showed signs consistent with 
ochronotic osteoarthropathy progressing throughout their lifespan. Once 
pigmentation was initiated it progressed with age which then led to the appearance 
of osteoarthritic changes in the tibio-femoral joint. Again these features were very 
similar to those observed in ochronosis in humans. One feature that is still not 
understood in ochronosis, in both humans and mice, is how HGA becomes situated 
at the site(s) of deposition. As cartilage is avascular there are no blood vessels 
directly supplying the chondrons, therefore there must be another route that 
pigment is transferred to the tissue. One route may be through diffusion of HGA 
from the synovial fluid to the cartilage, however with calcium present in the ACC it 
may be difficult for the pigment to penetrate through. Another route may be 
through the SCB vascular system. Pigmentation has been shown to initiate in 
chondrons deep in the ACC, in both humans and mice, therefore HGA may 
accumulate in blood vessels in the SCB and diffuse through to the ACC before 
becoming deposited in chondrons. The discovery of ochronosis in the Hgd-/- mice is 
important as it provides a robust model to evaluate new novel therapies for the 
treatment of AKU while also providing a new model of experimental OA. 
 
 
 
 
 
120 
 
 
 
 
 
 
 
 
 
 
 
4. Initiation, distribution and localization of ochronotic pigmentation 
in Hgd-/- mice 
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4.1 INTRODUCTION 
Following the identification of ochronotic pigmentation and associated 
osteoarthropathy in Hgd-/- mice (Chapter 3), further analysis was undertaken to try 
and identify the mechanism of pigment deposition. Until recently the mechanism 
behind HGA polymer deposition in the collagenous tissues of AKU patients was 
unknown [20, 35, 41]. Following work by Taylor et al [28] which suggested the 
presence of a preferential binding site(s) for ochronotic pigment on collagen fibres, 
the same authors proposed a mechanism for the initiation of ochronotic 
arthropathy in AKU patients [36]. They suggested that the initiation of pigmentation 
followed focal changes in the matrices of the ACC, thus allowing ochronotic 
pigment to bind to collagen fibres. The authors also describe the progression of 
pigmentation from its initiation in the ACC to its blanket distribution throughout the 
entire articular cartilage.  
 
Chapter 3 of this thesis describes in detail the natural history of ochronosis in 
BALB/c and BL/6 Hgd-/- mice. Previous to this, little was known about the 
pathogenesis of ochronosis in Hgd-/- mice [51, 110]. This Chapter proposes a partial 
mechanism for the initiation and progression of ochronosis in a murine model of 
AKU. Following apparent changes in the composition and/or organisation of the 
matrices in the ACC of Hgd-/- mice, ochronotic pigment became deposited in the 
PCM. Cellular material then became pigmented resulting in widespread 
pigmentation of the ACC. Although the HAC appears to be unaffected by ochronosis 
in Hgd-/- mice, the data presented in this chapter shows the initiation and 
progression of pigmentation, in mice, to be almost identical to the mechanism 
proposed by Taylor [36]. 
  
Although ochronosis is most severe in articulating joints, other tissues in the body 
can become pigmented. There have been many cases in which pigmentation has 
been found in aortic valves [31, 165-167], the sclera of the eye [168, 169] and the 
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ear, including the earwax [170, 171] of AKU patients. For this thesis, large scale 
analysis was limited to the knee joint as this becomes severely ochronotic in 
humans. However, several other joints including the femoral head, the calcaneus 
and the humerus epicondyle (elbow joint), from a BALB/c Hgd-/- mouse aged 65.7 
weeks, were examined in order to establish whether ochronosis was present in 
other articulating joints in Hgd-/- mice as it is in AKU patients. This Chapter details 
the distribution of ochronotic pigment in these tissues, highlighting the practicality 
of the Hgd-/- mice as a model of ochronosis. 
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4.2 DESIGN OF STUDY 
Tissue samples from the knee joints of BALB/c and BL/6 Hgd-/- mice were stained 
with H&E and Schmorl’s stain in order to investigate the initiation and progression 
of ochronotic osteoarthropathy. 
 
Several other articulating joints, as noted in the introduction, were also stained 
with H&E and Schmorl’s stain to determine if pigmentation was located in these 
areas. 
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4.3 RESULTS 
4.3.1 A proposed mechanism for the initiation of ochronosis in Hgd-/- mice 
Pigmentation was first identified in BALB/c Hgd-/- mice at 15.7 weeks of age and at 
10.4 weeks of age in BL/6 Hgd-/- mice (Chapter 3). Upon closer examination of the 
BALB/c Hgd-/- mouse, pigmentation was localised to the PCM of two chondrons in 
the ACC both of which appeared healthy (Fig. 4.1). No cellular staining was present 
indicating a change must have occurred in the PCM leading to deposition of 
ochronotic pigment. Peri-cellular staining of these two chondrons represented the 
initiation of pigmentation in BALB/c Hgd-/- mice, and was consistent with the 
proposed mechanism of ochronosis in AKU patients [36]. 
 
 
 
 
 
Figure 4.1 – Initiation of ochronotic pigmentation in the pericellular matrix. 
Two chondrons showed pericellular pigmentation in ACC of the MFC of a 15.7 
week old BALB/c Hgd-/- mouse; the first stage of pigmentation in ochronotic 
chondrons. Section taken from BALB/c Hgd-/- 94.1 & stained with Schmorl’s. Bar 
= 10µm. 
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In Hgd-/- mice of advancing age there was an increased amount of pigmentation, as 
detailed in the Chapter 3. In these mice, pigmentation of chondrons had progressed 
intracellularly (Fig. 4.2). This was probably due to the increasing amounts of HGA 
being deposited in the chondrons following the initial change in their pericellular 
environment. Although the number of pigmented chondrons increased, non-
pigmented cells were still visible in the ACC. This demonstrated the individuality 
between chondrons, as although a large percentage of them were pigmented, some 
appeared to have been completely unaffected or were in the very early stages of 
pigmentation. Again, this progression of pigmentation was consistent with that 
previously observed in AKU tissue samples [36]. 
 
 
 
 
 
 
Figure 4.2 – Intracellular progression of ochronotic pigmentation. Pigmented 
chondrons in ACC of the MFC of a 27.4 week old mouse in which pigmentation 
had progressed intracellularly. Non-pigmented chondrons were still located in 
the cartilage; two are located adjacent to the highlighted pigmented chondrons. 
Section taken from BALB/c Hgd-/- 99.1 & stained with Schmorl’s. Bar = 10µm. 
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The final stage of pigmentation involved chondrons becoming pyknotic and heavily 
pigmented both intra- and extracellularly. Staining of these chondrons was very 
intense indicating a large amount of pigment was deposited in the cell (Fig. 4.3). 
Most of the chondrons in the ACC displayed this phenotype, however a small 
number were still in the early stages of pigmentation. This is shown best in a 
section of the LTP from BALB/c Hgd-/- 50.3, aged 65.7 weeks, where the complete 
staging of chondron pigmentation can be observed (Fig. 4.4).  
 
 
 
 
 
 
Figure 4.3 – End stage pigmentation of ochronotic chondrons. Heavily 
pigmented chondrons located throughout the ACC of the LFC of a 65.7 weeks 
old mouse. Although most chondrons were pyknotic, some chondrons in the 
early stages of pigmentation were observed. Section taken from BALB/c Hgd-/- 
50.3 & stained with Schmorl’s. Bar = 10µm. 
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When pigmentation was first identified in BL/6 Hgd-/- mice at 10.4 weeks, the 
pigmented chondrons showed heavy staining of their nuclear material as well as 
PCM staining (Fig. 4.5). This was unusual as it appeared not to follow the same 
pattern of pigmentation as BALB/c Hgd-/- mice. However in a BL/6 Hgd-/- mice 
aged 41.3 weeks (BL/6 Hgd-/- 82.1) the same staging of chondrons was visible (Fig. 
4.6), indicating that the mechanism of pigmentation was similar in both strains of 
mice. 
 
Figure 4.4 – Stages of pigmentation in the lateral tibial plateau of a 65.7 week 
old BALB/c Hgd-/- mice. (1) Healthy chondron with no staining, (2) healthy 
chondron with staining of the PCM, (3) chondron with both intracellular and 
extracellular staining, and (4) a heavily pigmented pyknotic chondron. Section 
taken from BALB/c Hgd-/- 50.3 & stained with Schmorl’s. Bar = 10µm. 
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Figure 4.5 – A heavily stained chondron in the lateral tibial plateau of a 10.4 
week old BL/6 Hgd-/- mouse. A chondron in the LTP of a 10.4 weeks old BL/6 
mouse displaying heavy nuclear staining. Section taken from BL/6 Hgd-/- 162.2 
& stained with Schmorl’s. Bar = 20µm. 
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The identification of a possible mechanism for pigment initiation and the ability to 
show each stage of pigmentation in chondrons in Hgd-/- mice is an important step 
for AKU research. The initiation of pigmentation appeared to follow a change in the 
composition and/or organisation of the PCM which is consistent with human data. 
Once deposition of ochronotic pigment begins it undoubtedly has a detrimental 
effect on the health of the chondrocyte, leading to an increase in pigment 
deposition. The entire chondron then becomes pigmented rendering it inactive and 
leaving the chondrocyte unable to participate in cartilage/matrix turnover. This, in 
all probability contributes to degradation of the matrix and the osteoarthropathy 
associated with AKU. 
 
Figure 4.6 – Stages of pigmentation in the medial femoral condyle of BL/6 Hgd-
/- 82.1, a 41.3 week old Hgd-/- mouse. (1) Healthy chondron with no staining, 
(2) healthy chondron with staining of the PCM, (3) a lightly pigmented chondron, 
and (4) a heavily pigmented pyknotic chondron. Section taken from BL/6 Hgd-/- 
82.1 & stained with Schmorl’s. Bar = 20µm. 
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4.3.2 Quantitative analysis of the proposed pigmentation pathway 
As previously stated in this Chapter, a pathway for the stages of pigmentation seen 
in Hgd-/- mice has been proposed. Although the total numbers of pigmented 
chondrons in BALB/c and BL/6 Hgd-/- mice were quantified for the natural history 
studies (Chapter 3), these counts did not show the amount of each type of 
chondrocyte (1-non-pigmented, 2-PCM staining, 3-lightly pigmented chondron and 
4-heavily pigmented chondron) at each individual time point. Sections from the 
natural history studies (Chapter 3) were re-counted to determine the percentage of 
each type of chondrocyte at each time point in BALB/c and BL/6 Hgd-/- mice (Fig. 
4.7) 
 
  
 
 
 
Figure 4.7 – The percentage of each type of chondrocyte in BALB/c and BL/6 Hgd-
/- mice. The percentage of each type of chondrocyte, (A) non-pigmented, (B) PCM 
staining, (C) lightly pigmented chondron(s) and (D) heavily pigmented chondron(s), 
was plotted against the age of the Hgd-/- mice to provide a visual representation 
of their association. 
A B 
C D 
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It is clear from the charts in Fig. 4.7 that the number of non-pigmented chondrons 
decreases significantly with age (Fig. 4.7 (A)). This was an expected outcome as it 
had been previously shown in Chapter 3 that aged Hgd-/- mice are populated with 
large numbers of heavily pigmented chondrons, something which is clearly shown 
in Fig. 4.7 (D). There appeared to be slightly more variability in the amount of PCM 
stained and lightly stained chondrons with age, however this was not surprising as 
both these types of chondrons were present in Hgd-/- mice throughout the majority 
of their lifetime. 
 
Univariate regression analysis was performed to determine if there was any 
statistical significance between the association of different chondron types in both 
strains of Hgd-/- mice (Table. 4.1). 
 
 BALBc (n=23)  BL6 (n=18) 
 Estimate 95% CI p-
value 
 Estimate 95% CI p-
value 
Non-
Pigmented 
-1.55 (-1.94, -
1.15) 
<0.001  -1.51 (-2.04, -
0.98) 
<0.001 
PCM -0.09 (-0.25, 
0.07) 
0.238  -0.04 (-0.25, 
0.18) 
0.725 
PCM and LCS 0.54 (0.37, 
0.71) 
<0.001  0.21 (-0.11, 
0.53) 
0.188 
PCM and 
HCS 
1.10 (0.75, 
1.45) 
<0.001  1.33 (1.09, 
1.58) 
<0.001 
  
 
 
As seen in Table. 4.1, there was a statistically significant association (p<0.001) 
between the percentage of non-pigmented, lightly stained and heavily stained 
chondrocytes with age in BALB/c Hgd-/- mice. Aged BALB/c Hgd-/- mice were 
associated with a lower percentage of non-pigmented chondrocytes, and a higher 
percentage of lightly stained and heavily stained chondrons. BL/6 Hgd-/- mice 
Table 4.1 – Univariate regression analysis showing the significance of the 
association between the four different chondron types in BALB/c and BL/6 Hgd-/- 
mice.  
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showed a statistically significant association between the percentage of non-
pigmented and heavily stained chondrocytes with age. Aged BL/6 Hgd-/- mice were 
associated with a lower percentage of non-pigmented chondrocytes and a higher 
percentage of heavily stained chondrons, similar to that seen in aged BALB/c Hgd-/- 
mice.  
 
4.3.3 Distribution of ochronotic pigment in the articulating joints of an aged 
BALB/c Hgd-/- mouse 
Ochronosis is not limited to the knee joint in humans. It has been found in many 
different tissues, all of which have showed varying degrees of severity. Although 
large scale analysis of Hgd-/- mice was confined to the knee joint, the femoral head, 
calcaneus, and the lateral epicondyle of the humerus from a 65.7 week old BALB/c 
Hgd-/- (ID: BALB/c Hgd-/- 50.3) mouse were all examined to identify if 
pigmentation, like in humans, was located in other load bearing joints. 
 
4.3.3.1 Femoral head 
Schmorl’s staining revealed widespread pigmentation throughout the entire 
femoral head (Fig. 4.8). Heavily pigmented and lightly pigmented chondrons were 
easily identifiable (Fig. 4.9) indicating the pattern of pigmentation was similar to 
that seen in the knee joints of the mice. There appeared to be some significant 
cartilage damage along the surface of the femoral head (Fig. 4.8) which is consistent 
with that seen in the knee joint of aged Hgd-/- mice. 
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Figure 4.8 – Pigmentation and cartilage damage in the femoral head of a 65.7 
week old BALB/c Hgd-/- mouse. Widespread pigmentation and severe cartilage 
erosion of cartilage was observed in the femoral head. Section taken from 
BALB/c Hgd-/- 50.3 & stained with Schmorl’s. Bar = 10µm. 
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4.3.3.2 Calcaneus 
Large numbers of pigmented chondrons were clustered at the site of insertion of 
the Achilles tendon (Fig. 4.10). This area is subject to significant loading over time 
which may have had an effect on the amount of pigmentation at this area. Most of 
the chondrons located in the calcaneus were heavily pigmented and hypertrophic, 
both consistent with the data obtained from the tibio-femoral joint of aged Hgd-/- 
mice. 
 
Figure 4.9 – Different stages of pigmentation in the femoral head of a 65.7 
week old BALB/c Hgd-/- mouse. Both heavy and lightly stained chondrons were 
located in close proximity to one another. Section taken from BALB/c Hgd-/- 50.3 
& stained with Schmorl’s. Bar = 20µm. 
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4.3.3.3 Humerus epicondyles 
Significant amounts of pigmentation were located at the lateral epicondyle and 
radius of the humerus (Fig. 4.11). Heavily pigmented chondrons were scattered 
throughout the ACC of this area (Fig. 4.12) which was consistent with the location 
of pigmented chondrons in the tibio-femoral joint of the mice. Again, this area is 
heavily loaded in mice which may account for the high proportion of pigmented 
chondrons located in this area.  
 
Figure 4.10 – Clustering of pigmented chondrons in the calcaneus of a 65.7 
week old BALB/c Hgd-/- mouse. Large numbers of heavily pigmented chondrons 
were located adjacent to the insertion of the Achilles tendon in the calcaneus. 
Section taken from BALB/c Hgd-/- 50.3 & stained with Schmorl’s. Bar = 20µm. 
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Figure 4.11 – Dense pigmentation in the lateral epicondyle of the humerus and 
the radius from a 65.7 week old BALB/c Hgd-/- mouse. Large numbers of 
heavily pigmented chondrons were spread throughout the joint, similar to that 
observed in the tibio-femoral joint. Section taken from BALB/c Hgd-/- 50.3 & 
stained with Schmorl’s. Bar = 10µm. 
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The identification of pigmented chondrons in all three joints examined was 
encouraging as it highlighted the validity of the Hgd-/- mice as a model of 
ochronosis in humans. The amount of pigmented chondrons, and the phenotype 
they displayed was consistent with previous observations in the tibio-femoral joints 
of aged BALB/c Hgd-/- and BL/6 Hgd-/- mice. Although no young mice were 
examined it is expected they would show the same age related pattern of 
increasing pigmentation as seen in the tibio-femoral joint (Chapter 3).  
 
 
 
Figure 4.12 – Localisation of pigmentation to articular calcified cartilage in the 
radius of a 65.7 week old BALB/c Hgd-/- mouse. Pigmented chondrons where 
all located within the ACC, identical to that observed in the tibio-femoral joint. 
Section taken from BALB/c Hgd-/- 50.3 & stained with Schmorl’s. Bar = 20µm. 
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4.3.4 Localization of ochronotic pigment to articular calcified cartilage 
Microscopic analysis of human AKU samples has shown in severe cases that 
pigmentation, although initiating in the ACC, progresses throughout both the ACC 
and HAC. From the murine studies it was clear that pigmentation initiated in, and 
was localised to areas of calcified cartilage only. Calcified cartilaginous areas of 
articular cartilage, fibrocartilage, meniscus, and osteophytes, all became pigmented 
in the tibio-femoral joint of both strains of Hgd-/- mice. In the following 
photomicrograph (Fig. 4.13), the tidemark has been highlighted which separates 
the HAC and ACC, making it easy to identify that pigmentation was localised to the 
ACC in the femoral condyles and TP. 
 
 
 
 
 
Figure 4.13 – Localisation of pigmentation to the articular calcified cartilage in 
the medial tibial plateau of a 31.7 week old BL/6 Hgd-/- mouse. Arrows 
indicating the tidemark highlight the localisation of pigmented chondrons to the 
ACC. Section taken from BL/6 Hgd-/- 99.4 & stained with Schmorl’s. Bar = 20µm. 
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Dense areas of pigmented chondrons were located in the calcified fibrocartilage of 
entheses attached to the femoral condyles (Fig. 4.14). These areas are exposed to 
significant amounts of mechanical loading which may account for the large quantity 
of pigmentation seen in them.  
 
 
 
 
 
 
Ossification of the menisci was observed in several of the Hgd-/- mice, in each case 
pigmented chondrons were identified in the calcified cartilage of the meniscus. The 
formation of bone in the meniscus of mice is not an uncommon occurrence [127], 
however it is in humans [128, 172]. Although meniscal ossicle’s were observed in 
mice with OA changes, their formation is a normal phenomenon associated with 
Figure 4.14 – Pigmentation in the enthesis of a 61.3 week old BALB/c Hgd-/- 
mouse. Pigmented chondrons were seen in the calcified area of the 
fibrocartilage. Section taken from BALB/c Hgd-/- 59.2 & stained with Schmorl’s. 
Bar = 20µm. 
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ageing. The following photomicrograph, from the LM of a 60 week old BALB/c Hgd-
/- mouse, shows pigmented chondrons in calcified cartilage surrounding an area of 
ossification (Fig. 4.15). Osteophyte formation was also common in Hgd-/- mice. 
Pigmented chondrons were present in every osteophyte and located in the calcified 
cartilage surrounding the new bone which had formed (Fig. 4.16). 
 
 
 
 
 
 
 
Figure 4.15 – Pigmentation of the lateral meniscus in a 60 week old BALB/c 
Hgd-/- mouse. Pigmented chondrons, both heavily and lightly stained, were 
located adjacent to the formation of new cortical bone in the meniscus. A thin 
layer of uncalcified cartilage (bottom arrow) contained no pigmented chondrons. 
Section taken from BALB/c Hgd-/- 61.3 & stained with Schmorl’s. Bar = 20µm. 
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The localization of pigmentation to calcified cartilage is an interesting observation 
as it differs slightly from that seen in human ochronotic samples where 
pigmentation is seen in both the ACC and HAC. Little is known about the exact 
structure of ochronotic pigment or how it becomes deposited in chondrons and 
cartilage however this finding appears to show that the initial key interactions take 
place in calcified cartilage.   
 
 
Figure 4.16 – Pigmented chondrons in the calcified cartilage of an osteophyte. 
The formation of the osteophyte (O), denoted by the red line, is associated with 
osteoarthropathy. All pigmented chondrons (arrowed) in the osteophyte were 
localised to the calcified cartilage. This is highlighted by the yellow line which is 
representative of the tidemark separating uncalcified and calcified cartilage. 
Section taken from BALB/c Hgd-/- 61.4 (60 weeks) & stained with Schmorl’s. Bar 
= 20µm. 
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4.5 DISCUSSION 
The results detailed in this Chapter reveal interesting pathological features of Hgd-
/- mice, most of which show similarities to the pathogenesis of AKU in humans. 
Taylor and colleagues [36] have previously proposed a mechanism for the initiation 
and progression of ochronotic osteoarthropathy in humans involving the ACC and 
SCB. They state that pigmentation initiates following a change in the matrices of the 
ACC which alters their composition and/or organisation thus facilitating deposition 
of ochronotic pigment, initially in the PCM before progressing intracellularly. It is 
vitally important that the mechanism of pigment deposition is identified as it will 
provide a greater understanding of the pathogenesis of AKU and could lead to the 
identification of new therapeutic targets. Following on from the natural history 
study of ochronotic osteoarthropathy in Hgd-/- mice, in Chapter 3 of this thesis, 
further data analysis of the histological samples obtained revealed details about the 
staging of chondron pigmentation in Hgd-/- mice. 
 
The first identifiable sign of pigmentation in BALB/c Hgd-/- mice was the presence 
of pericellular staining in a 15.7 week old mouse (Fig. 4.1). Consistent with the 
human data reported by Taylor et al [36], pigmentation appeared to initiate in the 
PCM of individual chondrons specifically located in the ACC. Pigmentation then 
progressed intracellularly (Fig. 4.2) before the cells became pyknotic (Fig. 4.3). This 
process appears to be very similar to the process of pigmentation in humans 
suggesting that the pathogenesis of ochronosis in the two species may be closely 
related. The appearance of pigmentation in the PCM, the first stage of ochronotic 
osteoarthropathy, is likely linked to an initial change in the composition and/or 
organisation of the matrix in this area (Fig. 4.17). It is possible this is linked to 
repetitive and abnormal loading of the articulating joints which has also been linked 
with the development of OA [173]. Abnormal loading can cause chondrocytes to 
express catabolic phenotypes resulting in expression and upregulation of matrix 
degrading proteases which may further increase pigment deposition. The PCM of 
chondrons is rich in molecules including HA [174], large and small proteoglycans 
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including perlecan [175], biglycan [176], decorin [177], and types VI [69], IX [178], 
and X [179] collagen. These molecules are vitally important to cellular activity and 
any alteration to them, and subsequently the PCM may render the chondrons 
susceptible to pigment deposition (Fig. 4.16). It has been shown that the PCM of 
chondrons in disease states has drastically different mechanical properties to the 
PCM of normal chondrons [180] which is almost certainly a factor in AKU and 
pigment deposition. As initial pigment deposition takes place in the PCM it is 
possible a change occurs in this area which leads to the deposition of pigment. It 
may be that the mechanical properties of the PCM become altered prior to or 
following initial pigment deposition, resulting in abnormal strain distribution across 
the tibio-femoral joint and thus leading to further damage and increased pigment 
deposition (Fig. 4.16). However it is still not known what the initiating factor(s) are 
that lead to deposition of ochronotic pigment in the PCM. Using a selection of 
different techniques to isolate chondrons it may be possible to determine if altered 
mechanical properties of the PCM play a role in pigment deposition. Low-speed 
homogenisation [181] and enzymatic isolation [182] can be used to characterize 
chondrons however both have limitations with regards to the amount, and 
structure of the chondrons isolated. Alexopoulos and colleagues have developed a 
novel method to mechanically isolate chondrons using what they term a 
‘microaspirator’ [180]. Using this technique the Young’s modulus of isolated 
chondrons can be determined and any change in the mechanical properties of the 
chondron identified. This technique would be useful to determine if the PCM of 
ochronotic chondrons from Hgd-/- mice differs from the PCM of chondrons isolated 
from WT mice. Any variations observed in the Young’s modulus between 
ochronotic and normal chondrons would then appear to show that the PCM of 
ochronotic chondrons becomes altered resulting in deposition of pigment. Taylor 
and colleagues have shown there is less extractable proteoglycans in ochronotic 
cartilage, compared to normal and OA cartilage, which further highlights the 
apparent association between altered mechanical properties and pigment 
deposition [183]. Collagens present in the PCM are the most probable deposition 
site for pigment; evidence for this has been presented by Taylor et al [28]. Cleavage 
of proteoglycans in the PCM may precede pigment deposition as once they are 
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cleaved binding sites on collagen fibres become uncovered, exposing a site where 
the pigment polymer can bind. Whether these biomechanical and biochemical 
changes are specific to AKU tissues is still unknown. It is possible that these changes 
occur in non-AKU (normal) tissues and HGA is simply a marker of tissue damage. 
Preliminary studies have shown that incubating normal cartilage in a solution of 
HGA leads to areas of focal pigmentation in the tissue [184]. Further work is 
required to validate the initial findings however they appear to suggest that 
molecules such as HGA may be able to identify areas of tissue damage. This would 
explain why some chondrons are pigmented, yet others in very close proximity are 
non-pigmented. 
 
The quantitative analysis shown in Fig. 4.7 supports the proposed staging of 
pigmentation in BALB/c and BL/6 Hgd-/- mice. The decrease in the number of non-
pigmented chondrons as the mice aged is consistent with the hypothesis that 
increased amounts of pigment are deposited with age. The fact that non-pigmented 
chondrons are present even in the oldest BALB/c and BL/6 Hgd-/- mice appears to 
show that a change must occur in the PCM of individual chondrons in order for 
them to become pigmented. Staining of the PCM of chondrons was identified as the 
first sign of pigment deposition in Hgd-/- mice. The appearance of PCM stained 
chondrons throughout the lifetime of Hgd-/- mice suggests that pigmentation 
initiates in individual chondrons at different time points, and continues throughout 
life. The gradual increase of light and heavily stained chondrons with age was 
expected as it was shown in the natural history study of Hgd-/- mice that 
pigmentation increases with age. With increasing amounts of ochronotic pigment 
becoming deposited in the tibio-femoral joint over time, the appearance of more 
heavily stained chondrons is not surprising. This is consistent with the proposed 
pigmentation pathway, both in Hgd-/- mice and in humans. The data obtained from 
the quantitive analysis of the proposed pigmentation pathway supports the 
differing stages of chondron staining and shows that pigmentation does initiate 
extracellularly before progressing into the cell. 
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Figure 4.17 – Diagram of the stages of pigmentation in Hgd-/- mice. Although the 
exact mechanism of pigmentation is still unknown, certain key factors appear to 
play important roles. Mechanical loading is involved in the development of OA and 
appears to be implicated in the initiation and progression of ochronotic 
osteoarthropathy. Changes in the PCM following abnormal loading seems to result 
in healthy chondrons (1) becoming susceptible to pigment deposition which 
initiates in the PCM (2). Alterations in strain distribution resulting from changing 
PCM mechanical properties likely leads to an increase in the amount of pigment 
deposited in the cells (3). Changes in chondrocyte function and activity also appear 
to play a role in pigment deposition and may ultimately result in them becoming 
heavily pigmented (4). 
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Mechanical and oxidative damage are key factors in cartilage and chondron 
breakdown, and have been linked with OA initiation and progression [185-189]. The 
early onset of OA is linked with AKU in humans [190] and results from this thesis 
have also shown it to be present in the murine model of AKU. There appears to be a 
role for both mechanical and oxidative damage in the pigmentation process. It is 
possible that mechanical damage, through abnormal load distribution, is involved in 
the initiation and progression of pigmentation. Data from Taylor et al [36] has 
shown that presence of pigment stiffens the cartilaginous matrix altering its 
biomechanical properties. Damage resulting from abnormal load distribution may 
result in the tissue becoming susceptible to pigmentation. As seen from the figures 
(Figs. 4.1, 4.2, 4.3 & 4.4) once pigmentation is initiated it triggers a cascade of 
downstream events leading to accumulation of pigment and the formation of OA. 
Oxidative damage may also be involved in the proliferation of pigmentation. Both 
HGA and its quinone intermediate, BQA, have previously been shown to induce 
DNA damage through the formation of reactive oxygen species (ROS) [59, 191]. ROS 
also leads to senescence in chondrocytes [192]. It is possible increased formation of 
HGA/BQA causes damage to the DNA of healthy chondrons through generation of 
ROS, rendering them senescent and susceptible to pigmentation. The depletion of 
anti-oxidants by both HGA and BQA can result in damage to macromolecules in 
cartilage [193]. The resulting structural alterations of the cartilaginous matrix make 
this another possible mechanism of pigment deposition. The close association of 
AKU and OA, and the possible roles of mechanical and oxidative damage underline 
the importance of these processes to the initiation and progression of ochronotic 
osteoarthropathy. 
 
Although the staging of chondrons in BL/6 Hgd-/- mice did not appear to initially 
follow the pattern observed in BALB/c Hgd-/- mice (Fig. 4.5), sections from older 
mice showed the chondrons did appear in all four stages of pigmentation (Fig. 4.6). 
It is possible that heavy staining of chondrons in young mice is linked to the 
apparent association between ochronotic pigment, also known as pyomelanin 
[158], and melanin. BL/6 mice have a considerable amount more melanin than 
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BALB/c (albino) mice therefore, as ochronotic pigment and melanin are believed to 
be structurally related, it is possible they have an increased amount of ochronotic 
pigment forming leading to earlier detection and increased amounts of deposition 
in BL/6 Hgd-/- mice. 
 
The identification of pigmentation in the femoral head (Fig. 4.8), calcaneus (Fig. 
4.10), and humerus epicondyles (Fig. 4.11) in Hgd-/- mice was a significant 
discovery as it highlighted the practicality of the Hgd-/- mice as a model of human 
AKU. The femoral head in particular is a site of severe ochronotic osteoarthropathy 
in humans [30, 194] so it is of great importance that Hgd-/- mice showed signs of 
ochronotic osteoarthropathy in this joint. Pigmented chondrons in the femoral 
head, similar to those in the tibio-femoral joint, were localized to the ACC and 
appeared to show the same initiation and progression process (Fig. 4.9). 
Macroscopically no pigment was observed however this is consistent with all 
ochronotic joints in Hgd-/- mice. All three joints were heavily pigmented which is 
consistent with the finding that pigmentation increases with age. Although none of 
these joints were looked at in younger Hgd-/- mice previous results obtained from 
the tibio-femoral joint of younger mice suggest that they would be sparsely 
pigmented and the number of pigmented chondrons would increase linearly with 
age. Mechanical damage resulting from persistent heavy loading of all the joints is 
likely to have contributed to pigmentation, as is the case in the tibio-femoral joint. 
As expected all pigmented chondrons identified were hypertrophic and located to 
the ACC, consistent with data already obtained from Hgd-/- mice. The majority of 
pigmented chondrons in the calcaneus and humerus epicondyles were heavily 
stained indicating they were in the final stages of pigmentation. There were some 
lightly stained chondrons in the femoral head (Fig. 4.9) which is consistent with the 
appearance of some chondrons in the tibio-femoral joint of old Hgd-/- mice. 
Although the three different joints were only examined in one aged BALB/c Hgd-/- 
mouse, the data collected provides important information on the pathogenesis of 
ochronosis in the murine model of AKU. 
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One interesting pathological feature of ochronosis in Hgd-/- mice was the 
localization of pigmented chondrons to the ACC (Figs. 4.12, 4.13, 4.14 & 4.16). 
Calcified cartilage has been less extensively studied than hyaline cartilage and bone 
due to their significant involvement in OA however in the case of AKU it is of critical 
importance. It is still unclear as to why pigmentation initiates in the ACC, rather 
than in the HAC. There must be a close association between molecules present in 
the ACC and ochronotic pigment, as in both humans [36] and mice pigmentation 
initiates in this region. Little is known about the complete mineral content of the 
ACC [195], however studies have shown that the major mineral component by 
weight is hydroxyapatite [196, 197], similar to the SCB. It is unlikely that ochronotic 
pigment binds to hydroxyapatite as no pigmentation was located in the bone 
matrix, of which a significant amount is hydroxyapatite. Chondrocytes located in 
the ACC exhibit a hypertrophic phenotype while those in HAC do not. It is possible 
this is linked to the initiation of pigmentation in the ACC as hypertrophic 
chondrocytes are known to express factors which actively degrade components of 
the matrix. Alteration of the PCM and its mechanical properties may result in initial 
pigment deposition leading to further disruption of matrix mechanical properties 
and in turn, proliferation of pigment deposition in affected chondrons. 
 
The most probable binding sites for pigment in the ACC are collagen [28]. Type VI 
collagen is the primary collagen in the PCM of chondrons [198, 199] therefore these 
fibre types are likely to be one of the principal binding sites for ochronotic pigment. 
Type VI collagen is also found in calcified fibrocartilage, particularly in the menisci 
and intervertebral discs [200]. Pigmentation is present in the menisci of Hgd-/- mice 
(Chapter 3) and although the intervertebral discs have not been examined in the 
Hgd-/- mice, they are a primary site of pigmentation in AKU patients. With large 
numbers of pigmented chondrons observed in the calcified fibrocartilage of the 
entheses it is possible that type VI collagen is a preferential binding site for 
ochronotic pigment. Type II and type X collagen are found in the ACC [195, 201], 
whilst type II is also the major component of the HAC [160, 195]. Therefore it’s 
possible both are alternative binding sites for ochronotic pigment. Type X collagen 
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is expressed by hypertrophic chondrons [179, 202] and is found in their PCM [203], 
along with small amounts of HA [204]. All of the pigmented chondrons in the ACC 
expressed a hypertrophic phenotype. With pigmentation thought to initiate in the 
PCM of ochronotic chondrons in both humans [36] and Hgd-/- mice (Chapters 3 & 
4) it is possible that type X collagen, along with type VI, is a primary binding site for 
ochronotic pigment. In humans it is likely that the pigment also binds to type II 
collagen, GAGs and other molecules as blanket pigmentation of the entire articular 
cartilage is often observed. However as this stage is never reached in Hgd-/- mice 
binding of pigment is most probably reserved to the collagens located in the PCM of 
hypertrophic chondrons in the ACC. 
 
The data discussed in this Chapter further highlights the strength of the murine 
model of AKU to replicate the pathogenesis seen in human AKU patients. The 
proposal of a mechanism which is identical to the one seen in humans, the 
discovery of pigmentation in several different articulating joints, and the 
localization of pigmentation to the ACC suggests that the murine model of 
ochronotic osteoarthropathy is an excellent model for AKU research. 
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5. Testing the efficacy of nitisinone in treating ochronotic 
osteoarthropathy in Hgd-/- mice 
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5.1 INTRODUCTION 
This Chapter investigated the effects of the compound nitisinone on the initiation 
and progression of ochronotic osteoarthropathy in alkaptonuric mice. Treatment 
options for AKU are currently restricted to pain relief and eventually joint 
replacement surgery(s) leaving patients with persistent and excruciating pain for 
extended periods of time. Following the identification of ochronotic 
osteoarthropathy in Hgd-/- mice (Chapter 3) there is now a model which can be 
used to test the efficacy of different therapies for the treatment of AKU. Nitisinone 
acts on the tyrosine catabolic pathway (Fig. 1.1) and has been a major success in 
alleviating the fatal effects of HT-1 [49]. By inhibiting the HPPD enzyme, nitisinone 
not only prevents the formation of toxic products key to the development of HT-1 
but also the formation of HGA. As a result nitisinone was previously trialled as a 
treatment for AKU patients [52, 53]. The three year trial undertaken at the National 
Institute of Health [53] provided disappointing results, primarily due to the end-
point chosen. Hip rotation was selected as the parameter to determine the efficacy 
of nitisinone however, the results showed there to be significant variability in the 
range of motion in the same patients from visit to visit.  The data collected from this 
trial highlighted the need for a whole of life study to determine the benefits and 
detrimental effects of treating AKU patients with nitisinone for long periods of time. 
This Chapter details several studies undertaken in which the aims were to identify 
the effects of nitisinone on pigment deposition and plasma HGA levels throughout 
the lifespan of Hgd-/- mice. Until now there has been no previous evidence offered 
to show that nitisinone does inhibit ochronotic pigmentation. The results detailed 
in this Chapter show nitisinone is able to completely prevent pigmentation when 
given throughout life, stop further deposition of ochronotic pigment when given 
mid-life and reduce lifetime levels of plasma HGA, with little or no side-effects. 
These results reveal that early-stage treatment of AKU with nitisinone can be 
effective in preventing deposition of ochronotic pigment and the severe 
osteoarthropathies associated with AKU. 
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5.2 DESIGN OF STUDY 
In both the lifetime and mid-life treated groups the dosage of nitisinone provided in 
the drinking water of the mice was 4 mg/l. This dosage was selected from HPLC 
studies which showed this to be the lowest dose which had an effect on HGA levels. 
  
Once the in vivo portion of the study was completed, the left knee was dissected 
out from each mouse and serial sections were stained with H&E and Schmorl’s stain 
to highlight differences in pigmented chondron numbers, and joint changes. 
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5.3 RESULTS 
5.3.1 Lifetime treatment with nitisinone 
A cohort of 16 BALB/c Hgd-/- mice (eight male, eight female) were provided with an 
ad libitum supply of water containing 4mg/l of nitisinone from 8 to 67 weeks of age. 
The control group of 16 BALB/c Hgd-/- mice (nine male, seven female) had no drug 
in their drinking water from birth until 71 weeks of age. Plasma was taken 
immediately prior to treatment, and then sampled regularly by tail bleed over the 
lifespan of the mice. 
 
5.3.1.1 Treated group 
Of the sixteen mice treated with nitisinone, seven were kept in the study until the 
end of their lives and six were culled halfway through the study. Three mice were 
discovered to be deceased upon inspection of their cages. All three were male, 
aged 37 weeks (2) and 53 weeks (1) respectively. The deaths of these mice were not 
considered to be a consequence of nitisinone administration as death rates similar 
to these are often observed in long term animal studies. These mice were kept out 
of the study as they had started to undergo tissue necrosis before fixation therefore 
the results obtained from them could not be seen as consistent with the other mice 
in the study. Histology was performed on the mice culled halfway through the 
study. None of the six mice showed any pigmentation of chondrons and articular 
cartilage when examined under light microscopy. This was the first observation in 
alkaptonuric mice that nitisinone may be effective in preventing ochronosis. 
 
The following results are from a selection of the mice treated with nitisinone over 
their lifetime. Some mice have been excluded as the results seen in all BALB/c Hgd-
/- mice were identical. 
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5.3.1.1.1 BALB/c Hgd-/- 24.4 (♂) – 67 weeks 
No pigmentation of chondrons or their surrounding matrices was identified 
throughout the knee joint of BALB/c Hgd-/- 24.4 (♂). 
 
 
 
 
 
 
Figure 5.1 highlighted the effect of nitisinone when given for whole of life. No 
pigmented chondrons were located in the MFC or in any other area of the joint. 
Pigmented chondrons are usually localised to the ACC in Hgd-/- mice, however 
treatment with nitisinone prevented any chondrons from becoming pigmented.  
 
Figure 5.1 – Ochronotic pigment was not detectable in the medial femoral 
condyle of BALB/c 24.4, a 67 week old Hgd-/- mouse treated with nitisinone. 
Schmorl’s staining did not reveal any chondrocytic (arrowed) or matrix 
pigmentation in ACC of the MFC. Bar = 20µm. 
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Figure 5.2 showed absence of pigmentation from the intercondylar area of the tibia 
in BALB/c Hgd-/- 24.4. This area becomes heavily pigmented in aged Hgd-/- mice, 
characterised by the dark blue staining of chondrons, yet is completely free of 
pigmentation when nitisinone is administered. There was no cartilage degeneration 
seen, although an osteophyte was present on the MTP.  
 
5.3.1.1.2 BALB/c Hgd-/- 25.3 (♀) – 67 weeks 
Pigmentation was absent from the knee joint of BALB/c Hgd-/- 25.3 (♀). Chondrons 
in all areas of the joint including the LFC (Fig. 5.3) and LTP (Fig. 5.4) were not 
pigmented and the articular cartilage showed no signs of damage or degeneration. 
Figure 5.2 – Ochronotic pigmentation was not detectable in the intercondylar 
area of BALB/c 24.4, a 67 week old Hgd-/- mouse treated with nitisinone. 
Schmorl’s staining did not reveal any pigmentation in the intercondylar area of 
the tibia (arrowed). This area becomes heavily pigmented in Hgd-/- mice. Bar = 
20µm. 
156 
 
 
 
 
 
Figure 5.3 - Ochronotic pigmentation was not detectable in the lateral femoral 
condyle of BALB/c 25.3, a 67 week old Hgd-/- mouse treated with nitisinone. 
Schmorl’s staining did not reveal any pigmented chondrons in the LFC of BALB/c 
Hgd-/- 25.3 (arrowed). Bar = 20µm. 
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The absence of pigmentation in another mouse treated with nitisinone highlighted 
the efficacy of the drug in preventing the deposition of pigment in the tibio-femoral 
joint. The chondrons in the joint appeared healthy and did not seem to be overly 
hypertrophic, especially in the LTP (Fig. 5.4). The lack of both cartilage degeneration 
and associated osteoarthropathy in the mice was encouraging and further 
demonstrated the efficacy of nitisinone to treat AKU. 
 
 
5.3.1.1.3 BALB/c Hgd-/- 26.1 (♀) – 67 weeks 
BALB/c Hgd-/- 26.1 (♀) displayed no signs of pigmentation throughout the knee 
joint. Chondrons in the ACC appeared relatively healthy and showed no signs of 
Figure 5.4 - Ochronotic pigmentation was not detectable in the lateral tibial 
plateau of BALB/c 25.3, a 67 week old Hgd-/- mouse treated with nitisinone. 
Schmorl’s staining did not reveal any pigmented chondrons (arrowed) in the LTP 
of BALB/c Hgd-/- 25.3. Bar = 20µm. 
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ochronosis (Fig. 5.5). There did appear to be a small amount of SCB remodelling in 
the MTP (Fig. 5.5) and LFC (Fig.5.6). Cartilage damage and changes in bone are not 
uncommon to mice of old age, especially those on a BALB/c background as this 
strain is known to be associated with the onset of spontaneous OA [159]. 
 
 
 
 
 
 
 
Figure 5.5 - Ochronotic pigmentation was not detectable in the medial tibial 
plateau of BALB/c 26.1, a 67 week old Hgd-/- mouse treated with nitisinone. 
Schmorl’s staining did not reveal any pigmented chondrons (left arrows) in the 
MTP. Bar = 20µm. 
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Again, nitisinone prevented the deposition of ochronotic pigment in the chondrons 
and matrices in the cartilage. No blue staining, which is characteristic of pigmented 
chondrons, was observed in any areas of the joint. Signs of OA were present in the 
joint with cartilage degeneration and SCB remodelling both observed (Figs. 5.5 & 
5.6).  
 
 
 
Figure 5.6 – Very minor fibrillation of the articular surface and subchondral 
bone remodelling in the lateral femoral condyle of BALB/c 26.1, a 67 week old 
Hgd-/- mouse treated with nitisinone. Very minor damage (left arrow) was seen 
on the articular surface of the LFC. Small amounts of SCB remodelling (right 
arrow) were located in the condyle which resulted in thinning of the ACC in 
some areas. Section stained with Schmorl’s. Bar = 20µm. 
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5.3.1.1.4 BALB/c Hgd-/- 26.2 (♀) – 67 weeks 
Like all previous mice described in the study, BALB/c Hgd-/- 26.2 (♀) contained no 
pigmented chondrons in any areas of the joint (Fig. 5.7). There did appear to be a 
very small amount of SCB remodelling taking place, most prominently in the LTP 
(Fig. 5.8). No cartilage degeneration was observed on any of the femoral condyles 
or along the TP. 
 
 
 
 
 
 
 
 
Figure 5.7 – Ochronotic pigmentation was not detectable in the medial femoral 
condyle of BALB/c 26.2, a 67 week old Hgd-/- mouse treated with nitisinone. 
Chondrons throughout the knee joint showed no signs of pigmentation. Two 
chondrons highlighted (arrowed) showed staining with the counter-stain NFR. 
Section stained with Schmorl’s. Bar = 20µm. 
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Administration of nitisinone to BALB/c Hgd-/- 26.2 prevented pigmentation in the 
articular cartilage and the chondrons located within it. This was consistent with 
what had been seen previously in all of the BALB/c Hgd-/- mice administered 
nitisinone, regardless of whether they were culled halfway into the study or left 
until the end. Small amounts of SCB remodelling indicated the joint may have been 
becoming osteoarthritic however with no pigment deposited in the joint it was 
unlikely that the osteoarthropathy was associated with AKU. It is more likely to be 
related to the ageing of the mouse. 
 
Figure 5.8 – Subchondral bone remodelling in the medial tibial plateau of 
BALB/c 26.2, a 67 week old Hgd-/- mouse treated with nitisinone. Small 
amounts of SCB remodelling were located in the MTP (arrowed). Chondrons 
above this area in the ACC showed no signs of pigmentation. Section stained 
with Schmorl’s. Bar = 20µm. 
162 
 
From the results shown it was clear that when given from the start of life, nitisinone 
prevented any deposition of ochronotic pigment throughout the whole knee joint. 
There were small signs of osteoarthropathy in a few of the mice but it is likely this 
was related to the ageing of the mice and not AKU. No adverse effects were 
reported which was encouraging as previous clinical trials with nitisinone, both in 
humans and rats, have seen tyrosine crystal formation and corneal lesions [53, 
205]. These results show nitisinone to be an effective therapy in treating nitisinone 
when given for the whole of life and should be considered as a treatment for 
patients.  
 
5.3.1.2 Control group 
Of the sixteen mice in the control group, seven were culled halfway through the 
study and the remaining nine were kept until the end of the study. The results 
gained from the control group are similar to those of age matched samples included 
in the natural history study (Chapter 3) which was expected. They all showed signs 
of advanced pigmentation and associated osteoarthropathy. 
 
5.3.1.2.1 BALB/c Hgd-/- 16.3 (♂) – 69 weeks 
Large numbers of pigmented chondrons were scattered throughout the ACC of both 
femoral condyles and the TP. All pigmented chondrons were hypertrophic with the 
majority severely hypertrophic (Fig. 5.9). There was also damage to the articular 
surface of the LTP (Fig. 5.10) as well as osteophyte formation on the MTP. 
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Figure 5.9 – Hypertrophic pigmented chondrons in the medial tibial plateau of 
BALB/c 16.3, a 69 week old Hgd-/- mouse not treated with nitisinone. Large 
numbers of hypertrophic pigmented chondrons were located in the ACC of the 
MTP (arrowed). The tidemark, which represents the boundary between calcified 
and uncalcified cartilage, is highlighted (red arrowhead). Section stained with 
Schmorl’s. Bar = 20µm. 
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BALB/c Hgd-/- 16.3 showed signs of severe ochronotic osteoarthropathy consistent 
with those seen in age-matched Hgd-/- mice in the natural history study. There 
were significant amounts of pigmentation throughout the knee joint and symptoms 
of OA including chondron hypertrophy, osteophyte formation and cartilage 
degeneration. 
 
 
Figure 5.10 – Fibrillation on the articular surface of the lateral tibial plateau in 
BALB/c 16.3, a 69 week old Hgd-/- mouse not treated with nitisinone. 
Fibrillation of the articular surface and a minor vertical cleft were present on the 
LTP (top right arrow). A cluster of pigmented chondrons was seen deep in the 
ACC (bottom right arrow) while a chondron in the early stages of pigmentation, 
being only peri-pigmented, was located towards the ligamentous fibres in the 
intercondylar area of the tibia. Section stained with Schmorl’s. Bar = 20µm. 
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5.3.1.2.2 BALB/c Hgd-/- 18.1 (♀) – 69 weeks 
BALB/c Hgd-/- 18.1 (♀) displayed severe signs of ochronotic osteoarthropathy. This 
was expected as all previous age-matched Hgd-/- mice had shown similar signs 
including large numbers of pigmented hypertrophic chondrons, cartilage 
degeneration and SCB remodelling. Dense areas of pigmentation were located 
towards the ligamentous fibres of the intercondylar area of the tibia (Fig. 5.11). 
Small amounts of SCB remodelling were also observed (Fig. 5.12). 
 
 
 
 
 
 
 
Figure 5.11 – Dense pigmentation in the intercondylar area of BALB/c 18.1, a 
69 week old Hgd-/- mouse not treated with nitisinone. Pigmented chondrons 
were located at the intercondylar area of the tibia and highlight the stress 
placed upon this area of the joint. Minor fibrillation of the articular surface 
(arrowed) was also situated adjacent to this area. Section stained with 
Schmorl’s. Bar = 20µm. 
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Both figures display the presence of pigmented chondrons in BALB/c Hgd-/- 18.1 
and also show the severity of the associated osteoarthropathy in the knee joints. 
The thinning of the ACC and the resulting tidemark duplication and thinning of the 
HAC are all factors in the initiation and progression of ochronotic osteoarthropathy 
both in mice and in humans. 
 
 
 
 
Figure 5.12 – Subchondral bone remodelling in the lateral femoral condyle of 
BALB/c 18.1, a 69 week old Hgd-/- mouse not treated with nitisinone. SCB 
resorption and remodelling (arrowed) were found in the LFC. This led to 
calcification and ossification of a significant portion of the ACC, resulting in 
thinning of this area. Section stained with Schmorl’s. Bar = 20µm. 
167 
 
5.3.1.2.3 BALB/c Hgd-/- 18.2 (♀) – 69 weeks 
BALB/c Hgd-/- 18.2 (♀) displayed large amounts of pigmented chondrons, especially 
in osteophytes located on the MFC (Fig. 5.13) and MTP (Fig. 5.14) respectively. 
Osteophyte formation has long been associated with OA and findings from the 
natural history study of Hgd-/- mice (Chapter 3) showed them to be present, 
especially in mice which had severe pigmentation. 
 
 
 
 
 
 
 
 
Figure 5.13 – A heavily pigmented osteophyte on the medial femoral condyle 
of BALB/c 18.2, a 69 week old Hgd-/- mouse not treated with nitisinone. An 
osteophyte (O) located on the MFC contained large numbers of pigmented 
chondrons. Section stained with Schmorl’s. Bar = 20µm. 
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Along with osteophyte formation and pigmentation, there was damage to the 
articular surface of the MFC. The results highlighted the significance of the 
administration of nitisinone as mice in the treated group displayed no pigmentation 
while the control group, including BALB/c Hgd-/- 18.2, showed very high levels of 
pigmentation. 
 
 
 
 
Figure 5.14 – A heavily pigmented osteophyte on the medial tibial plateau of 
BALB/c 18.2. An osteophyte (O) located on the MTP contained large numbers of 
pigmented chondrons. Ossification of the osteophyte is also highlighted 
(arrowed). Section stained with Schmorl’s. Bar = 20µm. 
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5.3.1.2.4 BALB/c Hgd-/- 18.3 (♀) – 69 weeks 
BALB/c Hgd-/- 18.3 (♀) was one of the most heavily pigmented mice in the control 
group and showed especially dense pigmentation towards the intercondylar area of 
the tibia (Fig. 5.15). This area regularly shows intense pigmentation which is 
probably linked to the sheer biomechanical stress this area undergoes. Large 
amounts of hypertrophic pigmented chondrons were located in the MFC. This area 
also showed some SCB resorption and remodelling (Fig. 5.16). 
 
 
 
 
 
 
 
 
Figure 5.15 – Dense pigmentation of the intercondylar area of the tibia in 
BALB/c 18.3, a 69 week old Hgd-/- mouse not treated with nitisinone. Large 
amounts of pigmented chondrons were located towards the ligamentous fibres 
of the intercondylar area of the tibia; an area of high stress in the joint. Section 
stained with Schmorl’s. Bar = 20µm. 
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The results gained from BALB/c Hgd-/- 18.3 are consistent with those seen in all of 
the mice in the control group and of those age-matched mice in the natural history 
study. 
 
5.3.1.3 Quantification of pigmented chondrons (lifetime nitisinone study) 
Pigmented chondron counts were made of the control and treated groups to 
emphasise the effect nitisinone had on the deposition of ochronotic pigment and to 
compare numbers against those obtained in the natural history study (Fig. 5.17). 
There was some variation between the number of pigmented chondrons in the 
Figure 5.16 – Subchondral bone remodelling in the medial femoral condyle of 
BALB/c 18.3, a 69 week old Hgd-/- mouse not treated with nitisinone. A small 
amount of SCB resorption and remodelling (arrowed) was observed in the MFC 
which also contained large numbers of hypertrophic pigmented chondrons. 
Section stained with Schmorl’s. Bar = 20µm. 
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control group (lowest = 132, highest = 341) however this was in-line with what was 
seen in the natural history study (Chapter 3). 
 
 
 
 
 
 
 
 
5.3.1.4 Plasma HGA levels (lifetime nitisinone study) 
Lifetime HGA plasma levels were obtained from the control and treated groups to 
highlight the effect nitisinone has on these levels (Fig. 5.18). The statistical 
significance of treatment was examined by analysis of HGA concentrations at four 
time points: immediately prior to treatment at 8 weeks (mean (SE) 0.115±0.011 
mM), and after treatment at 14 weeks (mean (±SE) 0.009±0.004 mM), 39 weeks 
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Figure 5.17 – The effect of lifetime nitisinone administration on the number of 
pigmented chondrons in BALB/c Hgd-/- mice. Scatter chart showing lifetime 
nitisinone administration prevented any chondrons from becoming pigmented. The 
control group showed levels of pigmentation comparable with those seen in the 
natural history study. Quantification of pigmented chondrons was performed on a 
single section from each mouse; this does not represent the total cell number in 
each mouse. 
172 
 
(mean (±SE) 0.011±0.002 mM) and 67 weeks (mean (±SE) 0.008±0.001 mM). A 
significant difference (p<0.001) was found between HGA concentrations before and 
after treatment at 8 and 14 weeks, respectively, with no further significant change 
observed throughout the study. After treatment with nitisinone there was an 88% 
drop of plasma HGA which was maintained for the duration of the study. Statistical 
analysis was performed using a two-tailed, two sample, unequal variance t test. 
Although a one-tailed test could have been used as it could have been expected 
that nitisinone would show a one way direction (suppression of plasma HGA, one-
tailed) a two-tailed test was used to allow for greater statistical rigor. A two sample, 
unequal variance test was used as the two population variances were not assumed 
to be equal. Although the study started with similar numbers of BALB/c Hgd-/- mice 
in both the control and treated groups, some died before the end of the study, so 
the final population size of each group was different. The variance in the nitisinone 
treated BALB/c Hgd-/- mice is much smaller than the variance within untreated 
BALB/c Hgd-/- mice hence why an unequal variance t test was performed. Growth 
curves from both groups showed no significant difference between the mice in the 
control and treated groups (Fig. 5.19). This work was carried out by Dr. A. Preston. 
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Figure 5.18 – The effect of lifetime nitisinone administration on plasma HGA 
levels in BALB/c Hgd-/- mice. Scatter chart showing lifetime treatment with 
nitisinone led to a significant reduction in plasma HGA levels. All measurements 
and data analysis performed by Dr. A. Preston. 
Figure 5.19 – Comparison of growth curves in BALB/c Hgd-/- mice with and 
without lifetime nitisinone treatment. Scatter chart showing lifetime treatment 
with nitisinone had no significant effect on the growth of both male and female 
Hgd-/- mice. All measurements and data analysis performed by Dr. A. Preston. 
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This study provided significant results about the effectiveness of nitisinone in 
preventing the initiation of ochronosis. Nitisinone maintained its efficacy over the 
mouse lifetime, and caused no obvious health or behavioural changes between the 
treated and control groups. The data collected provides evidence that early 
intervention with nitisinone in individuals with AKU will halt the pathogenesis of the 
disease which results in the devastating osteoarthropathy seen. 
 
5.3.2 Mid-life treatment with nitisinone 
A cohort of 8 BALB/c Hgd-/- mice (four male, four female) were provided with 
filtered water from 8 to 34 weeks of age. They were then provided with an ad 
libitum supply of water containing 4mg/l of nitisinone from 35 to 80 weeks of age. 
The control group of 8 BALB/c Hgd-/- mice (four male, four female) had no drug in 
their drinking water from 8 to 80 weeks of age.  
 
5.3.2.1 Treated group 
Of the eight mice treated with nitisinone mid-way through their lives, three were 
discovered to be deceased upon inspection of their cages at different time points 
during the study. Again, the deaths of these mice were not considered to be a 
consequence of nitisinone administration as death rates similar to these are often 
observed in long term animal studies. These mice were kept out of the study as 
they had started to undergo tissue necrosis before fixation therefore the results 
obtained from them could not be seen as consistent with the other mice in the 
study. All five of the mice that reached the endpoint of the study showed a 
significant reduction in terms of their overall number of pigmented chondrons 
present in the knee joint. What was immediately clear was that treatment with 
nitisinone did not reverse any previous pigment deposition; it only prevented 
further deposition of pigment throughout the joint. 
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5.3.2.1.1 BALB/c Hgd-/- 47.3 (♀) – 80 weeks 
BALB/c Hgd-/- 47.3 (♀) displayed a large reduction in the amount of pigmented 
chondrons present in the ACC of the knee joint when compared to the control 
group (Fig. 5.30). Although pigmented chondrons could be seen in both the femoral 
condyles and along the TP there were significantly less of them than seen in 
untreated mice. Minor fibrillation of the articular surface of the MFC was observed 
(Fig. 5.21) and a large osteophyte could be seen on the MTP (Fig. 5.22). 
 
 
 
 
 
Figure 5.20 – Fibrillation on the articular surface of the medial femoral condyle 
of BALB/c 47.3, an 80 week old Hgd-/- mouse treated with nitisinone. A small 
amount of damage (arrowed) was observed on the articular surface of the MFC. 
Section stained with Schmorl’s. Bar = 20µm. 
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Although there was a reduction in the number of pigmented chondrons in the ACC, 
the appearance of early osteoarthritic changes in the knee joint of BALB/c Hgd-/- 
47.3 suggested that nitisinone may only be useful when given early on in life. 
 
5.3.2.1.2 BALB/c Hgd-/- 48.1 (♂) – 80 weeks 
There was a very large reduction in the number of pigmented chondrons present in 
BALB/c Hgd-/- 48.1 (♂) in comparison to the mice in the control group (Fig. 5.22 & 
5.30). However, as seen previously in BALB/c Hgd-/- 47.3, there were also signs of 
osteoarthritic changes in the joint. There was complete erosion of the HAC on the 
MTP exposing the underlying layer of the ACC (Fig. 5.23). This type of damage is 
Figure 5.21 – Osteophyte formation on the medial tibial plateau of BALB/c 
47.3, an 80 week old Hgd-/- mouse treated with nitisinone. A large fully 
formed osteophyte (O) was located on the MTP. Early signs of osteoarthritis are 
often prevalent on the medial aspects of joints. Section stained with H&E. Bar = 
20µm.  
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associated with severe osteoarthropathy in joints and again shows that the 
effectiveness of nitisinone may only be seen when given at an earlier time point in 
life. 
 
 
 
 
 
 
Figure 5.22 – Prevention of pigmentation in chondrons in the medial femoral 
condyle of BALB/c 48.1, an 80 week old Hgd-/- mouse treated with nitisinone. 
Nitisinone treatment significantly reduced the amount of pigmented chondrons 
that would normally be present in this area in Hgd-/- mice. Section stained with 
Schmorl’s. Bar = 20µm. 
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5.3.2.1.3 BALB/c Hgd-/- 50.1 (♀) – 80 weeks 
BALB/c Hgd-/- 50.1 (♀) displayed the highest number of pigmented chondrons from 
the treated group (Fig. 5.30). The total number was still lower than the lowest of 
the control group by 40-50 chondrons which is a reasonable amount. A large 
pigmented osteophyte was located on the MTP (Fig. 5.24); this seemed to be a trait 
with all of the mice in the treated group. Small areas of SCB remodelling and 
cartilage fibrillation could also be seen. 
 
Figure 5.23 – Severe erosion of the hyaline articular cartilage on the medial 
tibial plateau of BALB/c 48.1, an 80 week old Hgd-/- mouse treated mid-life 
with nitisinone. Exposure of the ACC (arrowed) highlighted the severe 
osteoarthritic nature of the medial aspect of the knee joint in BALB/c Hgd-/- 
48.1. Section stained with Schmorl’s. Bar = 20µm. 
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5.3.2.2 Control group 
Of the eight mice in the control group, six continued until the planned end of the 
study, while two others were found deceased upon inspection of their cages. The 
results gained from the control group are similar to those of age matched samples 
included in the natural history study (Chapter 3). They all showed signs of advanced 
pigmentation and associated osteoarthropathy. 
 
 
 
Figure 5.24 – A large osteophyte present on the medial tibial plateau of 
BALB/c 50.1, an 80 week old Hgd-/- mouse treated with nitisinone. An 
osteophyte (O) containing pigmented chondrons was located on the MTP of 
BALB/c Hgd-/- 50.1. Section stained with Schmorl’s. Bar = 20µm. 
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5.3.2.2.1 BALB/c Hgd-/- 47.2 (♀) – 80 weeks 
BALB/c Hgd-/- 47.2 (♀) showed a significant increase in the number of pigmented 
chondrons when compared to the mice in the treated group. Chondrons in the LTP 
were heavily pigmented and very hypertrophic (Fig. 5.25) indicating they were in 
the final stages of pigmentation and close to death. A large, pigmented osteophyte 
was located on the MTP (Fig. 5.26) which was indicative of the associated 
osteoarthropathy seen previously in age-matched Hgd-/- mice in the natural history 
study. 
 
 
 
 
 
 
 
 
Figure 5.25 – Fully pyknotic chondrons in the lateral tibial plateau of BALB/c 
47.2, an 80 week old Hgd-/- mouse not treated with nitisinone. Large numbers 
of pigmented pyknotic chondrons were located in the ACC of the LTP. Section 
stained with Schmorl’s. Bar = 20µm. 
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5.3.2.2.2 BALB/c Hgd-/- 47.4 (♀) – 80 weeks 
BALB/c Hgd-/- 47.4 (♀) displayed serious cartilage damage on the medial aspect of 
the knee joint. There was complete erosion of around 50% of the HAC on both the 
MFC and MTP leading to the exposure of the underlying ACC (Fig. 5.27). This was 
some of the most severe osteoarthropathy seen in any of the Hgd-/- mice 
examined, underlining how debilitating ochronosis and the associated OA can be 
without treatment. Large osteophytes were also located on both the MFC and MTP; 
the osteophyte on the MTP was very heavily pigmented (Fig. 5.28). The number of 
pigmented chondrons in the joint was much higher than in any of the treated mice. 
 
Figure 5.26 – A large, fully formed osteophyte located on the medial tibial 
plateau of BALB/c 47.2, an 80 week old Hgd-/- mouse not treated with 
nitisinone. A pigmented osteophyte was located on the MTP; formation of the 
osteophyte (O) is marked (arrows). Section stained with Schmorl’s. Bar = 20µm. 
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Figure 5.27 – Severe cartilage damage on the medial aspect of the knee joint in 
BALB/c 47.4, an 80 week old Hgd-/- mouse not treated with nitisinone. Erosion 
of the HAC (arrows) and osteophyte formation (O), both signs of severe 
osteoarthropathy, were present on the medial aspect of the knee joint. Section 
stained with H&E. Bar = 100µm. 
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5.2.2.2.3 BALB/c Hgd-/- 51.1 (♂) – 80 weeks 
BALB/c Hgd-/- 51.1 (♂) had the lowest number of pigmented chondrons from the 
control group, yet this number was still higher than any of the treated group 
showing the effect of nitisinone in preventing any further pigment deposition. 
Along the LFC was the densest area of pigmentation (Fig. 5.29); all chondrons in this 
area were heavily pigmented and hypertrophic. There was no obvious major 
cartilage damage; some minor fibrillation of the articular surface on both the femur 
and tibia was seen but it was not severe. 
 
Figure 5.28 – Pigmentation of an osteophyte located on the medial tibial 
plateau in BALB/c 47.4, an 80 week old Hgd-/- mouse not treated with 
nitisinone. Pigmented chondrons were located in the osteophyte (O) and at the 
boundary of formation of the osteophyte (arrowed). Section stained with 
Schmorl’s. Bar = 20µm. 
184 
 
  
 
 
 
 
 
5.3.2.3 Quantification of pigmented chondrons (mid-life nitisinone study) 
Pigmented chondrons were quantified in the control and treated groups to 
determine the effect nitisinone had on preventing further deposition of pigment in 
Hgd-/- mice (Fig. 5.30). There was some variation between the number of 
pigmented chondrons in the control group (lowest = 142, highest = 273) however 
this was in-line with what was seen in the natural history study (counts in Chapter 
4) and was not excessive. It was clear from the scatter chart that treatment with 
nitisinone prevented HGA from becoming deposited in chondrons. The numbers of 
pigmented chondrons in the treated group were comparable to mice much younger 
and those still in the early stages of ochronosis. 
 
Figure 5.29 – Pigmentation of the lateral femoral condyle in BALB/c 51.1, an 80 
week old Hgd-/- mouse not treated with nitisinone. A dense area of pigmented 
chondrons was located along the LFC. Section stained with Schmorl’s. Bar = 
20µm. 
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An independent samples t-test was generated in order to compare the number of 
pigmented chondrons between the nitisinone treated and control Hgd-/- mice. A 
statistically significant difference was observed between the mean number of 
pigmented chondrons for the nitisinone treated Hgd-/- mice (88.2) and the control 
Hgd-/- mice groups (201.17) (p=0.001). In other words, the control Hgd-/- mice had 
a statistically significantly higher mean number of pigmented chondrocytes than 
the nitisinone treated Hgd-/- mice. 
 
This study has shown that mid-life treatment with nitisinone can prevent further 
pigment deposition however it does not appear that it can reverse any 
pigmentation and/or damage already present in the knee joint. This is important as 
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Figure 5.30 – The effect of nitisinone in BALB/c Hgd-/- mice when given after 34 
weeks of age. Scatter chart showing that starting nitisinone treatment midway 
through life prevented further pigment deposition. The control group showed 
levels of pigmentation comparable with those seen in the natural history study. 
Quantification of pigmented chondrons was performed on a single section from 
each mouse; this does not represent the total cell number in each mouse. 
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it shows pigment deposition is probably not reversible and that joint damage 
caused by pigmentation will continue to proceed. It also highlights the need to treat 
patients with AKU as early as possible to prevent any ochronotic pigment from 
being laid down as once this occurs it appears inevitable that some form of 
osteoarthropathy will develop. 
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5.4 DISCUSSION 
This Chapter described the evaluation of the efficacy of nitisinone as a treatment 
for the prevention of AKU in BALB/c Hgd-/- mice. Nitisinone was originally 
developed as a herbicide, but has been used in the treatment of HT-1 since the 
early 1990s [206]. It has also seen some success in the treatment of oculotaneous 
albinism [207] where elevation of plasma tyrosine, induced by nitisinone, stabilises 
the Tyrc-h mutant protein resulting in the production of melanin and improving 
visual function. It is currently the first line of treatment for HT-1, replacing liver 
transplantation and has helped lead to a decrease in fatalities [50, 208]. Manning 
and colleagues when working with Fah-/-, Hgd+-/ mice, discovered that withdrawal 
of nitisinone, used to prevent liver failure resulting from HT-1, caused a small 
number of mice to undergo a spontaneous loss of heterozygosity and revert to the 
Hgd-/- genotype, becoming phenotypically AKU [125]. Taylor and colleagues [111] 
published data showing these mice to be a model of ochronosis. However due to 
the spontaneity of their formation and their associated renal pathology they were 
never considered as a practical experimental model of AKU. The murine model of 
AKU presented in this thesis is a consistent model of AKU that shows the same 
metabolic and cellular characteristics of AKU in humans. As this was the case it was 
decided to see if nitisinone, which had already been shown to reduce plasma HGA 
levels in humans [53], could prevent the progression of ochronosis in a model that 
reproduced the pathology seen in patients. 
 
The first study analysed the effects of lifetime nitisinone administration on BALB/c 
Hgd-/- mice. The treated group were given a dose of 4mg/l of nitisinone; this was 
selected from HPLC studies which showed this to be the lowest dose which had an 
effect on HGA levels. Mice from both the control (filtered water) and treated 
groups were culled halfway through the study to determine the efficacy of 
nitisinone up to that point. Although no data from these mice was shown in this 
Chapter, the treated group showed no signs of ochronosis and/or pigmentation 
whilst the control group all contained pigmented chondrons in numbers similar to 
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those seen in age-matched Hgd-/- mice in the natural history study (Chapter 3). The 
remaining mice in both groups were left in the study and culled at a pre-determined 
end-point. All of the mice in the control group showed extensive pigmentation 
throughout the ACC in both the femur and tibia which was expected. There were 
slight variations in the number of pigmented chondrons between each mouse in the 
control group (Fig. 5.17) however this was no different from what was seen in 
BALB/c Hgd-/- mice in the natural history study (Chapter 3). The variations in the 
number of pigmented chondrons may be attributed to how active each individual 
mouse was on a daily basis. Repetitive and continuous mechanical loading of the 
knee joint is known to cause changes in the composition and organisation of the 
ECM, micro fracture of the underlying SCB and to accelerate cartilage degradation, 
[209-211] which has already been cited in this thesis as a possible mechanism for 
pigmentation initiation. Mice which are not as active as others are less likely to 
cause as much significant damage to their ECM and therefore it is reasonable to 
assume less chondrons in these mice will undergo the necessary cellular and 
extracellular changes required to become pigmented.  
 
Signs of osteoarthropathy including cartilage fibrillations and osteophyte formation 
were observed in most of the control mice (Figs. 5.10, 5.12 & 5.14), again this was 
expected. It is possible these changes resulted from the deposition of pigment in 
the joint, as this is thought to alter the biomechanics of the joint leading to the 
development of OA. However some of these changes may simply be related to the 
advancing age of the mice. Quantifying the joint damage between control and 
treated groups, using the OARSI histopathology initiative [120], may help to 
determine if the damage observed was as a consequence of pigment deposition or 
ageing. The mice treated with nitisinone showed different pathology as no 
chondron pigmentation was observed throughout the knee joint (Fig. 5.17), 
although some cartilage damage was observed. The result is consistent with the 
findings obtained from Hgd-/- mice culled halfway through the lifetime study. 
Nitisinone efficacy was maintained during the mouse lifetime and there were no 
noticeable changes in the behaviour and health between the control and treated 
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groups. Nitisinone works by inhibiting the HPPD enzyme [212, 213] consequently 
preventing the formation of HGA. This step is critical in the treatment of AKU 
however it can result in abnormally high tyrosine levels therefore a low tyrosine 
diet is usually recommended when treating with nitisinone. Previous clinical trials in 
humans have reported adverse effects resulting from high tyrosine levels [53], 
whilst another study reported impaired cognitive function in some patients 
receiving nitisinone [214]. With no adverse effects reported in any of the mice it 
demonstrated that the right dosage of nitisinone can prevent any manifestation of 
ill effects. It is highly significant that the study was completed over the whole life as 
it provided vital data that would otherwise be unobtainable in other species or 
indeed AKU patients. The study of the natural history of ochronotic 
osteoarthropathy in Hgd-/- mice showed that pigment deposition begins at a very 
early age and continues to progress, to the point of severe osteoarthropathy. This 
data was used to determine the starting point for the treatment regime and also 
allowed for a study of the effects on the initiation, progression and prevention of 
AKU with long term nitisinone treatment. Determination of HGA levels in Hgd-/- 
mice also provided important data with regards to the efficacy of nitisinone. 
Lifetime plasma HGA levels measured in both groups showed an 88% drop in 
plasma HGA when Hgd-/- mice were treated with nitisinone (Fig. 5.18). Age-related 
loss of renal function normally occurs in humans [215] and mice [216]; therefore it 
is possible declining excretion may lead to rising plasma HGA levels which lead to 
the midlife observation of pathological, ochronotic changes. However, as the mean 
HGA plasma level remained broadly steady across the Hgd-/- mouse lifetime (Fig. 
5.18), it suggested that decreasing kidney function did not initiate ochronosis. It 
appears from the data presented in this thesis that in AKU patients the midlife 
onset of ochronotic osteoarthropathy is the clinical manifestation of a pathological 
process beginning much earlier than when decline in kidney function occurs. The 
data gathered in this Chapter strongly suggests that early intervention with 
nitisinone will prevent the pathological process that leads to irreversible cartilage 
damage and joint destruction. It should be noted that although no adverse effects 
were reported in Hgd-/- mice, administration of nitisinone particularly from a very 
young age may have detrimental effects. Previous reports have suggested mental 
190 
 
impairment may develop as a result of 4-HPPD inhibition by nitisinone, as this 
results in tyrosinemia type III which is thought to be associated with neurological 
problems [52]. This is something that would have to be taken into account and 
monitored closely in clinical trials involving young AKU patients. The data from the 
lifetime nitisinone study should be of significant use for future clinical trials 
involving AKU and nitisinone as they offer evidence that nitisinone administration 
earlier in life provides beneficial effects by preventing the onset of ochronotic 
osteoarthropathy. 
 
The second study detailed in this Chapter described the efficacy of nitisinone 
administration midway through life, again in BALB/c Hgd-/- mice. The treated group 
were given the same dose of nitisinone (4mg/l) as used in the lifetime study whilst 
the control group were again kept on filtered water. The control group showed 
signs consistent with severe ochronotic osteoarthropathy including large numbers 
of pigmented chondrons (Fig. 5.25), osteophyte formation and pigmentation (Fig. 
5.26), and erosion of the HAC (Fig. 5.27). These mice presented with some of the 
most severe osteoarthropathy seen in Hgd-/- mice, yet a few of them had relatively 
low numbers of pigmented chondrons for their age. Variation between the 
numbers of pigmented chondrons in individual mice has been a consistent 
observation throughout all the studies described in this thesis, however some 
individual counts were particularly low. BALB/c Hgd-/- 51.1 (♂) had only 142 
pigmented chondrons throughout its knee joint which is more akin to a Hgd-/- 
mouse aged 45 weeks, not 80 (Fig. 5.30). Again this may be linked to the inactivity 
of aged mice when compared to that of younger mice. Decreased renal function is 
probably not involved as steady levels of plasma HGA were maintained over the 
lifetime. The results obtained from the treated group were expected, at least in 
relation to the numbers of pigmented chondrons identified. All six mice in the 
treated group showed a significant drop in the number of pigmented chondrons in 
the ACC (Fig. 5.30). The numbers of pigmented chondrons in the treated mice were 
in a range that would be expected in mice aged between 25 and 38 weeks. The 
prevention of further pigment deposition when nitisinone treatment began 
191 
 
highlighted the efficacy of the compound. However nitisinone was only able to 
prevent further pigmentation of the cartilage and not reverse the effects of 
ochronosis which had taken place up to the point of administration. These results 
are important as they provide further evidence that nitisinone treatment should 
begin early in life to completely prevent any pigment deposition and the associated 
osteoarthropathy. Once pigment has been laid down in the ACC the pathological 
process resulting in severe osteoarthropathy appears to have already begun; 
treatment with nitisinone appears to do little to halt this process. Osteophytes 
(Figs. 5.21 & 5.24) were identified in several of the treated mice and severe 
cartilage erosion was also seen (Fig. 5.23). The presence of these osteoarthritic 
markers leads to the assumption that nitisinone can do little to prevent 
osteoarthropathy from setting in once the process has begun. 
 
This Chapter demonstrated the first ever inhibition of ochronotic pigment with 
nitisinone. This result is an important advance in AKU research as it shows that 
nitisinone, whether given from the start of life or at a selected time point, prevents 
pigmentation in the articular cartilage of the tibio-femoral joint. The ability to study 
the effects of nitisinone in an AKU murine model provides data that otherwise 
would not be available. There is difficulty in obtaining data from human trials due 
to a number of factors including the length of the study, regular access to patients 
and most importantly in the case of AKU, the inability to analyse articulating joints 
histologically at selected time intervals. The studies described in this Chapter also 
provide very important data about how and when treatment should commence 
with nitisinone. The data suggest that nitisinone treatment should begin as early as 
possible in order to prevent the initiation of the pathological process which 
culminates in irreparable cartilage damage and severe ochronotic 
osteoarthropathy. The data collected from the trials described in this Chapter have 
been presented to the European Medicines Agency in support of the Suitability of 
Nitisinone in Alkaptonuria (SONIA) 1 and 2 clinical trials. Future clinical trials using 
nitisinone to treat AKU, including SONIA 2, would be well advised to include young 
patients who have yet to develop any joint arthropathies, to establish whether 
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cartilage damage and eventual joint destruction in humans can be delayed or 
prevented. 
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6.  Surgical and chemical interventions in Hgd-/- mice 
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6.1 INTRODUCTION 
The identification of ochronotic pigment in Hgd-/- mice (Chapter 3) has provided 
opportunities to investigate further whether interventions, both preventative and 
potentially damaging, can halt or accelerate pigmentation. The use of nitisinone as 
a therapeutic treatment for AKU has been described in Chapter 5 of this thesis and 
is shown to prevent pigmentation in Hgd-/- mice. This Chapter details the 
effectiveness of surgical and chemical intervention in increasing the amount of 
ochronotic pigment deposited in Hgd-/- mice. 
 
DMM is a surgical technique developed by Glasson et al [118] which has been 
shown to induce mild to moderate OA in mice four weeks post-operatively (post-
op), and moderate to severe OA eight weeks post-op. Early onset of severe OA is a 
recognized consequence of AKU [20], and micro damage resulting from repetitive 
mechanical loading is thought to be a factor in the initiation and progression of this 
ochronotic osteoarthropathy [36]. This Chapter details whether the damage caused 
by DMM surgery resulted in an increased number of pigmented chondrons in the 
ACC due to a possible association between microdamage and the initiation of 
ochronosis and OA. 
 
HGA is the “culprit molecule”, the single most important factor in the pathogenesis 
of AKU. Elevated plasma levels of HGA are essential in the initiation and continued 
progression of ochronosis both in humans [9] and mice [217]. Other factors are also 
involved in the process of pigmentation leading to specific tissues becoming 
susceptible to pigment deposition. Although large amounts of HGA are excreted in 
urine, high levels remain in plasma which ultimately leads to the development of 
ochronotic osteoarthropathy. This Chapter details whether supplementing Hgd-/- 
mice with 5mM HGA increased plasma HGA levels even further, and led to an 
increase in the number of pigmented chondrons in Hgd-/- mice. 
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6.2 DESIGN OF STUDY 
6.2.1 Surgical intervention 
DMM surgery was performed on the left knee of six BALB/c Hgd-/- mice (three 
males, three females). All mice were aged between 48 and 52 weeks when the 
surgery was completed. Three of the mice were left for eight weeks post-op and 
three for twelve weeks post-op before being culled. Once the in vivo portion of the 
study had concluded both experimental (left) and contralateral control (right) knees 
were dissected out from the mice and stained with H&E and Schmorl’s stain. One 
whole section of the entire tibio-femoral joint was quantified to identify any effect 
on the level of pigmentation between the experimental and contralateral control 
joints. 
 
6.2.2 Chemical intervention 
Water containing 5mM of HGA was given to a group of ten BL/6 Hgd-/- mice over 
their whole lifespan. A control group had access to normal drinking water in the 
same timeframe. Plasma HGA levels were measured and one whole section of the 
entire tibio-femoral joint was quantified to identify if any effect could be observed 
on the level of pigmentation. 
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6.3 RESULTS 
6.3.1 Destabilization of the medial meniscus 
6.3.1.1 Eight weeks post-op 
6.3.1.1.1 BALB/c Hgd-/- 100.1 (♀) – 60 weeks 
Signs of OA were discovered in both the medial and lateral aspects of the tibio-
femoral joint in the experimental knee of BALB/c Hgd-/- 100.1 (♀). The 
photomicrograph below (Fig. 6.1) shows the formation of an osteophyte on the 
MTP, and the MM slightly out of place due to the transection of the MMTL (Fig. 
6.1). There appeared to be no obvious cartilage degradation on either the MFC or 
the MTP, and only minor fibrillations on the LTP (Fig. 6.2) indicating the 
osteoarthritic changes in the joint were mild to moderate, not severe. 
  
 
 
 
Figure 6.1 – Osteophyte formation on the medial tibial plateau of BALB/c 
100.1, a 60 week old Hgd-/- mouse culled at 8 weeks post-op. Schmorl’s 
staining showed significant amounts of pigmentation in the osteophyte (O) and 
MTP and MFC. Bar = 100µm. 
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Quantification of the pigmented chondrons showed numbers similar to those seen 
in Hgd-/- mice aged 48 weeks (data from Chapter 3) (Fig. 6.11). Variation in the 
number of pigmented chondrons was observed throughout the natural history 
study so these results are not unexpected. It does appear to show however, at least 
in this mouse, that DMM has not increased the amount of pigmentation present. 
 
Analysis of the contralateral control showed very minor fibrillations on the LFC (Fig. 
6.3). No other damage was observed throughout the rest of the joint, and no 
osteophytes or SCB sclerosis or remodelling was present. Quantification of the 
Figure 6.2 – Minor fibrillations on the lateral tibial plateau in the experimental 
knee of BALB/c 100.1, a 60 week old Hgd-/- mouse culled at 8 weeks post-op. 
Fibrillations were observed on the LTP and were consistent with mild to 
moderate OA (arrowed). Schmorl’s staining also highlighted heavily pigmented 
chondrons in the ACC. Bar = 20µm. 
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pigmented chondrons revealed a higher number located in the control knee joint 
(183) in comparison to the experimental knee joint (110) (Fig. 6.11 & Table. 6.1). 
One possible explanation for this data is that the mouse placed more pressure on 
its control knee joint as constant loading of its experimental knee joint was too 
painful. 
 
 
 
 
 
 
 
6.3.1.1.2 BALB/c Hgd-/- 100.2 (♀) – 60 weeks 
Obvious signs of OA were observed in the experimental tibio-femoral joint of 
BALB/c Hgd-/- 100.2 (♀). Small osteophytes were located on both the MFC and 
Figure 6.3 – Minor fibrillations on the lateral femoral condyle in the control 
knee of BALB/c 100.1, a 60 week old Hgd-/- mouse culled at 8 weeks post-op. 
Schmorl’s staining showed fibrillations on the LFC consistent with very mild OA 
(right arrow). Heavily pigmented chondrons were present in large numbers in 
the ACC of the LFC (left arrow). Bar = 20µm. 
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MTP along with loss of surface lamina on both (Figs. 6.4 & 6.5). Fibrillations of the 
HAC were present on the MTP and there was also detachment of the HAC from the 
ACC in one area of the MTP (Fig. 6.4). These data suggest DMM surgery caused 
moderate to severe OA in the experimental knee joint. 
 
 
 
 
 
 
 
Quantification of the pigmented chondrons showed numbers similar to those 
observed in Hgd-/- mice of around 56 weeks of age (data from Chapter 3) (Fig. 
6.11). Again, similar to BALB/c Hgd-/- 100.1, this result was consistent with the level 
of variability observed in Hgd-/- mice in the natural history study. The result also 
Figure 6.4 – Identification of osteophytes and hyaline articular cartilage 
damage in the experimental knee of BALB/c 100.2, a 60 week old Hgd-/- 
mouse culled at 8 weeks post-op. H&E staining revealed the presence of two 
small osteophytes (O) on the MTP and MFC. Loss of the surface lamina was 
located along the MTP (left arrow), while detachment of the HAC from the ACC 
was observed in a small area of the MTP (right arrow). Bar = 100µm. 
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appeared to show that DMM surgery did not increase the amount of pigmented 
chondrons in Hgd-/- mice. 
 
 
 
 
 
 
 
Analysis of the contralateral control showed minor damage along the articular 
surface on the MFC (Fig. 6.6). An osteophyte was located on the MFC (Fig. 6.6) 
however the rest of the knee joint showed no damage. Quantification of the 
pigmented chondrons revealed a lower number of pigmented chondrons (148) than 
the experimental knee joint (172) (Fig. 6.11 & Table. 6.1).  
Figure 6.5 – Hyaline articular cartilage damage in the experimental knee of 
BALB/c 100.2, a 60 week old Hgd-/- mouse culled at 8 weeks post-op. 
Schmorl’s staining of the MTP showed damage along the articular surface 
(arrowed) and the presence of hypertrophic heavily pigmented chondrons in the 
ACC. Bar = 20µm. 
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6.3.1.1.3 BALB/c Hgd-/- 101.1 (♂) – 60 weeks 
BALB/c Hgd-/- 101.1 (♂) displayed the most severe OA out of the three mice culled 
at eight weeks post-op. There was significant HAC erosion on the MTP exposing the 
underlying ACC (Fig. 6.7). A large ossified osteophyte was present on the MTP and 
significant damage was located along the articular surface of the MFC (Fig. 6.7). 
More severe damage was located on both the LFC and LTP. There appeared to be 
≥90% of HAC eroded on the LFC and ≤50% eroded on the LTP, exposing the ACC 
underneath (Fig. 6.8). 
 
Figure 6.6 – Minor damage along the articular surface of the medial femoral 
condyle in the control knee of BALB/c 100.2, a 60 week old Hgd-/- mouse 
culled at 8 weeks post-op. Schmorl’s staining showed minimal damage along 
the MFC with definite loss of the surface lamina (arrowed). Large numbers of 
pigmented chondrons were located throughout the ACC in both the MFC and 
MTP. Bar = 100µm. 
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Figure 6.7 – Severe cartilage erosion on the medial tibial plateau, and partial 
erosion of the cartilage on the medial femoral condyle in the experimental 
knee of BALB/c 101.1, a 60 week old Hgd-/- mouse culled at 8 weeks post-op. 
H&E staining revealed a small but significant loss of HAC leading to the exposure 
of ACC on the MTP (right arrow). Loss of surface lamina and small amount of 
cartilage erosion were located on the MFC (left arrows). Bar = 100µm. 
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Clusters of heavily pigmented chondrons were located adjacent to the damaged 
areas (Fig. 6.9). Quantification of the pigmented chondrons revealed numbers 
consistent with those seen in Hgd-/- mice aged 36-40 weeks (data from Chapter 3) 
(Fig. 6.11). Although variability is expected between individual mice, BALB/c Hgd-/- 
101.1 having numbers similar to mice 20-24 weeks younger was slightly surprising. 
 
Figure 6.8 – Severe cartilage erosion on the lateral tibial plateau and lateral 
femoral condyle in the experimental knee of BALB/c 101.1, a 60 week old Hgd-
/- mouse culled at 8 weeks post-op. H&E staining revealed extensive loss of 
HAC on both the LTP and LFC (arrowed). The severity of OA seen in the lateral 
aspect of this joint represents some of the most severe observed in any Hgd-/- 
mouse examined. Bar = 100µm. 
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The contralateral control showed virtually no sign of OA, only very minor loss of the 
surface lamina was located along the MFC (Fig. 6.10). There were no signs of any 
cartilage loss or osteophyte formation throughout the rest of the knee joint. 
Quantification of pigmented chondrons revealed there to be a higher number in the 
control joint (151) to that observed in the experimental joint (109) (Fig. 6.11 & 
Table. 6.1). This was also seen in BALB/c Hgd-/- 100.1 which again appeared to 
imply that DMM surgery did not increase the number of pigmented chondrons 
present in the ACC. 
 
Figure 6.9 – Heavily pigmented chondrons located adjacent to cartilage erosion 
in the medial tibial plateau of the experimental knee of BALB/c 101.1, a 60 
week old Hgd-/- mouse culled at 8 weeks post-op. Schmorl’s staining showed 
pyknotic chondrons located close to the damaged area (arrowed). Bar = 20µm. 
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6.3.1.1.4 Quantification of pigmented chondrons at eight weeks post-op 
Pigmented chondrons in both the experimental and contralateral control tibio-
femoral joints were quantified to determine if DMM surgery had had any effect on 
their numbers (Fig. 6.11). It is apparent from the data shown on the scatter chart 
that DMM surgery did not have the proposed effect of increasing the number of 
pigmented chondrons present in the ACC of BALB/c Hgd-/- mice. 
 
Figure 6.10 – Loss of surface lamina along the medial femoral condyle in the 
control knee of BALB/c 101.1, a 60 week old Hgd-/- mouse culled at 8 weeks 
post-op. Schmorl’s staining showed a small loss of the surface lamina along the 
MFC. Large numbers of hypertrophic pigmented chondrons were located in the 
ACC of the MFC and MTP. Bar = 100µm. 
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6.3.1.2 Twelve weeks post-op 
6.3.1.2.1 BALB/c Hgd-/- 102.2 (♂) – 60 weeks 
Signs of severe OA were observed on both the medial and lateral aspects of the 
experimental tibio-femoral joint in BALB/c Hgd-/- 102.2 (♂). Erosion of the HAC, 
exposing the underlying ACC was observed on ≥30% of the MTP (Fig. 6.12). A very 
large, fully ossified osteophyte was also located on the MTP while a small, 
developing osteophyte was located on the MFC (Fig. 6.12). Severe HAC erosion was 
observed on the LFC with ≤75% fully eroded exposing ACC (Fig. 6.13). Ossification of 
the LM was also seen (Fig. 6.13). Large clusters of heavily pigmented chondrons 
were located adjacent to the damaged area on the MTP (Fig. 6.14). This is 
consistent with the most severe OA observed in the mice at eight weeks post-op. 
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Figure 6.11 – The effect of DMM surgery, at eight weeks post-op, on the number 
of pigmented chondrons in BALB/c Hgd-/- mice. Scatter chart showing that DMM 
surgery did not appear to cause an increase in the number of pigmented 
chondrons in BALB/c Hgd-/- mice. Quantification of pigmented chondrons was 
performed on a single section from each mouse; this does not represent the total 
cell number in each mouse. 
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Figure 6.12 – Severe erosion of hyaline articular cartilage on the medial tibial 
plateau, and osteophyte formation in the experimental knee of BALB/c 102.2, 
a 60 week old Hgd-/- mouse culled at 12 weeks post-op. H&E staining showed 
loss of a significant portion of HAC along the MTP (right arrow) and fibrillations 
of HAC on the MFC (left arrow). Osteophytes (O) were located on both the MTP 
and MFC. Bar = 100µm. 
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Figure 6.13 – Severe erosion of hyaline articular cartilage on the lateral 
femoral condyle, and ossification of the lateral menisci in the experimental 
knee of BALB/c 102.2, a 60 week old Hgd-/- mouse culled at 12 weeks post-op. 
H&E staining showed loss of a significant portion of the HAC along the LFC (right 
arrows) and ossification of the LM (left arrow). Bar = 100µm. 
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Analysis of the contralateral control showed there to be very little damage. A small 
loss of surface lamina seen along the MTP was the only observed sign of cartilage 
degeneration. Large numbers of pigmented chondrons were present in the knee 
joint which was expected (Fig. 6.15). Quantification of both the experimental and 
control knee joints revealed there to be a higher number of pigmented chondrons 
in the experimental joint (156) than in the control joint (132) (Fig. 6.21 & Table. 
6.1). These levels were in line with Hgd-/- mice aged 50 weeks, again highlighting 
the variability between individual mice.  
 
Figure 6.14 – Clustering of heavily pigmented chondrons adjacent to hyaline 
articular cartilage erosion in the medial tibial plateau of the experimental knee 
of BALB/c 102.2, a 60 week old Hgd-/- mouse culled at 12 weeks post-op. 
Schmorl’s staining showed pyknotic chondrons adjacent to the damaged area of 
the MTP. Bar = 20µm. 
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6.3.1.2.2 BALB/c Hgd-/- 102.3 (♂) – 60 weeks 
Signs of severe OA were present in the experimental tibio-femoral joint of BALB/c 
Hgd-/- 102.3 (♂), particularly on the medial aspect. Erosion of HAC was observed on 
≥50% of the MTP and ≤50% on the MFC, exposing the ACC underneath (Fig. 6.16). A 
large ossified osteophyte was present on the MTP, and a small developing 
osteophyte was present on the MFC (Fig. 6.16). Fibrillations were seen along the 
articular surface of both the LTP and LFC (Fig. 6.17). The LM was also in the process 
of ossification (Fig. 6.17). Like previous mice in both DMM studies, pigmented 
chondrons were located adjacent to the areas of cartilage erosion on the MTP and 
MFC (Fig. 6.18).  
Figure 6.15 – Large numbers of pigmented chondrons in the medial tibial 
plateau of the control knee of BALB/c 102.2, a 60 week old Hgd-/- mouse 
culled at 12 weeks post-op. Schmorl’s staining showed heavily pigmented 
chondrons throughout ACC of the MTP. Bar = 20µm. 
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Figure 6.16 – Severe erosion of hyaline articular cartilage on the medial tibial 
plateau and medial femoral condyle in the experimental knee of BALB/c 102.3, 
a 60 week old Hgd-/- mouse culled at 12 weeks post-op. H&E staining showed 
loss of a significant portion of the HAC along both the MTP and MFC (arrowed). 
Osteophytes (O) were also seen on both the MTP and MFC. Bar = 100µm. 
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Figure 6.17 – Fibrillations along the hyaline articular cartilage on both the 
lateral tibial plateau and lateral femoral condyle in the experimental knee of 
BALB/c 102.3, a 60 week old Hgd-/- mouse culled at 12 weeks post-op. H&E 
staining showed fibrillation of the articular surface of both the LTP and LFC. The 
LM was also seen to be undergoing ossification. Bar = 100µm. 
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Analysis of the contralateral control showed minimal damage, with ossification of 
the LM the only observed degeneration. Quantification of both the experimental 
and control knee joints revealed there to be a higher number of pigmented 
chondrons in the experimental joint (86) than the control joint (71) (Fig. 6.21 & 
Table. 6.1). These numbers were particularly low for a mouse aged 60 weeks, 
however this was only observed in one of the six mice used in the study therefore it 
appeared to be an anomaly.  
 
 
Figure 6.18 – Pigmented chondrons located at areas of damage in the medial 
aspect of the experimental knee of BALB/c 102.3, a 60 week old Hgd-/- mouse 
culled at 12 weeks post-op. Schmorl’s staining showed heavily pigmented 
chondrons in the ACC located directly adjacent to areas of cartilage erosion on 
the MTP and MFC. Bar = 20µm. 
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6.3.1.2.3 BALB/c Hgd-/- 103.1 (♀) – 60 weeks 
Signs of severe OA were observed in the experimental tibio-femoral joint of BALB/c 
Hgd-/- 103.1 (♀) with the most obvious being the detachment of ≥75% of the HAC 
from the underlying ACC (Fig. 6.19) on the MTP. Although the cartilage still appears 
to be in the correct position it can clearly be seen to be detached from ACC. 
Pigmented chondrons were located directly opposite the damaged area in ACC of 
the MTP (Fig. 6.20). The lateral aspect of the joint showed no signs of OA. 
 
 
 
 
 
 
 
Figure 6.19 – Detachment of hyaline articular cartilage from articular calcified 
cartilage on the medial tibial plateau in the experimental knee of BALB/c 
103.1, a 60 week old Hgd-/- mouse culled at 12 weeks post-op. H&E staining 
revealed detachment of a large area of the HAC from the ACC on the MTP (black 
arrows). There did appear to be a small area still attached to the ACC (red arrow) 
however most was completely free from the cartilage underneath. Bar = 100µm. 
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Analysis of the contralateral control from BALB/c Hgd-/- 103.1 showed there to be 
minimal damage, with ossification of the LM the only observed degeneration. 
Quantification of both the experimental and control knee joints revealed there to 
be a higher number of pigmented chondrons in the experimental joint (151) than 
the control joint (130) (Fig. 6.21 & Table. 6.1). These numbers were consistent with 
what had been previously observed in the DMM study. 
 
 
 
Figure 6.20 – Pigmented chondrons at the site of detachment on the medial 
tibial plateau in the experimental knee of BALB/c 103.1, a 60 week old Hgd-/- 
mouse culled at 12 weeks post-op. Schmorl’s staining showed pigmented 
chondrons situated directly adjacent to the area of damage in the MTP. This was 
consistent with previous mice in the DMM study. Bar = 20µm. 
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6.3.1.2.4 Quantification of pigmented chondrons at twelve weeks post-op 
Pigmented chondrons in both the experimental and control tibio-femoral joints 
were quantified to determine if DMM surgery had had any effect on the number 
(Fig. 6.21). It was clear the data did not show an increase in pigmented chondrons 
present in the ACC of BALB/c Hgd-/- mice following surgery. Statistical analysis, 
performed using a paired t test, revealed no specific evidence of an increase in the 
number of pigmented chondrons in the experimental and contralateral control 
limbs (Table 6.1), both at 8 and 12 weeks post-op (P = 0.3872). 
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Figure 6.21 – The effect of DMM surgery, at twelve weeks post-op, on the 
number of pigmented chondrons in BALB/c Hgd-/- mice. Scatter chart showing 
that DMM surgery did not appear to cause an increase in the number of pigmented 
chondrons in BALB/c Hgd-/- mice. Quantification of pigmented chondrons was 
performed on a single section from each mouse; this does not represent the total 
cell number in each mouse. 
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6.3.1.3 Comparison of DMM Hgd-/- mice at eight and twelve weeks post-op 
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Figure 6.22 – A comparison of the effect of DMM surgery, at eight and twelve 
weeks post-op, on the number of pigmented chondrons in BALB/c Hgd-/- mice. 
Scatter chart showing that DMM surgery did not appear to cause an increase in the 
number of pigmented chondrons, both at eight and twelve weeks post-op, in 
BALB/c Hgd-/- mice. Quantification of pigmented chondrons was performed on a 
single section from each mouse; this does not represent the total cell number in 
each mouse. 
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BALB/c Hgd-/- 
Pigmented chondrons – 
control limb (R) 
Pigmented chondrons – 
experimental limb (L) 
100.1 (♀) 183 110 
100.2 (♀) 148 172 
101.1 (♂) 151 109 
102.2 (♂) 132 156 
102.3 (♂) 71 86 
103.1 (♀) 130 151 
Mean 135.8333 130.6667 
p 0.3872 
 
6.3.1.3 Histological scoring of OA in DMM 
 
 
Using the method described by the OARSI histopathology initiative for mice [120] 
both the experimental and contralateral control joints were scored to determine 
the severity of OA in the four quadrants (MTP, MFC, LTP, LFC). Statistical analysis, 
performed with a Wilcoxon signed-rank test, revealed a significant difference 
(p=0.0273) between the severity of OA in the experimental and contralateral 
control limbs (Tables. 6.2 & 6.3). 
 
 
 
 
 
 
Table 6.1 – Quantification of pigmented chondrons in Hgd-/- DMM mice at eight 
and twelve weeks post-op. Animals highlighted in yellow are eight weeks post-op; 
animals highlighted in green are twelve weeks post-op. 
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BALB/c Hgd-/- 
Grading of OA changes – 
control limb (R) 
Grading of OA changes – 
experimental limb (L) 
100.1 (♀) 3 5 
100.2 (♀) 2 7 
101.1 (♂) 1 15 
102.2 (♂) 1 15 
102.3 (♂) 1 13 
103.1 (♀) 1 9 
Mean 1.5 10.6667 
p 0.0273 
 
 
 
 
The results showed the highest severity of OA was located in the experimental 
tibio-femoral joints. There was a marked increase in the severity of OA at 12 weeks 
post-op however BALB/c 101.1 (8 weeks post-op) did show scores consistent with 
those observed at 12 weeks post-op. Another interesting observation was that 
three out of the six mice (100.1, 101.1, & 102.2) showed greater damage on the 
lateral aspect of the joint, rather than the medial aspect where the surgery was 
performed.  As the medial portion of the joint is more prone to OA changes [218-
220] the level of damage on the lateral aspect in these mice was somewhat 
surprising. 
 
Scoring of the histological sections from the DMM study showed a higher severity 
of OA in males compared to females. This is consistent with previously reported 
literature where males have been shown to develop more OA than females in both 
DMM and collagenase induced models of OA [221, 222]. 
Table 6.2 – Cumulative grading scores of OA damage in Hgd-/- DMM mice at eight 
and twelve weeks post-op. Animals highlighted in yellow are eight weeks post-op; 
animals highlighted in green are twelve weeks post-op. 
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BALB/c (8 weeks 
post-op) 
MTP MFC LTP LFC Total 
(MTP+MFC) 
Total   
(LTP+LFC) 
Cumulative 
Total 
100.1 (L) 60wks (♀) 0 1 2 2 1 4 5 
100.1 (R) 60wks 0 0 1 2 0 3 3 
100.2 (L) 60wks (♀) 2 2 0 3 4 3 7 
100.2 (R) 60wks 0 1 0 1 1 1 2 
101.1 (L) 60wks (♂)  3 2 4 6 5 10 15 
101.1 (R) 60wks 0 1 0 0 1 0 1 
 
BALB/c (12 weeks 
post-op) 
MTP MFC LTP LFC Total 
(MTP+MFC) 
Total   
(LTP+LFC) 
Cumulative 
Total 
102.2 (L) 60wks (♂) 4 3 3 5 7 8 15 
102.2 (R) 60wks 1 0 0 0 1 0 1 
102.3 (L) 60wks (♂) 5 4 2 2 9 4 13 
102.3 (R) 60wks 0 0 1 0 0 1 1 
103.1 (L) 60wks (♀) 6 1 1 1 7 2 9 
103.1 (R) 60wks 0 0 0 1 0 1 1 
 Table 6.3 – Histological scoring of osteoarthritic damage in DMM mice at eight and twelve weeks post-op. (L = experimental, R = control).  
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6.3.1.4 Retrospective power calculation 
In retrospect it appeared that the DMM study was most likely underpowered and 
therefore did not provide accurate or reliable data. To prevent this from occurring 
in future studies a retrospective power calculation was carried out using the data 
from the BALB/c Hgd-/- natural history study (Chapter 3) as a guide. 
 
6.3.1.4.1 8 weeks post-op 
The mean number of pigmented chondrons in the BALB/c Hgd-/- DMM control 
group equalled 160.7, whilst the BALB/c Hgd-/- DMM experimental group equalled 
130.3. The standard deviation of the difference between the two groups was equal 
to 49.54. These figures resulted in a power equal to 0.1029, meaning that a 
difference in the number of pigmented chondrons would be observed about 10% of 
the time. As a power of at least 80% is required for reliable data this shows the 
DMM study at 8 weeks post-op was underpowered. In case of any future studies, a 
total of 23 subjects would give an 80% chance of detecting the observed difference 
at a two-tailed significance level of 0.05. 
 
6.3.1.4.2 12 weeks post-op 
The mean number of pigmented chondrons in the BALB/c Hgd-/- DMM control 
group equalled 111, whilst the BALB/c Hgd-/- DMM experimental group equalled 
131. The standard deviation of the difference between the two groups was equal to 
4.58. These figures resulted in a power equal to 0.9416, meaning that a difference 
in the number of pigmented chondrons would be observed about 94% of the time. 
This data shows that the DMM study at 12 weeks post-op, even with only three 
subjects included, had more than enough power to detect the observed difference. 
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The use of animals in research is heavily regulated and there is a commitment to 
reduce the number used for scientific purposes. The 3Rs (Replacement, Reduction 
and Refinement) were introduced as a framework for humane animal research and 
are used to help develop alternative approaches which avoid the use of animals in 
scientific research. The use of power calculations is particularly relevant to the 3Rs 
(specifically Reduction) as it provides information on the numbers of mice needed 
per study to obtain reliable data. This helps to minimise the number of animals 
used in experiments, thereby reducing the overall number by avoiding unnecessary 
and excessive use of animals. Power calculations are a valuable contribution to the 
3Rs as they help to provide maximal data from minimal animal use. 
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6.3.2 5mM HGA supplementation 
6.3.2.1 Treated group 
Ten BL/6 Hgd-/- mice were given water containing 5mM of HGA over their lifetime. 
The mice were culled between the ages of 51 and 74 weeks and then processed 
histologically to allow for quantification of pigmented chondrons. Plasma HGA 
levels were measured regularly throughout their lifespan. One mouse from the 
treated group, BL/6 Hgd-/- 41.2 (45 weeks), was not included in the data shown as 
it was culled due to ill health. 
 
Photomicrographs from a small selection of mice in both the treated and control 
groups are shown. As the photomicrographs demonstrate the presence of 
pigmented chondrons in the joint, only a small number will be shown as they are 
similar to the photomicrographs contained in the natural history study (Chapter 3). 
 
6.3.2.1.1 BL/6 Hgd-/- 52.2 (♂) – 51 weeks (5mM HGA supplementation for 40 
weeks) 
Schmorl’s stain revealed a relatively low amount of pigmented chondrons 
throughout BL/6 Hgd-/- 52.2 (♂). Quantification of the chondrons showed the total 
amount to be lower than what would have been expected from a mouse aged 51 
weeks (Fig. 6.28) not supplemented with HGA. There was no obvious cartilage 
damage on each of the four quadrants of the tibio-femoral joint however there was 
a small amount of vascularisation of the MFC. Large pigmented hypertrophic 
chondrons were located prominently in the MTP (Fig. 6.23) which was consistent 
with previous data. 
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6.3.2.1.2 BL/6 Hgd-/- 57.2 (♀) – 63 weeks (5mM HGA supplementation for 56 
weeks) 
BL/6 Hgd-/- 57.2 (♀) showed significant osteoarthritic changes on the MTP with 
fibrillations and loss of the surface lamina observed (Fig. 6.24). There also appeared 
to be detachment of the ACC from the underlying SCB bone (Fig. 6.24), highlighting 
the severity of OA in the mouse. Quantification of the pigmented chondrons 
showed the total amount to be comparable to mice of similar age not 
supplemented with HGA (Fig. 6.28). 
 
Figure 6.23 – Hypertrophic pigmented chondrons in the medial tibial plateau 
of BL/6 52.2, a 51 week old Hgd-/- mouse supplemented with 5mM HGA for 40 
weeks. Large numbers of very hypertrophic chondrons (arrowed) were located 
in the MTP.  Section stained with Schmorl’s. Bar = 20µm. 
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6.3.2.1.3 BL/6 Hgd-/- 31.2 (♂) – 74 weeks (5mM HGA supplementation for 56 
weeks) 
BL/6 Hgd-/- 31.2 (♂) showed very severe osteoarthritic changes on the medial 
aspect of the joint with complete erosion of the HAC on both the MFC and MTP 
(Fig. 6.25). Fibrillations and loss of surface lamina were also observed on both the 
LFC and LTP. Quantification of the pigmented chondrons showed numbers 
comparable to those seen in mice of similar ages (Fig. 6.28). 
 
Figure 6.24 – Detachment of articular calcified cartilage from subchondral 
bone in BL/6 57.2, a 63 week old Hgd-/- mouse supplemented with 5mM HGA 
for 56 weeks. A substantial section of the ACC appeared to be removed from 
the SCB in the MTP.  Section stained with Schmorl’s. Bar = 20µm. 
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6.3.2.2 Control group 
Ten BL/6 Hgd-/- mice were supplied with standard drinking water for their lifespan. 
The mice were culled between the ages of 63 and 72 weeks and then processed 
histologically to allow for quantification of pigmented chondrons. Plasma HGA 
levels were measured regularly throughout their lifespan. One mouse from the 
control group, BL/6 42.1 (64 weeks), was not included in the data shown as it was 
culled due to ill health. 
 
 
 
Figure 6.25 – Complete loss of hyaline articular cartilage in BL/6 31.2, a 74 
week old Hgd-/- mouse supplemented with 5mM HGA for 56 weeks. The HAC 
had eroded completely exposing the underlying ACC.  Section stained with 
Schmorl’s. Bar = 100µm. 
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6.3.2.2.1 BL/6 Hgd-/- 49.1 (♀) – 68 weeks  
Areas of damage were observed throughout the tibio-femoral joint of BL/6 Hgd-/- 
49.1 (♀), with fibrillations present on the MFC (Fig. 6.26) and the MTP. SCB 
remodelling was visible in the MFC (Fig. 6.26) and MTP. Small amounts of damage 
were located on the lateral aspect of the joint however the most significant damage 
was in the medial portion of the joint. Quantification of the pigmented chondrons 
showed numbers similar to those seen in mice of the same age (Fig. 6.28). 
 
 
 
  
 
 
 
 
Figure 6.26 – Articular cartilage fibrillations and subchondral bone remodelling 
in BL/6 49.1, a 68 week old Hgd-/- mouse. A small fibrillation/cleft was located 
on the articular surface of the MFC (bottom arrow). Considerable amounts of 
SCB remodelling were also located in the condyle (top arrows). Section stained 
with Schmorl’s. Bar = 20µm. 
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6.3.2.2.2 BL/6 Hgd-/- 42.2 (♂) – 70 weeks 
Severe osteoarthritic changes were located on the MFC and MTP in BL/6 Hgd-/- 
42.2 (♂) (Fig. 6.27). Similar to BL/6 Hgd-/- 31.2 (♂) in the treated group, there was 
complete erosion of HAC leading to the exposure of the underlying SCB (Fig. 6.27). 
The lateral portion of the joint did not show as extreme damage, only minor 
cartilage fibrillations and loss of surface lamina. Quantification of the pigmented 
chondrons in the joint showed numbers slightly higher than previously seen in mice 
of similar ages (Fig. 6.28). 
 
 
 
 
 
 
 
Figure 6.27 – Complete erosion of hyaline articular cartilage in BL/6 42.2, a 70 
week old Hgd-/- mouse. The HAC had eroded completely exposing the 
underlying ACC.  Section stained with Schmorl’s. Bar = 100µm. 
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6.3.2.3 Quantification of pigmented chondrons  
Pigmented chondrons in both the 5mM HGA treated group and the control group 
were quantified to demonstrate the effect, if any, of 5mM HGA supplementation on 
the number of pigmented chondrons in the tibio-femoral joints of Hgd-/- mice.  
 
 
 
 
 
 
6.3.2.4 Plasma HGA levels (5mM HGA study) 
Lifetime plasma HGA levels were collected from both the treated and control 
groups to identify if 5mM HGA supplementation increased plasma HGA when 
compared to control (non-supplemented) Hgd-/- mice (Fig. 6.29). The data showed 
no significant increase in the lifetime plasma HGA levels of the mice supplemented 
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Figure 6.28 – The effect of 5mM HGA supplementation on the number of 
pigmented chondrons in BL/6 Hgd-/- mice. Scatter chart showing how HGA 
supplementation affects pigmentation levels in BL/6 Hgd-/- mice. Quantification of 
pigmented chondrons was performed on a single section from each mouse; this 
does not represent the total cell number in each mouse. 
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with 5mM HGA. The levels of plasma HGA measured in both groups were consistent 
with those observed in control Hgd-/- mice in the nitisinone study (Fig. 5.18).  
 
 
 
 
 
 
Both plasma HGA and chondron quantification data revealed no clear pattern of an 
increase in pigmented chondron numbers or plasma HGA in Hgd-/- mice 
supplemented with 5mM HGA. From the data obtained it appears that additional 
HGA in the diet did not cause an increase in pigment deposition. 
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Figure 6.29 – The effect of 5mM HGA supplementation in BL/6 Hgd-/- mice. 
Scatter chart showing lifetime supplementation with additional 5mM HGA had no 
effect on plasma HGA levels. (All measurements and data analysis performed by 
Dr. A. Preston). 
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6.4 DISCUSSION 
This Chapter investigated whether DMM surgery or supplementation with HGA 
increased the amount of ochronotic pigment deposited in the calcified cartilage of 
BALB/c (DMM) and BL/6 (5mM HGA) Hgd-/- mice. [118]. The development of 
severe osteoarthropathy is closely associated with the progression of AKU in 
humans [24, 223]. Data from the natural history study of ochronotic 
osteoarthropathy in Hgd-/- mice (Chapter 3) showed mild, moderate and severe OA 
at different ages throughout their lifetime. There was variability between individual 
mice, both of different and similar ages, in relation to the number of pigmented 
chondrons present in the ACC, and the severity of cartilage damage in the tibio-
femoral joint. Although a clear pattern did not emerge between these factors, it has 
been suggested that pigmentation is initiated following biomechanical damage at 
the ACC-SCB interface [36]. Changes in the biomechanical and structural properties 
of the ACC are also believed to lead to an increased deposition of ochronotic 
pigment [36], thus causing further cartilaginous destruction and resulting in 
increased OA severity. The mechanism appears to be similar to a positive feedback 
system as biomechanical damage leads to initial pigment deposition which then 
leads to further biomechanical damage and then an increase in pigment deposition. 
Data from Chapter 4 of this thesis identified a similar mechanism for the initiation 
of ochronotic pigment in Hgd-/- mice. With data from both human and murine 
studies showing an apparent association between biomechanical damage and 
pigmentation, DMM surgery was performed on Hgd-/- mice to identify if the 
damage caused by the procedure accelerated the rate of pigmentation, and/or 
increased the amount of pigment deposited. Correlation between these factors 
would provide evidence that biomechanical damage to the cartilage is a major 
cause of ochronotic osteoarthropathy in AKU. 
 
The first three DMM Hgd-/- mice to be analysed in the study, BALB/c Hgd-/- 100.1 
(♀), 100.2 (♀), and 101.1 (♂) were left for 8 weeks post-op. All three were aged 52 
weeks when the surgery took place and age 60 weeks when culled. As expected 
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with Hgd-/- mice at 60 weeks, signs of OA were identified in the tibio-femoral joint. 
Osteophyte formation (Figs. 6.1 & 6.4) and articular surface fibrillations (Figs. 6.2 & 
6.5) were observed to some extent in all of the mice, comparable to those seen in 
mice of a similar age in the natural history study (Figs. 3.10 – 3.13). However the 
use of DMM surgery did lead to very severe damage at 8 weeks post-op, located on 
the lateral portion of the experimental joint in BALB/c Hgd-/- 101.1 (Fig. 6.8). 
Although there was considerable cartilage erosion on the MTP (Fig. 6.7), both the 
LTP and LFC displayed significantly more erosion, with ≥90% of HAC on the LFC 
eroded. As expected the experimental joint showed increased osteoarthritic 
changes compared to the contralateral control, in all of the mice at 8 weeks post-op 
(Table. 6.3). What was surprising was the amount of damage inflicted on the lateral 
portion of the experimental joint in BALB/c Hgd-/- 100.1 and 101.1, with both 
showing more OA lesions on the LTP and LFC than the MTP and MFC (Table. 6.3). 
Loading of the tibio-femoral joint is known to be greater on the medial 
compartment with forces approximately 2.5 times greater than those on the lateral 
compartment [224], leading to a greater prevalence of medial lesions in OA [225]. 
Therefore it seems unexpected that there are more lateral lesions in two of the 
three mice at 8 weeks post-op, considering the DMM procedure is designed to 
cause maximal damage on the medial compartment. Research by Lapveteläinen et 
al [226], in which mice containing a mutation in the type II procollagen gene were 
provided with a running wheel, showed there to be an increase in the severity of 
OA in the LTP and LFC, when compared to the MTP and MFC. They state that this is 
likely due to structural abnormalities in the collagen network of the matrix, and 
uneven loading across the tibio-femoral joint. Although Hgd-/- mice do not contain 
this mutation, deposition of ochronotic pigment is thought to disrupt the 
composition and organisation of the collagenous matrix. Therefore it is reasonable 
to suggest that this phenomenon along with uneven loading of the experimental 
knee joint led to increased OA severity on the lateral aspect of the joint. It is 
possible that displacement of the MM caused uneven loading of the tibio-femoral 
joint in these two mice, leading to a disproportionate amount of pressure to be 
placed upon the lateral compartment of the joint, and increasing the severity of OA. 
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BALB/c Hgd-/- 102.2 (♂), 102.3 (♂), and 103.1 (♀), left for 12 weeks post-op, 
showed increased OA severity in comparison with the mice culled 8 weeks post-op. 
Like these mice, the three culled 12 weeks post-op were also aged 60 weeks. What 
was immediately obvious was the severity of OA in the experimental joints 
compared to the contralateral controls, which showed very little, if any damage 
(Fig. 6.15). Both BALB/c Hgd-/- 102.2 and 102.3 showed severe erosion of HAC 
exposing the underlying ACC, along with the large fully ossified osteophytes on the 
MTP (Figs. 6.12 & 6.16). Smaller osteophytes were located on the MFC in both mice 
while ossification of the LM was also observed (Figs. 6.13 & 6.17). Detachment of 
≥75% of the HAC on the MTP was visible in BALB/c 103.1 (Fig. 6.19), highlighting the 
severity of OA in the mouse. Although damage was located on the lateral 
compartment in all of the mice, in only one (BALB/c 102.2) was it more severe than 
that observed in the medial portion of the joint (Table. 6.3). The observation of 
increased OA severity on the MTP and MFC, in two of the three mice, is consistent 
with the data reported by Glasson et al in the original study [118]. 
 
The apparent association between biomechanical damage, and the initiation and 
progression of ochronotic pigmentation has been previously documented [36, 227]. 
NMR studies have also shown there to be disorder in the collagen network in 
ochronotic tissue [39], thus affecting its biomechanical properties. Along with 
inducing moderate to severe OA in Hgd-/- mice, DMM was performed to identify if 
the presence of significant damage in the joint led an increase in the amount of 
pigment deposited in the articular cartilage, therefore highlighting a possible link 
between damage and pigment deposition. Results from both 8 weeks (Fig. 6.11), 
and 12 weeks (Fig. 6.21) post-op showed no statistically significant increase in the 
total number of pigmented chondrons in Hgd-/- mice. In two of the three of the 
mice examined at 8 weeks post-op there was actually a greater number of 
pigmented chondrons in the contralateral control than the experimental tibio-
femoral joint (Fig. 6.11). At 12 weeks post-op the opposite effect was observed with 
a greater number of pigmented chondrons in the experimental tibio-femoral joint 
(Fig. 6.21). This was interesting as the mice at 12 weeks post-op also showed 
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increased OA severity in their experimental limb (Table. 6.1). However as the data 
shows (Fig. 6.22) no statistically significant increase in pigmented chondron 
numbers from 8 weeks post-op to 12 weeks post-op was observed. As mechanical 
damage is thought to be involved in the initiation and progression of pigmentation 
it is unclear why there was no significant increase in the number of pigmented 
chondrons. It is possible inter-individual variability contributed to the low number 
of pigmented chondrons in BALB/c Hgd-/- 100.1 and 101.1, which both displayed 
higher numbers of pigmented chondrons in the contralateral control limb. Although 
plasma levels of HGA in Hgd-/- mice remain steady across their lifetime there is 
variability with regards to the number of pigmented chondrons in Hgd-/- mice of 
the same age, as seen in Chapter 3 of this thesis. It is likely other factors are 
involved in the reduction of pigmented chondrons in these mice including catabolic 
factors expressed by damaged/abnormal chondrocytes however further analysis of 
an increased number of DMM Hgd-/- mice may reveal this data to be no more than 
an anomaly. There is little doubt changes resulting from biomechanical damage do 
play a role in the pathogenesis of AKU however, how much they are involved is still 
not fully understood. 
 
In the event of future DMM studies there are a number of improvements which 
could be made to ensure the data collected is reliable. Both non-surgical and sham 
controls should be included in any future studies as they provide important 
information. Using a sham control ensures that the effects observed in the 
experimental mice are as a result of the surgical procedure and no other factor(s). 
Although the contralateral limb was used as a non-surgical control in the DMM 
study it is possible this limb was placed under increased mechanical loading as a 
result of the mice refraining from placing weight on the surgically operated limb, 
possibly resulting in the development of OA in the control limb. This highlights the 
need to use a non-surgical control group. Following DMM surgery the mice were 
single housed to prevent any aggressive behaviour occurring between individuals. 
As each mouse had a surgical wound it was decided single housing would be best to 
prevent any problems post-surgery such as nibbling of the sutures, by other mice. 
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Once the wound was healed the mice were housed together with same sex siblings. 
This must be done to stop any fighting between the mice, especially when dealing 
with male mice. It has been reported in some studies that group housing does not 
appear to have any detrimental effects on the mice post-surgery, however it may 
be that the rough and tumble nature of mice housed together could possibly 
exacerbate the development of OA in some models of DMM. This would have to be 
carefully monitored against the mice in both the sham and control groups. In the 
event of any future DMM studies it may be best to house the mice together as they 
would be housed in groups of 3 or 4 pre-surgery, and monitor carefully for any 
problems with the healing of the skin incision. To determine the number of mice 
needed in each group (controls and experimental), a power calculation can be used 
as this will provide the maximum number of mice required to observe an effect. 
Power calculations are very helpful as they prevent the unnecessary use of animals 
in experiments; this helps to reduce the number of mice used which is in line with 
the 3Rs. In retrospect it may have been better to use young mice in the study as 
aged mice are more likely to develop spontaneous OA whilst also having high 
numbers of pigmented chondrons. As the aim of the DMM experiment was to 
determine if damage to the joint initiated pigmentation, using young animals which 
have yet to develop joint damage or pigmentation may have been the best strategy. 
Using the OARSI histopathology initiative for mice [120] the severity of OA induced 
by DMM can be assessed. This method provides a system to score the four 
quadrants of the tibio-femoral joint and determine the severity of OA throughout. A 
Kruskal-Wallis test can be used to determine if any statistically significant 
differences are present between the severity and amount of OA in the 
experimental and control groups whilst an independent samples t-test can be 
generated to compare the number of pigmented chondrons between the 
experimental and control groups. 
 
Supplementing the drinking water of Hgd-/- mice, with 5mM HGA, was also used as 
a possible method to increase the amount of ochronotic pigment deposited. Two 
groups, one containing mice supplemented with 5mM HGA and the other 
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containing mice with no HGA in their drinking water were analysed to see whether 
supplementation with HGA increased the number of pigmented chondrons and/or 
their plasma HGA levels. Histological analysis revealed little differences between 
the treated and control groups with mice from both groups showing severe OA 
lesions (Figs. 6.27 & 6.28) in the tibio-femoral joint. Quantification of the pigmented 
chondrons did not show a considerable difference in the number between both 
groups (Fig. 6.28). The highest number of pigmented chondrons was actually seen 
in one of the control mice suggesting supplementation with 5mM HGA had no 
effect on pigment deposition. Lifetime plasma HGA levels (Fig. 6.29) also revealed 
no significant difference between the treated and control groups. Some variation 
was seen over the lifetime however this was in line with that normally seen in Hgd-
/- mice (Fig. 5.18). Quantification of pigmented chondrons and analysis of plasma 
HGA levels showed supplementation with additional HGA did not increase the 
amount of pigment deposited in Hgd-/- mice, nor did it increase the circulating 
levels of HGA. Although some HGA remains in the plasma the majority is excreted in 
the urine, therefore it seems likely that any additional HGA is simply excreted and is 
never converted to ochronotic pigment. It is clear that this level of HGA 
supplementation does not have an effect on the amount of pigment present in 
plasma or deposited in Hgd-/- mice. 
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7. Ultrastructural analysis of cartilage in Hgd-/- and wild type mice 
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7.1 INTRODUCTION 
This Chapter presents in depth ultrastructural analysis of murine cartilage from 
both BALB/c Hgd-/- and WT mice. There has been little research performed on the 
ultrastructure of murine cartilage using TEM as it is known to be difficult to obtain 
high quality sections. Silberberg and colleagues [228, 229] performed TEM analysis 
on the femoral heads of mice of various ages but little attention was paid to the 
ACC in their studies. Ultrastructural analysis using scanning electron microscopy 
(SEM), such as the study by Hughes et al [230] have shown in detail the orientation 
of chondrocytes, and collagen fibres in the territorial and interterritorial matrices of 
murine HAC but have also neglected the ultrastructure of the ACC.  
 
The structure, ultrastructure and function of the HAC and SCB have been the 
subject of much investigation and their potential involvement in the pathogenesis 
of OA has been widely recognised [84, 100, 231, 232]. However much less attention 
has been focussed on the ACC and its significance in the development of OA has 
been largely ignored [233]. The ultrastructure and cell biology of the ACC is poorly 
described which often causes its role in OA to be overlooked. 
 
This Chapter highlights the differences between the HAC and ACC and the 
chondrocytes that reside in each zone. Analysis of both Hgd-/- and WT mice 
revealed the appearance of concentric lamellae structures surrounding 
hypertrophic chondrocytes located in the ACC. Extensive literature searches 
revealed this was a novel finding in mice. These concentric lamellae were more 
prevalent in Hgd-/- mice and further analysis revealed other structural differences 
between Hgd-/- and WT mice which may help us understand the progression of 
ochronotic osteoarthropathy. 
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7.2 DESIGN OF STUDY 
Young and aged BALB/c Hgd-/- mice and aged WT mice, ranging from 7.8 to 69 
weeks, were culled and their tissues harvested. Following fixation and 
decalcification small sections from the top of the MFC containing HAC, ACC and a 
small amount of SCB, were taken and processed for TEM analysis. 
 
Detailed ultrastructural analysis of the HAC and ACC were carried out to identify if 
any changes had occurred which could help further understand the relationship 
between AKU and the onset of severe osteoarthropathy. 
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7.3 RESULTS 
7.3.1 Ultrastructural analysis of cartilage and chondrons in BALB/c Hgd-/- mice 
Detailed TEM photomicrographs from an area of the MFC highlighted the 
ultrastructure of HAC and ACC and the cells and collagenous matrices contained 
within them (Figs. 7.1 & 7.2). 
 
 
 
 
 
Figure 7.1 – TEM photomicrograph of an area of the medial femoral condyle from 
BALB/c 145.3, a 53 week old Hgd-/- mouse. Calcified and uncalcified regions of 
cartilage and the boundary (tidemark) separating them are highlighted. Tissue fixed 
in glutaraldehyde (x1250). Bar = 10μm. 
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The tidemark, which is labelled in the above figure (Fig. 7.1), is reported to be a 
composition of several different molecules including alkaline phosphatase [234], 
adenosine triphosphate [235], and apoptotic bodies from chondrocytes [236]. The 
inclusion of these constituents ensures that even though the tissue has been 
decalcified, the tidemark still remains. 
   
 
 
 
 
Figure 7.2 – TEM photomicrograph of an area of the medial femoral condyle from 
BALB/c 145.3, a 53 week old Hgd-/- mouse. Detailed structures including the 
calcified cartilage and SCB and the cells within them are highlighted. Tissue fixed in 
glutaraldehyde (x1250). Bar = 10μm. 
ACC 
SCB 
Hypertrophic chondrons 
Osteocyte 
Marrow cells 
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The following images highlight the different phenotypes of chondrons located in 
the HAC and ACC of the MFC. As discussed in Chapters 3 & 4, hypertrophic 
pigmented chondrons were localised to the ACC. Chondrons located in the HAC, 
which did not pigment, were much smaller and flatter in comparison to those 
located in the ACC.  
 
 
 
 
 
Figure 7.3 – TEM photomicrograph of a flattened chondron located in the 
superficial zone of the hyaline articular cartilage from BALB/c 145.3, a 53 week 
old Hgd-/- mouse. Individual collagen fibres located in the PCM of the chondron 
(arrowed) are highlighted. (x26,500). Inset: TEM image showing the location of the 
chondron in HAC. Tissue fixed in glutaraldehyde (x8250). Bar = 0.5 μm. 
Art. surf 
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Chondrons located in the superficial zone lay parallel to the articular surface and 
were small in size (Fig.7.3). The next zone of cartilage, the middle zone, contained 
chondrons which were similar to those located in the superficial zone, but were 
larger in size, and appeared more rounded.  
 
 
 
 
 
 
Figure 7.4 – TEM photomicrograph of a chondron located in the deep zone of the 
hyaline articular cartilage of BALB/c 145.3, a 53 week old Hgd-/- mouse. 
Ultrastructure of the chondron is detailed, highlighting specific structures within 
the cell. (x9900). Bar = 2μm. Inset: TEM photomicrograph showing the location of 
the chondron in the HAC. Tissue fixed in glutaraldehyde (x2500).  
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Chondrons located in the deep zone were large in size and had a rounded 
appearance (Fig. 7.4). These chondrons lay perpendicular to the articular surface as 
did the collagen fibres in the surrounding matrices. All chondrons present in the 
HAC appeared healthy suggesting they were metabolically active and involved in 
the turnover of the cartilaginous matrix. The next zone of cartilage, ACC, differs 
from HAC due to the presence of calcium in the matrix. 
  
 
 
 
 
Figure 7.5 – TEM photomicrograph of healthy chondrons located in the articular 
calcified cartilage of BALB/c 145.3, a 53 week old Hgd-/- mouse. Both chondrons 
highlighted appeared healthy as opposed to the second set of chondrons located 
deep in the calcified cartilage. Tissue fixed in glutaraldehyde (x2500). Bar = 5μm. 
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Although the majority of the chondrons located in the calcified cartilage were 
hypertrophic, a small number located directly adjacent to the tidemark were not 
and appeared healthy (Fig. 7.5). What was apparent from looking at the chondrons 
was the appearance of concentric lamellar structures around the chondrons. The 
lamellae initially looked as if they formed part of the PCM but upon further 
observation it was clear that they reached out into areas of the TM. Further analysis 
revealed the presence of the lamellae around the large majority of chondrons in the 
ACC; this will be shown in detail in the next part of this chapter. 
 
As the chondrons progressed deeper into the ACC, close to the boundary with the 
SCB, they became increasingly hypertrophic and chondroptotic. Patchy condensing 
of nuclear chromatin, increasing amounts of rough endoplasmic reticulum (rER) and 
cellular disintegration (Figs 7.6 & 7.7), which are hallmarks of chondroptosis [237], 
were observed in all of the aged mice. 
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Figure 7.6 – TEM photomicrograph of a hypertrophic chondron in the articular 
calcified cartilage of BALB/c 145.3, a 53 week old Hgd-/- mouse, displaying 
signs of chondroptosis. Patchy condensation of both heterochromatin and 
euchromatin and cell disintegration indicated the cell was in the process of 
chondroptosis. Tissue fixed in glutaraldehyde (x11,500). Bar = 2μm. 
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Figure 7.7 – TEM photomicrograph of end stage chondroptosis. The chondron, 
which was located deep in the ACC, had undergone complete chondroptosis 
with only remnants of the cell left behind. Section taken from BALB/c Hgd-/- 
138.3, a 56 week old Hgd-/- mouse. Tissue fixed in glutaraldehyde (x4200). Bar = 
5μm.  
Cell remnants 
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7.3.2 Identification of concentric lamellae in the articular calcified cartilage of 
BALB/c Hgd-/- and wild type mice 
7.3.2.1 Hgd-/- mice 
During the initial study which highlighted the different regions of cartilage and the 
chondrons present in them, a distinct pattern of concentric circles or lamellae was 
observed around chondrons located in the ACC. These lamellae encircled both 
viable chondrons located towards the mineralisation front (Fig. 7.8) and 
hypertrophic and necrotic chondrons which were located deep in the ACC, close to 
the boundary with the SCB (Fig. 7.9). 
 
 
 
 
 
 
Figure 7.8 – TEM photomicrograph highlighting the identification of concentric 
lamellae. The chondron, which was located adjacent to the tidemark, was 
surrounded by lamellae (arrowed) in what appeared to be a periodic-like 
manner. Image taken from BALB/c Hgd-/- 145.3, a 54.4 week old Hgd-/ mouse. 
Tissue fixed in glutaraldehyde (x8200). Bar = 2μm. 
Tidemark 
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The number of lamellae and the distance between each one appeared to vary with 
individual chondrons. It is interesting to note that the lamellae surround both viable 
and hypertrophic chondrons suggesting that their formation is not linked to any 
apoptotic processes. 
 
Chondrons that were located towards the mineralisation front appeared to be 
partially engulfed by the lamellae (Fig. 7.10), before progressing deeper into the 
ACC (Fig. 7.11). Stages of this progression were identified in all Hgd-/- mice. 
Figure 7.9 – TEM photomicrograph of concentric lamellae surrounding a 
chondron deep in the articular calcified cartilage. Concentric lamellae were 
seen surrounding the cell (arrowed) in a periodic manner, identical to what was 
seen in the chondron at the mineralisation front (Fig. 7.8). Image taken from 
BALB/c Hgd-/- 145.3, a 54.4 week old Hgd-/ mouse. Tissue fixed in 
glutaraldehyde (x8200). Bar = 2μm. 
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Figure 7.10 – TEM photomicrograph of a chondron located at the 
mineralisation front partially engulfed by concentric lamellae. The chondron 
appeared to be partially engulfed by concentric lamella, while not fully 
immersed in the ACC. Image taken from BALB/c Hgd-/- 61.3, a 60 week old Hgd-
/- mouse. (x6000). Bar = 5μm. Inset: Location of the chondron in the ACC 
showing apparent ‘opening’ of the tidemark (arrowed) allowing the chondron 
to be engulfed by the concentric lamellae in the ACC. Tissue fixed in PBFS 
(x2500).  
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Figures 7.10 and 7.11 appeared to an apparent ‘opening’ and ‘closing’ of the 
tidemark as the chondron(s) become partially, and then completely engulfed by the 
concentric lamellae once embedded in ACC. This process is most probably linked to 
increased calcification of the cartilage matrix as the lamellae appeared to be laid 
down in association with the advancing tidemark; these processes are known to be 
linked, especially in the pathogenesis of OA. 
 
Figure 7.11 – TEM photomicrograph of a chondron located at the 
mineralisation front progressing deeper into the articular calcified cartilage. 
The chondron was almost completely encircled by lamellae as it progressed 
deeper into the calcified cartilage. Image taken from BALB/c Hgd-/- 61.3, a 60 
week old Hgd-/- mouse. (x6000). Bar = 5μm. Inset: Location of chondron in the 
ACC showing apparent ‘closing’ of the tidemark (arrowed) once the chondron 
had been completely engulfed by the concentric lamellae and is embedded in 
the ACC. Tissue fixed in PBFS (x2500).  
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As the chondrons progressed deeper into the ACC the lamellae became more 
defined and appeared to increase in number in a proportion of the chondrons (Fig. 
7.12). Hypertrophy is a common feature of chondrons in the ACC so this may 
account for the changes seen deeper in ACC. Alkaline phosphatase is released 
during hypertrophy and is known to contribute to calcification of the surrounding 
matrices so it may be the release of alkaline phosphatase is involved in the 
formation of the lamellae. 
 
 
 
 
 
 
 
Figure 7.12 – TEM photomicrograph of a chondron located deep in the 
articular calcified cartilage with clearly defined concentric lamellae. The 
chondron appeared completely engulfed by lamellae (arrows) which were more 
defined than lamellae surrounding chondrons at the mineralisation front. Image 
taken from BALB/c Hgd-/- 61.4, a 60 week old Hgd-/- mouse. Tissue fixed in 
glutaraldehyde (x8200). Bar = 2μm. 
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As the lamellae became more defined it became easier to quantify them. This 
allowed us to show whether the amount of them increased or decreased with age 
and whether their size changed with age. Ten samples were subjected to 
quantitative analysis, however most were from aged mice. Only two out of the ten 
samples were from young mice (6.5 and 7.8 weeks), the rest were from mice aged 
53 weeks or older (included one WT). Although this limited the scope of the study, 
it was still possible to draw initial conclusions from the data obtained. 
 
Preliminary analysis of all the samples appeared to show that there was an increase 
in the number of lamella present in aged mice. BALB/c Hgd-/- 132.1 (♀, 6.5 weeks) 
and BALB/c Hgd-/- 131.1 (♂, 7.8 weeks) both showed a decreasing trend in lamellae 
width and quantity (Fig. 7.13), in comparison to aged Hgd-/- mice (Figs. 7.14 & 
7.15). 
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Figure 7.13 – TEM photomicrograph of a chondron, from BALB/c 131.1, a 7.8 
week old Hgd-/- mouse, surrounded by lamellae. Measurements of the 
lamellae showed, apart from the first lamellae, an increase in width as they 
progressed further from the cell. UA precipitate has been labelled to make clear 
it is not shards of ochronotic pigment. Tissue fixed in glutaraldehyde (x16,500). 
Bar = 1μm. 
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Figure 7.14 – TEM photomicrograph of a chondron, from BALB/c 145.3, a 53 
week old BALB/c Hgd-/- mouse, surrounded by a large number of lamellae. 
The number of lamellae surrounding the chondron increased in comparison to 
the young Hgd-/- mouse (Fig. 7.13), with several appearing narrower than what 
was seen in the young BALB/c Hgd-/- mice (Fig. 7.13). Tissue fixed in 
glutaraldehyde (x26,500). Bar = 1μm. 
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Figures 7.14 and 7.15 showed an increase in the amount of lamellae in aged mice. 
What also appeared to be apparent from the images is that the widths of the 
majority of the lamellae become narrower as they become more frequent and the 
mice become older. From the data obtained there appeared to be an initial trend of 
a decrease in width of the lamellae throughout the samples analysed. In younger 
mice (Fig. 7.13) the lamellae were fewer and thicker than what was seen in the 
aged mice. 
 
Figure 7.15 – TEM photomicrograph of a chondron, from BALB/c 59.3, a 61 
week old BALB/c Hgd-/- mouse, surrounded by a large number of lamellae. 
Measurements of the lamellae found the majority to be narrower than younger 
Hgd-/- mice (Fig. 7.13). This is consistent with what was found in another aged 
Hgd-/- mouse (Fig. 7.14). Tissue fixed in PBFS (x16,500). Bar = 1μm. 
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Further analysis of the lamellae revealed details about their composition. Most of 
the high powered photomicrographs shed little detail about what comprised the 
lamellae but a small number did show the presence of collagen fibres in the 
lamellae of aged mice (Figs 7.16 & 7.17). 
 
 
 
 
 
 
 
Figure 7.16 – TEM photomicrograph of collagen fibres in lamellae. Collagen 
fibres were identified in the lamellae of BALB/c 138.3, a 56 week old Hgd-/- 
mouse (arrows). Periodic banding can be seen along the fibre(s) which is 
distinctive of collagen. Bar = 0.5μm. Inset: Low power image highlighting the 
location of the collagen fibres in the lamellae. Tissue fixed in glutaraldehyde 
(x60,000). Inset bar = 1μm. 
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Figure 7.17 – TEM photomicrograph of collagen fibres in lamellae II. Collagen 
fibres were identified in the lamellae of a chondron deep in the ACC BALB/c 
61.4, a 60 week old Hgd-/- mouse. Again, periodic banding can be seen along 
the fibre(s) which is distinctive of collagen. Bar = 0.2μm. Inset: Low power 
image highlighting the location of the collagen fibres in the lamellae. Tissue 
fixed in PBFS (x87,000). Inset bar = 0.5μm. 
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7.3.2.2 Wild type mice 
Following the discovery of concentric lamellae around chondrons in the ACC of 
BALB/c Hgd-/- mice, WT mice were analysed to see if chondrons in the ACC of these 
mice displayed the same or similar features. 
 
 
 
 
 
 
 
Figure 7.18 showed the presence of concentric lamellae in the ACC of WT mice. The 
chondron and its surrounding lamellae depicted in the figure were almost identical 
to what was seen in the aged Hgd-/- mice (Figs. 7.10 & 7.11). Again, similar to what 
was observed in the Hgd-/- mice, there appeared to be an ‘opening’ of the tidemark 
Figure 7.18 – TEM photomicrograph highlighting structures and lamellae 
widths in a 69 week old wild type mouse. The lamella values appeared to be 
very similar to what was seen in aged BALB/c Hgd-/- mice (Figs. 7.14 & 7.15). 
Although not as many lamella were identified when compared to the aged Hgd-
/- mice, the comparable values of the lamella widths is important. Tissue fixed 
in PBFS (x6000). Bar = 5μm. 
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leading to the chondron being engulfed by lamellae in the ACC. Although the 
lamellae were present in WT mice, only a small number of chondrons appeared to 
be engulfed by them in comparison to the Hgd-/- mice. The number of lamellae 
surrounding the chondrons also appeared to decrease in WT mice. The width of the 
lamellae seemed to be consistent with Hgd-/- mice of similar age (Fig. 7.15), which 
appears to confirm that an increase in the age of the mice leads to a decrease in the 
width of the lamellae present in the cartilage. 
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7.4 DISCUSSION 
The first part of this Chapter detailed the ultrastructure of the HAC and ACC, as well 
as the underlying SCB of BALB/c Hgd-/- mice. These mice are a model of 
experimental OA as well as a model of AKU due to the osteoarthritic phenotype 
they show including cartilage degeneration, SCB remodelling and increasing 
amounts of calcification. As this was the case, there was a desire to see if changes 
in the cartilage ultrastructure could be identified and how these changes can help 
in understanding the role played, especially by the ACC in the initiation and 
progression of OA.  
 
TEM photomicrographs taken from aged BALB/c Hgd-/- mice depicted the location 
and orientation of chondrons in both areas of the articular cartilage. Chondrons 
located in the superficial zone of the HAC appeared flattened and lay parallel 
towards the articular surface (Fig. 7.3), as did the surrounding collagen fibres in the 
PCM. These chondrons appeared active and healthy suggesting they were 
unaffected by the associated osteoarthropathy. Chondrons located in the middle 
and deep zones were larger in size and had a more rounded appearance (Fig. 7.4). 
These chondrons lay perpendicular to the articular surface as did the collagen fibres 
in the surrounding matrices. Again these chondrons appeared to be active and 
healthy. They showed no signs of hypertrophy and/or chondroptosis, nor did they 
appear to be pigmented. The orientation and location of the chondrons and 
collagen fibres in mice have been studied in detail by Hughes and colleagues [230] 
and the findings from the Hgd-/- mice are consistent with what they report. 
 
Analysis of the ACC in Hgd-/- mice revealed the presence of concentric lamellae 
around the majority of chondrons scattered throughout this zone of cartilage. The 
lamellae were also present around chondrons in the ACC of WT mice but to a much 
lesser extent. Extensive literature searches revealed that these lamellae were a 
novel finding in the ACC. The structures may be related to the lamellae detected 
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using SEM by Hirotani et al [238], who proposed the existence of a lamellar system 
around chondrocytes in the deep zone of the articular cartilage in patients with 
secondary OA. It must be noted however that these were found only in the HAC 
and not in the ACC. No definitive reasoning is given by Hirotani et al [238] as to why 
they believe a lamellae system appears in the cartilage, although it is suggested it 
may be as a result of shrinkage from tissue preparation, and with no other 
literature describing this phenomenon, the mechanism behind their formation is 
not clearly understood. There is evidence, both from the work described in this 
chapter and the results gained by Hirotani that the lamellae are related to the 
pathogenesis of OA. The lamellae appeared around both viable chondrons towards 
the tidemark, which appeared to be partially engulfed by lamellae, and to a much 
higher degree around hypertrophic chondrons located deep in the ACC (Figs. 7.8 & 
7.9). The fact they appear much more regularly around hypertrophic chondrons 
may be significant as to the origins of their formation. Hypertrophic chondrons 
express type X collagen [144, 179], and release increased levels of alkaline 
phosphatase [239] leading to cartilage calcification [143, 240]. Cartilage calcification 
has been associated with both ageing of tissues [241, 242] and OA pathogenesis 
[164, 240]. Calcification of cartilage associated with OA pathogenesis leads to 
thinning of HAC [243] and thickening of ACC [83], and can be identified by 
advancement of the tidemark [244, 245]. Thinning of the ACC can also occur during 
OA if the rate of subchondral remodelling is quicker than the rate of tidemark 
advancement [246]. Cartilage degeneration and SCB changes are hallmark features 
of OA. The lamellae identified in the ACC appeared to be laid down in association 
with the advancing tidemark which would indicate they are formed during cartilage 
calcification. Viable chondrons at the mineralisation front could be seen to be 
partially engulfed by the lamellae (Figs. 7.10 & 7.11). This suggests that chondrons 
in the HAC which are close to the tidemark are engulfed by ACC and the lamellae 
are then laid down during calcification of the cartilage.  
 
The mechanisms behind the formation of the lamellae are at present unknown and 
have proven difficult to establish from the data collected for this chapter. However 
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as they may be linked to calcification it is possible their formation is related to one 
or more of the mechanisms and/or signalling molecules involved in cartilage 
calcification. Increased levels of IL-1 have been associated with increased levels of 
cartilage calcification [247], as have increased levels of insulin-like growth factors 
[248]. Although levels of these cytokines have yet to be determined in Hgd-/- mice 
it is probable they are sufficiently high enough to be a significant cause of 
calcification and are a factor in the formation of lamellae. Collagen is a major 
component of articular cartilage and it has been suggested that it can promote 
calcium pyrophosphate dihydrate (CPPD) deposition as collagen fibrils have been 
shown to be nucleators of CPPD [249], which along with basic calcium phosphate 
(BCP) are generated in OA cartilage [250]. Collagen can also bind different growth 
factors as well as interact with matrix proteins that regulate hydroxyapatite, both of 
which can affect cartilage calcification [248]. It is reasonable to assume that 
collagen plays a significant role in lamellae formation as not only can it directly 
influence calcification of the cartilaginous matrix, it was identified in the lamellae in 
a number of the Hgd-/- mice examined (Figs. 7.19 & 7.20). Although difficult to 
distinguish, individual collagen fibrils could be seen in portions of the lamellae. The 
complete structure of the lamellae could not be entirely identified but collagen 
fibres were clearly present thus highlighting collagen controlled calcification as a 
contributor to lamellae formation. Matrix vesicles which contain apatite crystals in 
OA cartilage are known to be involved in the calcification process [164]. Although 
they play a role in cartilage calcification and are almost certain to be involved in 
lamellae formation, as are both BCP and CPPD, decalcification of the tissue prior to 
processing will have removed any trace of them so it is difficult to determine what 
their actual role is. 
 
The lamellae appeared in both aged and young, and Hgd-/- and WT mice. Although 
the presence of the lamellae in WT mice may seem surprising, as their formation is 
associated with increased levels of calcification, it can be explained by taking into 
account the age of the mice. All of the WT mice examined were over 69 weeks of 
age; both cartilage degeneration and small amounts of calcification are linked with 
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ageing [251] therefore some lamellae formation is not unexpected. Hgd-/- mice 
showed around an 80-90% increase in the number of chondrons engulfed by the 
lamellae in comparison with WT mice highlighting the apparent association 
between them and AKU. The greater abundance of lamellae in Hgd-/- mice, which 
are a model of OA, show that they may have a role in the pathogenesis of OA. To 
confirm this, more samples from BALB/c Hgd-/- and WT mine need to be examined 
to identify the number of chondrons associated with lamellae formation. The 
comparison between young and aged mice can only be made in reference to Hgd-/- 
mice as no young WT mice were examined for the study. Lamellae were present in 
young Hgd-/- mice (Fig. 7.13) suggesting that cartilage calcification and OA initiation 
begins at a young age in OA mice. There were fewer individual lamellae surrounding 
the chondrons in young Hgd-/- mice and they appeared thicker than those seen in 
aged Hgd-/- mice. As the mice increased in age the lamellae became thinner and 
more frequent around the chondrons. This correlates with the increased 
calcification and cartilage thinning seen in aged mice. Increased calcification which 
is associated with OA progression [233] appears to be linked to increasing amounts 
of lamellae formation around chondrons in ACC of aged Hgd-/- mice. 
 
Although it is possible the lamellae may be involved in the development and 
progression of OA, they may also form as a result of ageing. Lamellae were present 
in both young and aged Hgd-/- mice; the number of lamellae around chondrocytes 
increased in aged Hgd-/- mice. The lamellae were also identified in an aged WT 
mouse which showed very little cartilage degeneration, suggesting that their 
formation, at least in this mouse, may have been related to ageing. Increasing the 
number of mice examined, over a wide range of ages, should help determine 
whether the lamellae are linked to either the development of OA or the process of 
ageing.  
 
No ochronotic pigment was observed ultrastructurally in any of the samples 
analysed. During dissection of the tissues no pigmentation could be observed 
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macroscopically as opposed to human ochronotic joints when it is routinely 
observed [20, 252, 253]. The lack of macroscopic pigmentation is certainly a factor 
in the absence of identifiable ultrastructural pigmentation in Hgd-/- mice. Taylor et 
al [28] identified ochronotic pigment ultrastructurally in the ligamentous capsule, 
however Di Franco and colleagues noted that it may be almost impossible to 
identify pigment granules in calcified cartilage due to the presence of calcification 
nodules [37]. It is clear work needs to be done on refining the method of identifying 
pigment ultrastructurally. 
 
The development of early, severe OA is associated with the progression of AKU [36] 
and it has been previously shown in Chapter 3 of this thesis that Hgd-/- mice show 
many similar signs of OA to those seen in AKU patients. Analysis of both Hgd-/- and 
WT mice revealed the appearance of novel concentric lamellae like structures 
surrounding hypertrophic chondrons in the ACC. Their possible association with 
mineralisation and advancement of the tidemark, and their greater abundance in 
OA indicate that the formation of these lamellae might be important in the 
pathogenesis of OA, since thinning of articular cartilage due to advancing 
mineralisation is reported to be a characteristic of joints undergoing OA. Further 
work on identifying the underlying mechanism(s) by how the lamellae are formed 
should provide a better understanding of the function and regulation of the ACC, 
and its role in the initiation and progression of OA. 
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8. General Discussion 
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Over one hundred years have passed since Sir Archibald Garrod described AKU as 
the first ‘inborn error of metabolism’ [1]. Around 50 years after Garrod made his 
initial observations on AKU, La Du and colleagues established that the defect in AKU 
was limited to the HGD enzyme [254], and that there was a link between arthritis 
and AKU [255]. Fernandez-Canon and colleagues, nearly 20 years ago, established 
that AKU results from a defect in the HGD gene [54, 56]. More recently there has 
been important discoveries relating to the pathogenesis of the disorder [9, 20], and 
the mechanism of ochronotic osteoarthropathy [28, 36, 183]. Whilst significant 
improvements have been made in understanding factors contributing to AKU there 
has been less progress made in preventing the disease, with no effective treatment 
currently available to AKU patients. Nitisinone has been shown to reduce plasma 
HGA levels in a clinical setting [53] however no results have been obtained to show 
whether prevented pigmented deposition in tissues. The lack of current treatment 
options available can be linked to the fact that a murine model of AKU showing 
pathology similar to humans, had prior to this thesis, never been reported. Studies 
on Hgd-/- mice by Montagutelli showed increased plasma levels of HGA but no 
ochronotic lesions in the tissues examined [110]. A more complex model of AKU 
was reported in mice containing an HT-1 mutation (Fah-/-) combined with Hgd 
heterozygosity [111], however this model was not considered practical as it relied 
on a spontaneous mutation. This thesis presents novel data, describing in detail the 
identification and progression of ochronotic osteoarthropathy in Hgd-/- mice, whilst 
also showing the progression of pigmentation in chondrons at different stages. It 
also discusses the efficacy of nitisinone as a therapeutic treatment for AKU, the use 
of surgical and chemical intervention to attempt modulate pigment deposition, and 
the discovery of concentric lamellae around hypertrophic chondrons in OA and WT 
mice. 
 
The data presented in Chapter 3 represented the first time that ochronotic 
pigmentation and its associated osteoarthropathy, had been identified in Hgd-/- 
mice. As discussed in Chapter 3 it was originally thought Hgd-/- mice did not 
develop ochronotic lesions, even though they had abnormally high levels of plasma 
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HGA. Several reasons were given as to why this may have been the case including 
the short lifespan of mice, their ability to produce ascorbic acid endogenously [110], 
and possible low circulating levels of HGA. It was apparent from the data presented 
in Chapter 3 that none of these hypotheses were correct, and in fact Hgd-/- mice 
generally have higher circulating HGA than people with AKU and develop 
ochronotic osteoarthropathy over their life span. Although another mouse model of 
ochronosis has been described [111], the complexity of the genetic makeup of the 
model made it an unattractive and impractical model to study AKU. The importance 
of observing ochronotic osteoarthropathy in Hgd-/- cannot be underestimated as it, 
for the first time, provided an insight into the pathogenesis of AKU throughout the 
entire lifespan. Histological observations showed that pigment deposition began 
very early on in life, it was first detected at 15.7 and 10.4 weeks in BALB/c and BL/6 
Hgd-/- mice respectively, and became progressively worse with increasing age. Both 
BALB/c and BL/6 strains of Hgd-/- mice showed an increase in pigmented chondrons 
with age, highlighting the progression of AKU. Once pigmentation had reached a 
certain stage, osteoarthritic changes in the tibio-femoral joint were noticeable. 
Cartilage erosion, osteophyte formation, tidemark duplication, and SCB remodelling 
were all observed in the knee joints of a high proportion of Hgd-/- mice. The 
appearance of osteoarthritic changes in Hgd-/- mice further highlighted the 
pathological similarities between the murine and human model of AKU. Whilst the 
mice never reached the stage of ‘blanket’ pigmentation, as seen in advanced 
human ochronosis, they did show very similar signs of pigmentation initiation and 
progression. Analysis of tissue from Hgd-/- mice at an early age showed initial 
pigment deposition occurred at the pericellular level of chondrons in calcified 
cartilage, similar to that reported in humans [36]. Data from Chapter 4 of this 
thesis, and Preston et al [217] suggests that pigment deposition may initiate 
following compositional and organisational changes in the collagen network. 
Studies have shown that the matrix of ochronotic tissue is disordered at the atomic 
level [39], however it is unknown whether this leads to pigment deposition or is a 
consequence of pigmentation. Intracellular pigmentation, consistent with 
ochronosis in humans, was observed in Hgd-/- mice and most likely resulted from 
an increased amount of pigment deposition following initial transformation of the 
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pericellular environment. End stage ochronosis resulting in ‘blanket’ and 
macroscopic pigmentation of articular cartilage often seen in human tissues 
samples was not observed in Hgd-/- mice.  As discussed in Chapter 3 it is possible 
this is linked to the short murine lifespan, and reduced joint loading due to the 
quadrupedal nature of mice. It was clear from the data collected that BALB/c and 
BL/6 Hgd-/- mice developed ochronosis, and that the deposition of ochronotic 
pigment at a very early age in the mice showed that AKU, though presenting as 
painful syndrome in mid-life, is the result of a lifelong pathological process.  
 
The progression of ochronosis in Hgd-/- mice appeared to be associated with the 
development of mild to severe osteoarthropathy in the tibio-femoral joint. Studies 
of human AKU tissue have shown that the early onset of severe osteoarthropathy is 
linked to the progression of ochronosis [256-258]. Analysis of both Hgd-/- and WT 
mice appeared to show that the most severe signs of OA were linked with AKU. 
There were very few signs of cartilage degeneration in any of the WT mice 
analysed. In comparison, the majority of Hgd-/- mice, from around 30-40 weeks 
onwards, showed some form of osteoarthritic change in the knee joint. The most 
frequent markers of OA in Hgd-/- mice were osteophyte formation and tidemark 
duplication, both of which are heavily involved in OA initiation and progression 
[259, 260]. Pigmented chondrons were identified in all osteophytes, providing 
further evidence that cartilage becomes susceptible to pigmentation at a relatively 
early stage of development. The extreme OA phenotype observed in advanced 
human ochronosis [36], resulting in complete resorption of the SCB plate, was not 
seen in Hgd-/- mice however this was not surprising as the mice did not show such 
advanced stages of pigmentation. 
 
The data presented in Chapter 3 detailed the importance of the ACC and SCB in the 
development of ochronotic osteoarthropathy. The significance of SCB involvement 
in the pathogenesis of OA has been widely discussed [84, 126, 261-263], yet the 
involvement of the ACC in the initiation and progression of OA has often been 
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overlooked. ACC plays an important role in the distribution of load from HAC to SCB 
[264], both of which are heavily involved in OA, suggesting it also has a significant, 
yet undetermined role in OA pathogenesis. ACC certainly plays a key role in the 
initiation and progression of ochronotic osteoarthropathy, particularly in Hgd-/- 
mice where pigmentation is localized to mineralized cartilage. It is still unclear why 
pigmentation initiates in the ACC, and how the pigment actually moves to the sites 
of deposition in cartilage. Chondrocytes receive nutrients through diffusion 
therefore it may be that HGA diffuses through to the cartilage and chondrocytes 
from the synovial fluid surrounding the joints, before polymerizing and depositing 
in the cells. Another possible route is diffusion of HGA across the SCB-ACC interface. 
The SCB is vascularized therefore HGA may accumulate in the vessels of the SCB 
and diffuse across the SCB-ACC interface before becoming deposited as a 
polymerized pigment in chondrons. The primary binding site for ochronotic pigment 
appears to be associated with collagen, yet collagen fibres are located throughout 
the matrices of both the HAC and ACC. This suggests other factors in the ACC 
mediate the process of pigmentation. Chondrocytes in the ACC differ from those 
located in the HAC as they express a hypertrophic phenotype. These chondrocytes 
release factors which actively degrade the surrounding matrices thus altering the 
biomechanical properties of the cartilage. This altered state of biomechanics may 
lead to initial deposition in the PCM of chondrocytes in the ACC and then 
proliferation of chondron pigmentation following further biomechanical changes of 
the matrices. As chondrocytes in the ACC are surrounded by a calcified matrix it is 
surprising they survive as the level of nutrients they receive must be extremely low. 
It is possible this low level of nutrients leads to altered chondrocyte function, and 
an increased rate of chondrocyte death compared to the cells in the HAC. The 
altered function of chondrocytes in ACC may result in them becoming susceptible to 
pigment deposition. Collagen fibres are the most probable binding site for 
ochronotic pigment in particular types VI and X, both of which are located in the 
PCM of chondrons. Type X collagen is found in the PCM of hypertrophic chondrons 
yet it is also located throughout the ACC, and type VI collagen is also found in the 
PCM of chondrons in the HAC therefore the question remains, why does 
pigmentation initiate, and stay localized, in chondrons in the ACC? Proteomic and 
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metabolomic analyses may help provide some answers with regards to the make-up 
of cells at certain stages of pigmentation, however ultrastructural analysis of 
pigmented and non-pigmented chondrons in the ACC and HAC may provide the 
best opportunity to uncover the reasons behind this phenomenon. AKU presents 
with symptoms consistent with early onset, severe OA [36, 265, 266], resulting from 
pigment deposition and subsequent biomechanical changes in the ACC, 
demonstrating further the apparent involvement of the ACC in OA pathogenesis.  
 
A single pigmented chondrocyte was located in the EP of the tibia of both BALB/c 
Hgd-/- 61.3 (♀) and 61.4 (♀) (Figs. 3.10 & 3.11). Although pigmented chondrocytes 
were located throughout the tibio-femoral joint the presence of a single pigmented 
cell in the EP of just two mice appeared peculiar. Chondrocytes in the EP express a 
number of different phenotypes as they are involved in endochondral ossification, 
and also synthesize a number of different collagens and proteoglycans. There is 
scarce literature on the EP in adult mice, most is focussed on its role in bone 
development, however Chambers et al reported that the EP remains open in aged 
mice and the embedded chondrocytes remain viable and actively synthesize type II 
collagen and aggrecan [142]. The authors also stated the chondrocytes no longer 
synthesized type X collagen indicating the EP was not in a stage of active 
hypertrophy. It has been shown previously that ochronotic pigment binds 
preferentially to collagen fibres [28] so it is possible that pigment deposition in 
these two chondrocytes is due to the presence of collagen fibres which the cells 
synthesize. However as all of the cells in the EP synthesize collagen it is unclear why 
only these two cells pigmented. There are likely to be other factors involved which 
alter chondrocyte activity and function, and may have resulted in these cells 
becoming pigmented. Immunostaining for factors which alter chondrocyte function, 
including TNF-α and IL-1 which are both inflammatory cytokines may help 
determine if factors other than mechanical damage lead to pigment deposition. 
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It is impossible to fully understand the pathogenesis of AKU, or any other disorder 
without knowledge of the mechanism behind its initiation and progression. Taylor 
and colleagues [36] have previously suggested a possible mechanism for AKU 
initiation and progression in human tissue, however the work discussed in Chapter 
4 is the first time a staging of chondron pigmentation has been suggested in Hgd-/- 
mice. Histological analysis of the tibio-femoral joint showed pigmentation initially 
began in the PCM of hypertrophic chondrons in the ACC before progressing 
intracellularly, identical to what Taylor et al observed in human AKU tissue. The 
results appeared to indicate that a change had occurred in the PCM of Hgd-/- mice, 
possibly in its composition and/or organisation, prior to pigment deposition. The 
mechanical properties of the PCM are known to alter in disease states [180, 267] 
which fits in with the hypothesis proposed. It would be interesting to measure the 
Young’s modulus of cartilage from both Hgd-/- and WT mice to determine how 
much biomechanical alteration had occurred from pigment deposition. Recent work 
by Taylor et al [183] showed that ochronotic cartilage is much stiffer than both 
normal and OA cartilage highlighting further the possible role of mechanical 
damage in the progression of AKU. It is unclear whether the changes resulting in 
pigment deposition, both mechanical and age related, also occur in non-AKU 
tissues. Therefore it is possible that in the case of ochronosis HGA acts as a marker 
of tissue damage. In vitro incubation of OA tissue with varying concentrations of 
HGA may help elucidate whether this hypothesis is correct. Administration of HGA 
to other murine models of OA, as well as WT mice, may also help elucidate whether 
HGA is a marker of mechanical and age related degenerative changes in tissues. If 
the theory that tissues need to undergo mechanical damage or ageing to make 
them susceptible to pigmentation is correct, the detection of ochronosis in Hgd-/- 
mice, so early in their life, provides one of the earliest signs of ageing observed. 
 
Further similarities between the pathogenesis of AKU in mice and humans were 
reported in Chapter 4 with the identification of pigmentation in several other 
articulating joints. Although the tibio-femoral joint is severely affected in humans, 
ochronosis is also present in other tissues, particularly load-bearing joints. 
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Pigmented chondrons were located in the femoral head, calcaneus, and humerus 
epicondyles, all of which are heavily pigmented in humans. The majority of 
chondrons in all tissues were heavily pigmented, however a small proportion of 
lightly stained cells were located in the femoral head indicating the proposed 
mechanism of pigmentation applied to all ochronotic tissue. The three joints 
examined were obtained from a 65 week old, heavily pigmented, mouse therefore 
it is imperative that the same joints are examined from each mouse in the natural 
history study to determine whether they undergo the same age related decline as 
the tibio-femoral joint. 
 
No practical treatment option is currently available to AKU sufferers, and as a result 
AKU patients are forced to suffer severe pain prior to joint replacement surgery. 
The identification of pigmentation in Hgd-/- mice has provided a model, with 
pathology very similar to AKU in humans, to test therapeutics to treat AKU. In 
Chapter 5 of this thesis, nitisinone; originally developed as a herbicide and 
subsequently used in the treatment of HT-1, was administered to Hgd-/- mice to 
determine its efficacy in treating AKU. Nitisinone, previously trialled as a possible 
treatment for AKU [53], was administered to the mice for their entire lifespan, and 
mid-way through their life. Both studies were undertaken to determine if nitisinone 
prevented pigmentation and if so, when treatment should commence. Whole life 
treatment with nitisinone was shown to prevent any pigment deposition in the 
mice, this being the first time nitisinone had been shown to stop pigmentation. 
There was no evidence from the mid-life intervention study that nitisinone therapy 
could reverse previously laid down pigment as had been suggested anecdotally by 
patients and physicians. The results collected from the studies clearly showed that 
nitisinone is an effective treatment for AKU. The data from Chapter 5 was included 
as part of a successful clinical trial application, which has recently started, to use 
nitisinone in the treatment of AKU. This shows the availability and practicality of the 
AKU mouse model is important as it provides a practical model of AKU in which 
treatments can be tested. Research is currently being carried out using antisense 
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therapy, gene therapy, and enzyme replacement therapy as other possible 
treatments for AKU. 
 
Chapter 6 detailed the use of surgical and chemical intervention to attempt to 
accelerate the rate of pigment deposition. It was hypothesised that DMM surgery 
and HGA supplementation could significantly decrease the time required for Hgd-/- 
mice to develop severe ochronotic osteoarthropathy, due to increased mechanical 
damage and an increased amount of circulating HGA. Results from the DMM study 
showed no statistically significant increase between the number of pigmented 
chondrons in the experimental and contralateral control limbs. Although moderate 
to severe OA was observed in all of the mice, the results showed an apparent lack 
of correlation between joint damage and the number of pigmented chondrons in 
two of the six mice in the study. Both of these mice, BALB/c Hgd-/- 100.1 and 101.1, 
were culled at 8 weeks post-op yet they showed extensive signs of OA particularly 
BALB/c Hgd-/- 101.1 who displayed severe OA in the experimental limb. As 
mechanical damage is thought to be involved in the initiation and progression of 
pigmentation it is unclear why two of the mice displayed lower number of 
pigmented chondrons in the experimental limb. It is possible inter-individual 
variability at least contributes to the reduction in pigmented chondron numbers. 
Although the plasma levels of HGA in Hgd-/- mice remain steady across their 
lifetime there is variability with regards to the number of pigmented chondrons in 
Hgd-/- mice of the same age, as seen in Chapter 3 of this thesis. This may have 
played a role in the low pigmented chondron numbers observed in the 
experimental limbs of BALB/c Hgd-/- 100.1 and 101.1. It is likely other factors are 
involved in the reduction of pigmented chondrons in these mice including catabolic 
factors expressed by damaged/abnormal chondrocytes however further analysis of 
an increased number of DMM Hgd-/- mice may reveal this data to be no more than 
an anomaly. Supplementation with 5mM HGA also showed no significant difference 
in the number of pigmented chondrons between the experimental and control 
groups; the highest pigmented chondron count was actually observed in a control 
mouse. Plasma levels of HGA were also shown not to have increased. It appears 
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that the additional HGA given to the mice is simply excreted and therefore is never 
converted to ochronotic pigment. The inability to accelerate the rate of pigment 
deposition and to increase the amount of pigment deposited highlights possible 
protective pathways in Hgd-/- mice which may affect the pathogenesis of 
ochronotic osteoarthropathy. 
 
Although pigmentation was identified histologically, TEM examination of the ACC 
from Hgd-/- mice (Chapter 7) provided no clear evidence of ochronotic pigment at 
the ultrastructural level. Taylor et al [28] had previously showed ochronotic 
pigment to bind preferentially to collagen fibres in the matrices of the ACC. It has 
been suggested in this thesis that changes occur in the collagen network of the PCM 
of pigmented chondrons, rendering them susceptible to pigmentation. Using TEM it 
was thought these changes, and the pigment deposited following them may be 
identified, however this was not the case. Although frustrating, the inability to 
identify ochronotic pigment at the ultrastructural level may be related to the lack of 
macroscopic pigmentation. Human tissue samples analysed using TEM were at an 
advanced stage of the disease and showed macroscopic pigmentation, clearly 
demonstrating the large amount of pigment deposited. This stage of pigmentation 
was never observed in Hgd-/- mice which may have accounted for the inability to 
identify pigmentation on the ultrastructural level. Further work is required on Hgd-
/- mice of all ages to determine if changes in the collagen network of the matrices, 
which may lead to the initiation of pigmentation, can be identified. Initially the 
primary objective for TEM analysis of Hgd-/- mice was identification of ochronotic 
pigment however this was unsuccessful. Despite the failure to identify ochronotic 
pigment at the ultrastructural level, high resolution TEM revealed the presence of 
previously undescribed microanatomical concentric lamellae. The lamellae were 
located around both healthy and apoptotic chondrons in the ACC of Hgd-/- mice 
initially, and then were subsequently found in WT mice. Extensive literature 
searches revealed this to be a novel discovery in mice, however Hirotani et al [238] 
described a similar findings in the femoral heads of patients with secondary OA. The 
lamellae were more abundant in Hgd-/- mice, particularly around severely 
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hypertrophic chondrons, suggesting a possible link between their formation and the 
pathogenesis of OA. There was some evidence that appeared to show the lamellae 
were laid down were advancement of the tidemark and increased mineralisation of 
the cartilage, both of which are associated with OA. Further work is required to 
determine the periodicity of the lamellae and the mechanism behind their 
formation. Immunohistochemical analysis of the ACC from both Hgd-/- and WT 
mice, to determine how much type X collagen is present, may help elucidate if 
increased cartilage calcification is related to the formation of the lamellae. 
Measuring levels of IL-1 and insulin-like growth factors, both of which are also 
involved in cartilage calcification, may also help determine if the lamellae are 
formed through increased calcification. The lamellae, although a possible indicator 
of the development of OA, may also be a consequence of ageing. They were 
identified in both young and aged Hgd-/- mice with their frequency increasing 
significantly in the aged mice. The lamellae were also identified in an aged WT 
mouse which showed very little cartilage degeneration, suggesting that their 
formation at least in this mouse may have been related to ageing. Increasing the 
amount of samples examined at the ultrastructural level will help provide a clearer 
picture of whether the lamellae are linked to either the development of OA or the 
process of ageing. 
 
In summary the studies reported in this thesis present novel findings on the 
identification of pigmentation, and the pathogenesis of ochronotic 
osteoarthropathy in Hgd-/- mice. The prevention of ochronotic pigmentation, using 
the drug nitisinone, was also reported for the first time highlighting the 
effectiveness of the Hgd-/- mouse model. The results reported provide new 
information on the initiation and progression of ochronosis, the mechanisms 
involved, and the use of a potential therapeutic to prevent pigment deposition. 
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Appendix A: Pigmented chondron counts 
 
BALB/c 
Hgd-/- 
Age 
(weeks) 
Number of 
pigmented 
chondrons 
BALB/c 
Hgd-/- 
Age 
(weeks) 
Number of 
pigmented 
chondrons 
132.1 6.5 0 86.2 25.2 32 
132.2 6.5 0 99.1 27.4 61 
132.3 6.5 0 99.2 27.4 46 
129.2 7.8 0 92.1 30.9 88 
131.1 7.8 0 92.2 30.9 59 
131.2 7.8 0 91.1 34.4 80 
93.2 15.7 7 91.2 34.4 48 
94.1 15.7 7 86.3 40.4 156 
120.1 19.6 18 55.1 47.4 156 
120.2 19.6 13 54.3 49.6 111 
106.1 23.5 76 61.3 60 206 
106.2 23.5 53 61.4 60 247 
106.3 23.5 33 59.2 61.3 317 
86.1 25.2 37 59.3 61.3 187 
 50.3 65.7 254 
 
 
 
 
 
 
 
Table 1 – Pigmented chondron counts from BALB/c Hgd-/- mice natural history 
study (Chapter 3).  
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BL/6 Hgd-/- 
Age 
(weeks) 
Number of 
pigmented 
chondrons 
BL/6 Hgd-/- 
Age 
(weeks) 
Number of 
pigmented 
chondrons 
166.2 6.1 0 101.3 29.1 113 
166.3 6.1 0 102.3 29.1 117 
161.3 6.1 0 98.3 31.7 111 
161.4 6.1 0 99.4 31.7 123 
161.1 10.4 0 94.1 37.8 110 
161.2 10.4 0 95.1 37.8 144 
162.1 10.4 0 82.1 41.3 133 
162.2 10.4 5 83.1 41.3 176 
98.4 16.1 7 66.3 46.5 274 
99.3 16.1 7 67.1 46.5 157 
71.2 27.8 26 62.3 62.6 184 
72.1 27.8 37 49.2 68.3 90 
 35.1 71.7 156 
 
 
 
 
 
 
 
 
 
Table 2 – Pigmented chondron counts from BL/6 Hgd-/- mice natural history study 
(Chapter 3).  
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BALB/c 
Hgd-/- 
Age 
(weeks) 
Number of 
pigmented 
chondrons 
BALB/c 
Hgd-/- 
Age 
(weeks) 
Number of 
pigmented 
chondrons 
16.3 69 221 23.3 67 0 
18.1 69 136 24.4 67 0 
18.2 69 207 25.1 67 0 
18.3 69 256 25.2 67 0 
22.1 69 308 25.3 67 0 
13.3 71 200 26.1 67 0 
14.1 71 248 26.2 67 0 
14.2 71 341 
 
15.1 71 132 
 
 
 
 
BALB/c 
Hgd-/- 
Age 
(weeks) 
Number of 
pigmented 
chondrons 
BALB/c 
Hgd-/- 
Age 
(weeks) 
Number of 
pigmented 
chondrons 
47.2 80 273 45.1 80 108 
47.4 80 245 47.3 80 100 
48.2 80 177 48.1 80 70 
49.3 80 188 49.4 80 51 
50.2 80 182 50.1 80 112 
51.1 80 142  
  
 
 
Table 3 – Pigmented chondron counts from BALB/c Hgd-/- mice nitisinone whole-
life study (Chapter 5). (Left side no nitisinone / Right side whole-life nitisinone). 
 
 
 
 
 
Table 4 – Pigmented chondron counts from BALB/c Hgd-/- mice nitisinone mid-life 
study (Chapter 5). (Left side no nitisinone / Right side mid-life nitisinone). 
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